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1
IntroductIon
The lung contains the largest surface of our body that is exposed to the environment. Day 
in, day out, our lungs are being exposed to many injurious components, ranging from 
noxious gasses and particles caused by traffic and chemical industries to a multitude of 
microorganisms. The lung has a host of defense mechanisms to combat this constant 
invasion, ranging from the simplest, the nasopharyngeal barrier, to the most intricate 
one, the immune system1. This natural defense mechanism of the lung is dependent on 
an intact pulmonary epithelium, abundance of pulmonary macrophages, neutrophils and 
dendritic cells. But even with all these barriers, exogenous factors can still lead to lung 
injury. This thesis will characterize lung injury, and most importantly, lung repair, using 
animal models of two lung diseases: Bronchopulmonary Dysplasia and Chronic Obstruc-
tive Pulmonary Disease.    
Worldwide, 15 million babies are born prematurely each year, and this incidence is on 
the rise. In developed countries, 8.6% of babies are born premature2. Preterm birth is an 
important risk factor for the development of Bronchopulmonary Dysplasia (BPD). BPD is 
a disorder of the lungs that was first described in 1967 by Northway et al.3. It may develop 
in premature infants who underwent mechanical ventilation and oxygen supplementation 
in the setting of an immature, surfactant-deficient lung, with a relative shortage of anti-
oxidant defenses4. BPD was originally characterized by lung parenchymal fibrosis, edema, 
vascular changes and persistent inflammation of the airways5. Over the past 40 years, with 
the introduction of exogenous surfactant treatment, the use of prenatal steroids, improved 
modes of ventilation and better nutritional support, the survival of infants with very low 
birthweight (VLBW) has improved. The downside to this is that VLBW infants, partly due 
to their low gestational age and immature lungs, are prone to develop lung problems. This 
is called ‘new BPD’ which, in contrast to the ‘old BPD’, is characterized by interrupted 
septation and abnormal vascularization, leading to fewer and enlarged alveoli6. BPD 
is believed to have a multifactorial pathogenesis, with many pre- and postnatal factors 
playing a role7 (Figure 1). BPD is presently defined as the need for supplemental oxygen 
at 36 weeks post conception. The incidence is around 52% in infants with a birthweight 
between 501 and 750 gram, and decreases with increased birthweight to 7% in infants 
with a birthweight between 1251 and 1500 gram8, making it the most common chronic 
lung disease in infancy9. Long-term follow-up indicates that preterm infants with BPD de-
velop reduced lung function and abnormal lung structure through childhood10,11 and into 
adolescence12,13. Structural lung abnormalities resembling emphysema have been reported 
in young adults with BPD14.
Even though progress has been made in the management of infants with BPD, current 
treatment remains symptomatic and limited, and there is a need for more effective strate-
gies for prevention and treatment of BPD. Researchers have successfully used hyperoxia 
exposure in newborn mice during the postnatal period to establish an animal model of 
BPD. Sphingolipids are structural components of the cell membrane and have recently 
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been discovered to exhibit important functions as messenger molecules in the regula-
tion of proliferation and apoptosis. The function of sphingolipids, both in healthy and 
diseased state is described in detail in chapter 2. We aimed to examine the importance of a 
class of biologically active molecules, the sphingolipids, in the onset of BPD and set out to 
investigate the effect of a new therapeutic strategy, pharmacological sphingolipid inhibi-
tor treatment, in the hyperoxia-induced animal model of BPD (Chapter 3). Furthermore 
we examined the effect of hypoxia-inducible-factor 1 alpha (HIF-1α) overexpression on 
alveolarization and investigated its potential therapeutic effect in our hyperoxia-induced 
animal model (Chapter 4).
Pulmonary emphysema and chronic bronchitis, together chronic obstructive pulmonary 
disease (COPD), are the most common chronic lung diseases in adults in the developed 
world, and are associated with a high mortality risk15, the third leading cause of death in 
202016. Due to exacerbations leading to hospitalization and home oxygen use, COPD poses 
a large economic burden17, estimated at 60-70 billion dollars annually in the US18. Pulmo-
nary emphysema is characterized by progressive destruction of alveolar walls, leading to 
loss of elastic recoil, airflow obstruction and hyperinflation. Patients experience a decrease 
in lung function, shortness of breath and fatigue. The severity of the disease is deter-
mined by the amount of airflow limitation, measured by the Forced Expiratory Volume in 
1 second (FEV1) as percentage of the predicted value based on control values from healthy 
controls. Pulmonary emphysema has a multifactorial pathogenesis. Oxidative stress, 
sustained inflammation and protease-antiprotease imbalance are believed to be major 
contributors to the pathogenesis of COPD. These factors also play a role in the develop-
ment of BPD, and hence the pathogenesis of COPD and BPD have features in common19. 
Development of COPD is strongly related to air pollution and cigarette smoke exposure. 
Why only a minority of all smokers develops emphysema remains unclear. To date no 
Bronchopulmonary Dysplasia
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Figure 1. Multifactorial pathogenesis of BPD.
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1curative therapies are available. Smoking cessation and domiciliary oxygen supplementa-
tion only prolong survival in a small subset of patients with resting PaO
2
 < 60 mmHg20. 
Apoptosis plays an important role in the pathofysiology of COPD. Since sphingolipids 
have been shown to modulate the balance between apoptosis and proliferation, we set out 
to examine the role of sphingolipid metabolism in the pathofysiology of pulmonary em-
physema, and the effect of pharmacological inhibition on the sphingolipid pathway in an 
elastase-induced emphysema model (Chapter 5). The elastase-induced rodent emphysema 
model, which is based on the injection of porcine pancreatic elastase, mimics the histo-
logical findings seen in the lungs of emphysema patients and has been used for decades 
to investigate new treatment strategies in COPD. Another intriguing area of therapeutic 
research focuses on the use of stem cells to repair injured tissue. Therefore, as part of 
this thesis, we set out to investigate the effects of mesenchymal stem cell treatment in the 
elastase-induced pulmonary emphysema model (Chapter 6).
outLIne oF thIs thesIs
As an introduction to this thesis, Chapter 1 describes BPD and COPD, the two lung dis-
eases that will be addressed in this thesis. Chapter 2 introduces the topic of sphingolipids 
and focuses on the role of sphingolipids in healthy and diseased state and the influence 
of sphingolipids on lung growth and development. Chapter 3 focuses on the recovery 
period after hyperoxia-induced lung injury in a rodent model of BPD, and the positive 
effect of artificial sphingosine-1-phosphate supplementation on lung structure. Chapter 
4 focuses on the role of HIF-1α during lung development and the effects of activation of 
HIF-1α on hyperoxia-induced lung injury. Chapter 5 describes the role of ceramides in the 
development of elastase-induced emphysema, and the effect of multiple ceramide-based 
pharmacological treatments on lung structure and function. Chapter 6 reports a study on 
the effect of mesenchymal stem cell treatment on lung structure and function in elastase-
induced emphysema. Chapter 7 discusses the findings of the above mentioned chapters, 
puts them into perspective, and discusses future directions. Chapter 8 summarizes this 
thesis.
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abstract
Sphingolipids comprise a class of bioactive lipids that are involved in a variety of patho-
physiological processes, including cell death and survival. Ceramide and sphingosine-1-
phosphate (S1P) form the centre of sphingolipid metabolism and determine the pro-and 
anti-apoptotic balance. Findings in animal models have suggested a possible pathophysi-
ological role of ceramide and S1P in diseases such as COPD, cystic fibrosis and asthma. 
Sphingolipid research is now focusing on the role of ceramides during lung inflammation 
and its regulation by sphingomylinases. Recently, sphingolipids have been shown to play 
a role in the pathogenesis of bronchopulmonary dysplasia (BPD). Ceramide upregulation 
has been linked with VEGF suppression and decreased surfactant protein B levels, path-
ways important for the development of BPD. In a murine model of BPD, intervention with 
an S1P-analog had a favourable effect on the histological abnormalities and ceramide lev-
els. Ceramides and S1P also regulate endothelial permeability via cortical actin cytoskel-
etal rearrangement, which is relevant for the pathogenesis of the acute respiratory distress 
syndrome (ARDS). Based on these observations, the feasibility of pharmacological inter-
vention in the sphingolipid pathway to influence disease development and progression is 
presently explored, with promising early results. The prospect of new strategies to prevent 
and repair lung disease by interfering with sphingolipid metabolism is exciting and could 
potentially reduce morbidity and mortality in patients with severe lung disorders.
Sphingolipids in Lung Growth and Repair
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IntroductIon
Sphingolipids are structure-bearing components of the cell membrane which have been 
shown to function as messenger molecules, exhibiting effects on cell proliferation, apop-
tosis, cell contact and adhesion, endothelial barrier function and playing a role during the 
immune response1–9. They have recently been identified as an important class of molecules 
involved in a variety of diseases, such as atherosclerosis, chronic heart failure5, asthma10, 
diabetes, sepsis, cystic fibrosis, COPD11, Alzheimer’s disease12 and cancer13. Emerging evi-
dence also suggests an important role for sphingolipids in lung development and in dam-
age and repair processes after early lung injury. An important process in the development 
of the human lung is alveolarization, which occurs between 36 weeks of pregnancy and 
2 years postnatally, when secondary septa subdivide the immature saccules into smaller 
alveolar units14–16 to increase the surface area for gas exchange. Between birth and 3 years 
of age, the capillary monolayer is formed in these septa, thereby reducing the septal thick-
ness to improve gas exchange properties17. A host of growth factors, morphogens, recep-
tors, transcription factors, hormones, cellular processes and physical determinants are 
crucial during the various stages of lung development15,18. Disruption of any of the above 
mentioned processes during this critical developmental period results in structural and/
or functional abnormal lungs, such as can be seen, for instance, in bronchopulmonary 
dysplasia. This review will focus on the role of sphingolipids during lung development, 
damage and repair.
bIoLogIcaL Importance oF sphIngoLIpIds In the Lung
Sphingolipids consist of a hydrophobic sphingoid long chain base (sphingosine, sphinga-
nine or phytosphingosine) and a hydrophilic fatty acid that varies in chain length, degree 
of hydroxylation and saturation, creating a large variety in possible sphingolipid composi-
tion19,20. Two important sphingolipids are ceramide and sphingosine-1-phosphate (S1P). 
Ceramide is the centre of sphingolipid metabolism21, acts as precursor for the creation of 
all other sphingolipids and also functions as a stress signal for multiple stimuli, such as 
radiation, ischemia and reperfusion, chemotherapeutics and cytokines22,23. S1P functions 
as a pro-survival signal and promotes cell proliferation and differentiation. Since S1P is 
generated from ceramide via sphingosine, it has been proposed that these two sphingo-
lipids determine the apoptotic balance7. The regulation of sphingolipid metabolism is 
complicated and involves many enzymes (Figure 1). There are 3 main pathways to create 
ceramide: de-novo synthesis from serine and palmitoyl CoA by serine palmitoyltranfer-
ase; breakdown of sphingomyelin by acid or neutral sphingomyelinases and production 
from sphingosine by ceramide synthase. Spingosine can also be converted into S1P by 
sphingosine kinase. Various sphingolipids play an important role in cellular homeostasis. 
Ceramide leads to cell-cycle arrest and apoptosis, whereas S1P has an opposite role, facili-
tating proliferation and differentiation of cells. Therefore, ceramide and S1P are consid-
ered as a pro- and anti-apoptotic ‘rheostat’24,25. The interplay between these two processes 
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determines the formation of lung structure, both macroscopically and on a cellular level, 
during all stages of lung development. Based on these findings, sphingolipid research has 
intensified. Animal models showed altered sphingolipid levels in LPS-induced macro-
phage dysfunction26, colitis27, melanoma28, ischemia-reperfusion injury29 and spinal cord 
injury30. In the lung, sphingolipids have been shown to be involved in vascular perme-
ability, allergic response and apoptosis31. Altered sphingolipid levels have been shown to 
play a role in hyperoxia-induced lung injury or bronchopulmonary dysplasia32, radiation-
induced lung injury33, cigarette-smoke induced lung injury34–36, cystic fibrosis37, asthma38,39 
and pulmonary infection, stressing the biological importance of sphingolipid metabolism 
in lung disease (Table 1 shows an overview of sphingolipids in lung disease).
sphIngomyeLIn as bIomarker For FetaL Lung deveLopment
Alveolar sphingomyelin levels are thought to remain constant for the entire gestational 
period40. Dipalmitoylphosphatidylcholine (DPPC) is the main surface-active component in 
the alveolar lining during fetal development and its level remains constant for most of the 
gestation, and increases from week 32-33 towards term41. Since the alveolar compartment 
and the amniotic fluid are connected42, phosphatidylcholine (lecithin) levels also increase 
in the amniotic fluid towards term. The lecithin/sphingomyelin ratio in amniotic fluid 
is traditionally considered as a marker of lung maturation43. In 1997, Longo et al. had an 
in-depth look at sphingomyelin levels during lung development in rats and actually found 
that sphingomyelin and sphingosine levels in lung homogenates and microsomes in-
creased 2-fold and 6-fold, respectively, during fetal lung development, with highest levels 
at birth44. This increase was caused by an increase in serine palmitoyltransferase activity, 
the rate-limiting enzyme of de-novo synthesis of ceramide, the intermediate precursor of 
sphingomyelin. Acid and neutral sphingomyelinase activity increased during fetal lung 
development, peaking at day 19, but decreased towards low levels at birth. Ceramidases 
Sphingosine-1-Phosphate Ceramide SphingomyelinSphingosine
S1P-phosphatase
Sphingosine-Kinase
Ceramide-synthase
Ceramidase
Sphingomyelin-synthase
Sphingomyelinase
        Serine + 
Palmitoyl-CoA
de-novo 
synthesis
     Complex 
Sphingolipids
Ceramide-1- phosphatedegradation
Serine palmitoyltransferase
Figure 1. Pathway of sphingolipid metabolism. Enzymes are marked with italics.
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showed a similar pattern. These findings are similar to those found in the rabbit45,46. In 
contrast, sphingomyelin levels decreased during fetal lung development in monkey and 
lamb47,48. The above described variations in sphingolipid levels during gestation suggests 
that the paradigm of constant sphingolipid levels throughout pregnancy needs to be stud-
ied in humans in more detail, and perhaps reconsidered40.
sphIngoLIpIds and Lung InFLammatIon
Research on sphingolipids in lung disease has focused on their role in inflammation. An 
important finding was the accumulation of ceramide in the lungs of cystic fibrosis (CF) 
patients, as measured by histological staining on resected lungs when these patients 
received a bilateral lung transplantation due to severe CF49. Donor lungs that were not 
transplanted were used as controls. The number of neutrophils, detected using neutrophil 
elastase and myeloperoxidase staining, correlated with the amount of ceramide stain-
ing and so did Pseudomonas aeruginosa colonization. This was followed by publications 
in animal models of CF, showing that ceramide accumulation caused inflammation and 
increased the susceptibility to lung infection in CF mice50. Becker et al. showed that the 
levels of inflammation correlated to the amount of acid sphingomyelinase (ASMase) activ-
ity37, and that inhibition of ASMase reduced inflammation9. Dechecchi et al. showed that 
an inhibitor of de-novo ceramide synthesis decreased lipopolysaccharide-induced pulmo-
nary inflammation in CF mice51. Inflammation is an important process in chorioamnion-
itis, a common cause of preterm birth52,53. Most premature deliveries before 30 weeks of 
gestation exhibit histological chorioamnionitis54. Severe histological chorioamnionitis is 
associated with an increased risk for developing bronchopulmonary dysplasia (BPD)55,56. 
Animal models of chorioamnionitis show impaired alveolarization57–59 and disrupted 
microvasculature60 in the fetal lungs, most likely caused by the increased production of 
pro-inflammatory cytokines, together with the massive influx of inflammatory cells in the 
amniotic fluid and chorioamnion61. The role of sphingolipids in the pathogenesis of BPD 
is therefore of great interest, as it may represent a target for prevention and treatment of 
this severe condition.
sphIngoLIpIds and bpd
BPD is a chronic lung disease that develops in a subset of preterm infants who were sub-
jected to mechanical ventilation and/or supplemental oxygen62. The disease was originally 
described by Northway et al. in 196763 and was characterized by a heterogeneous pattern of 
persistent airway inflammation, parenchymal fibrosis, edema and abnormal pulmonary 
vascular development. The nature of BPD has changed in the last 40 years due to advance-
ments in neonatal care, such as less invasive ventilation, the use of steroids and exogenous 
surfactant and better nutrition. This has made it possible that extreme prematures now 
survive, and these often suffer from an arrest in lung development with interrupted septa-
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tion, vascular abnormalities, and reduced alveolar numbers and increased alveolar size, 
also called ‘new’ BPD64,65. BPD is a clinical diagnosis, and the incidence of ‘new’ BPD is 
estimated between 7 and 52% in infants born with a birthweight between 1500 and 500g, 
respectively66. BPD has a multifactorial origin with prematurity, often complicated by 
chorioamnionitis, oxygen toxicity, barotrauma from mechanical ventilation, lung infec-
tion and malnutrition being the most important risk factors67. BPD patients show lower 
lung volumes and decreased forced expiratory flows, during the first 2 years of life68, 
and lung function abnormalities often persist into adolescence and adulthood69,70. BPD 
survivors often have nonspecific and asthma-like respiratory symptoms and may develop 
chest deformities including flaring of the ribs and a funnel chest. Abnormal radiological 
findings are present in infants with BPD and persist into adulthood. A high prevalence of 
airtrapping71, parenchymal abnormalities72 and emphysema-like structural defects have 
been reported in over 80% of adult survivors of ‘old’ BPD73,74, and it seems likely that long-
term consequences of ‘new’ BPD will be similar if not worse, due to the lower gestational 
age that these ‘new’ BPD patients present themselves, as shown in CT-images of a 12 year 
old BPD patient (Figure 2). Is it possible that sphingolipids are involved in the pathogen-
esis of BPD? As we have recently demonstrated, altered sphingolipid levels do play a role 
A B
C D
Figure 2. Spirometer controlled inspiratory (A,C) and expiratory (B,D) chest CT scan of a 12 year old male 
patient with severe BPD in the axial and coronal plane. Note the emphysematous aspect of the left lung. 
Most functional lung tissue is present in the right lung as indicated by the density changes from inspiration 
to expiration. The lung architecture is severely distorted. The mosaic pattern of the right lung is caused by 
redistribution of blood flow through the healthier regions of the lung.
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in hyperoxia-induced lung injury or bronchopulmonary dysplasia32. We reported a rise in 
ceramide levels during hyperoxia exposure in newborn mice, correlating with decreased 
lung function, which returned to control levels during recovery in normoxia. By adding 
an artificial S1P analog, D-sphingosine, during the recovery period, ceramide levels de-
creased more rapidly and histological abnormalities were ameliorated. Recently, ceramide 
upregulation has been shown to decrease Vascular Endothelial Growth Factor (VEGF) via 
suppression of Hypoxia-Inducible Factor(HIF)-1α, suggesting a role for sphingolipids 
in VEGF regulation75. VEGF has an important role in pulmonary vascular development. 
Deletion of a single VEGF allele during embryogenesis is lethal76 and decreased postnatal 
VEGF expression leads to reduced alveolarization77,78. Decreased levels of VEGF have been 
measured in a rodent animal model of BPD79 and inhibition of VEGF-receptor 1 leads to 
a disorganized alveolar capillary network80. Together these findings suggest that sphin-
golipids may regulate lung vascular development via VEGF. Ceramides also decreased 
surfactant protein B (SP-B) formation by reducing DNA binding and transcriptional 
activity of Nkx2-1, an important transcription factor for SP-B gene expression81, thereby 
contributing to decreased SP-B production in a lung already deficient in surfactant. The 
possible involvement of the sphingolipid pathway in several aspects of the development of 
BPD is highly relevant, as to date there is no treatment available for BPD, and intervening 
via the sphingolipid pathway could provide a new approach to prevent or reduce neonatal 
lung damage in prematures.
sphIngoLIpIds and acute respIratory dIstress syndrome
Acute Respiratory Distress Syndrome (ARDS) is an important cause of death in preterm in-
fants and is characterized by decreased surfactant levels and a disrupted endothelial barri-
er, resulting in pulmonary edema. Endothelial barrier function is regulated by sphingolip-
ids via two distinct pathways. The first pathway is through S1P that binds to S1P
1
 receptors 
on endothelial cells which stabilizes barrier function via α-actinin-1 and 4 expression in 
caveolin-rich domains which results in cortical actin cytoskeletal rearragement82. Blocking 
of this pathway leads to pulmonary edema83. The second pathway is ASMase upregulation, 
leading to increased ceramide formation. Increased ceramide formation has been shown 
to induce inflammasome activation resulting in IL-1β production that damages the epithe-
lium, leading to TNF-α and IL-6 production and combined with a decreased trans-epithe-
lial resistance, leads to increased pulmonary vascular endothelial leakage84. One pathway 
to influence ASMase levels is via Caveolin-1, a resident protein of lipid rafts and caveolae 
of airway epithelium, smooth muscle cells, fibroblasts and pulmonary vasculature85 that 
plays a role in protein trafficking and signal transduction86. Caveolins are downregulated 
in many lung diseases87 and have been shown to increase ASMase levels and thereby 
ceramide production in LPS-induced chorioamnionitis88. Blocking the ASMase pathway 
decreased pulmonary edema formation84,89,90. These findings suggest that sphingolipids 
should be studied further as a therapeutic target in ARDS.
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sphIngoLIpIds In other Lung dIsorders
Exposure of adult mice to radiation increased expression of sphingosine kinase and 
ceramide levels in broncho-alveolar lavage, plasma and lung tissue. These sphingolipid 
changes were correlated with increased vascular endothelial leakage and more severe his-
tological abnormalities and were abrogated with the use of S1P analogs33.
Sphingolipid metabolism also plays a role during cigarette-smoke induced lung injury34–36. 
Cigarette smoke has been shown to upregulate neutral sphingomyelinase (nSMase), lead-
ing to increased ceramide production and alveolar cell apoptosis. This increase in nSMase 
is blocked by the addition of glutathione, suggesting a role for H
2
O
2
-production as a 
trigger for nSMase expression. Cigarette smoke also induces the expression of RTP801, a 
stress response protein that triggers NF-κB mediated inflammation. RTP801 and ceramide 
function as mutual up-regulators, thereby further increasing inflammation and alveolar 
cell apoptosis34. Apart from increased apoptosis, cigarette smoke, via ceramide upregula-
tion, leads to p38 mitogen-activated protein(MAP) kinase, JNK and Rho kinase activation, 
which causes actin cytoskeletal rearrangement, loss of junctional protein zonula oc-
cludens-1 and intercellular gap formation. All these effects were abolished by the addition 
of glutathione and nSMase inhibition using GW486936.
Although increased S1P is beneficial to most diseases in which sphingolipid levels are 
altered, findings in asthma also showed its potentially negative effects. Segmental airway 
challenge and BAL from asthma patients showed increased levels of S1P when compared 
to controls, and correlated with the amount of airway inflammation as measured by 
inflammatory cell number and differentiation count in the BAL. Human airway smooth 
muscle cells express S1P receptors, and S1P increases phosphoinositide turnover and 
intracellular calcium mobilization, two processes which play an important role in airway 
smooth muscle contraction. S1P has also been shown to modulate adenylate cyclase acitiv-
ity and cAMP accumulation and although inhibiting TNF-α, it induced IL-6 secretion. 
Another possible role for increased S1P levels in asthmatics is its mitogenic effect, playing 
a role in the remodelling that takes place in asthma10. The role of S1P in asthma has been 
extensively reviewed by Jolly et al.91 Figure 3 provides an overview of the proposed role of 
the Ceramide-S1P rheostat during lung injury and repair.
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InterventIons In the sphIngoLIpId pathway
Since altered sphingolipid levels seem to be involved in many diseases in multiple organ 
systems, pharmacological interventions have been developed to target sphingolipid 
metabolism92–96. At present, there is some evidence that such interventions are effective. 
Inhibition of acid sphingomyelinase by amitripyline, trimipramine and desipramine has 
shown significant improvement in lung function, histology and the incidence of Pseudo-
monas aeruginosa infections in an animal model of cystic fibrosis by decreasing ceramide 
levels9. Lin et al. have recently shown that neutrophils from patients with ARDS show 
elevated intracellular levels of ceramide, and that neutral sphingomyelin inhibition, using 
sphingolactone, sphingosine kinase inhibitor and p38 MAP-kinase inhibitor, decreased 
lung inflammation and increased survival in an LPS model of ARDS97. We found that S1P 
analog D-sphingosine promoted recovery of ceramide levels and histology, but not lung 
function, after hyperoxia-induced alveolar arrest in a mouse model of BPD32. As described 
earlier, S1P analogs also protect mice from radiation induced lung injury33 and has been 
shown to improve alveolar cell survival and decrease alveolar airspace enlargement in a 
vascular endothelial growth factor receptor (VEGFR)-inhibitor induced model of pul-
monary emphysema98. Inhibiting serine palmitoyltransferase by using Myriocin (Cay-
man Chemicals, Ann Arbor, MI) decreased lung inflammation and fibrosis, measured by 
External Injury:
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Air Pollution
Radiation
Aspiration of Fluids
Oxygen-Radicals
Pulmonary Infections
Ceramide > Sphingosine-1-phosphate
Increased inammation
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Decreased SP-B production
Intercellular gap formation via loss of JPZO-1
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Figure 3. An overview of the possible roles for ceramides and sphingosine-1-phosphate in lung homeostasis. 
JPZO-1: junctional protein zonula occludens-1. VEGF: vascular endothelial growth factor. SP-B: surfactant 
protein B. COPD: chronic obstructive pulmonary disease. BPD: bronchopulmonary dysplasia. ARDS: acute 
respiratory distress syndrome.
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collagen and α-smooth muscle actin expression, after thoracic radiation with 20 Gy and 
delayed the onset of radiation-induced death from 15 to 18 weeks99.
concLusIon
Sphingolipids play an important role in many biological processes, including apoptosis 
and proliferation, inflammation, vascular barrier integrity and smooth muscle cell con-
traction. The actions of S1P promote proliferation and increased vascular barrier integrity, 
whereas ceramide enhances apoptosis and decreases vascular barrier integrity. These 
effects have been shown in a number of human and animal disease models, in relation 
to severe and prevalent diseases such as COPD, BPD, asthma and ARDS. Interventions 
in the sphingolipid pathway aimed at restoring the balance between ceramide and S1P 
levels have produced promising results in animal models and pharmacological strategies 
to restore the balance of S1P and ceramide should now be tested in humans. Studies in 
newborns are specifically required to establish effects in BPD, and this will be a challenge. 
There is good reason to pursue the clinical use of sphingolipid inhibitors, as they may 
offer protection and benefit for patients with a variety of diseases that are associated with 
lung damage and repair, for which limited alternative treatments are available. 
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abstract
Aim: To characterize lung function and broncho-alveolar lavage sphingolipid profile of 
newborn mice during hyperoxia exposure and recovery in room air, and to examine the 
effect of D-sphingosine supplementation during recovery.
Methods: Newborn mice were exposed to 80% O
2
 for 4 weeks and allowed to recover in 
room air for another 4 weeks. Lung function measurements and morphometrical analysis 
of lung tissue were performed and BAL fluid was collected during hyperoxia and recovery 
with and without D-sphingosine supplementation.
Results: Hyperoxia exposure altered lung function, which partially recovered in room air. 
Lungs had fewer and enlarged alveoli which persisted during recovery. Multiple sphingo-
lipids were significantly increased after hyperoxia. Ceramides were increased after 2 weeks 
of recovery, but normalized to control values after 4 weeks. Addition of D-sphingosine 
during the first 5 days of recovery accelerated the normalization of ceramide levels at 2 
weeks and partially reversed the hyperoxia-induced increase in alveolar size and arrest in 
alveolarization at 4 weeks.
Conclusion: Exposure of newborn mice to hyperoxia caused restrictive and obstructive 
lung function changes that partially recovered in room air, while alveolar morphology 
remained abnormal. Hyperoxia increased ceramide levels, with normalization after re-
covery. D-sphingosine addition during recovery reduced ceramide levels and ameliorated 
hyperoxia-induced alveolar arrest.
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IntroductIon
Respiratory Distress Syndrome (RDS) in preterm infants is often managed by mechani-
cal ventilation and supplemental oxygen. This occurs in the setting of an immature, 
surfactant-deficient lung, devoid of anti-oxidant defenses. A subset of survivors develop 
Bronchopulmonary Dysplasia (BPD)1, originally characterized by parenchymal fibrosis, 
edema, vascular changes and persistent inflammation. Advances in neonatal care, includ-
ing exogenous surfactant, prenatal steroids, better nutritional management and new 
modes of ventilation have improved survival of infants with very low birthweight (VLBW). 
However, these VLBW infants are prone to develop ‘new BPD’ with fewer and larger alveoli 
as a result of interrupted septation and abnormal vascular organization2. Even though 
progress has been made in the management of infants with BPD, current treatment re-
mains symptomatic.
 
Studies looking at the hyperoxia-induced model of BPD are numerous, but to this date 
no studies have examined the influence of sphingolipids in this model. Sphingolipids 
are important structure-bearing constituents of the cell membrane which also function 
as regulatory molecules of cell proliferation and cell death, endothelial barrier function, 
angiogenesis, and immune response3. Altered sphingolipid levels have been found in a va-
riety of diseases, such as atherosclerosis, chronic heart failure4,asthma5, diabetes, sepsis, 
cystic fibrosis and COPD6. Two sphingolipids, ceramide and sphingosine-1-phosphate 
determine the pro- and anti-apoptotic balance7. In this ‘rheostat’, ceramide stimulates 
apoptosis and cell cycle arrest, and sphingosine-1-phosphate stimulates cell survival and 
proliferation. Increased apoptosis has been found in epithelial cells of BPD patients8 and 
in animal models of BPD9 and total lung ceramide levels are upregulated in hyperoxia-
exposed neonatal rats10. To date, no detailed analysis of the sphingolipid metabolome has 
been reported in the hyperoxia-induced BPD model11. Furthermore, little is known about 
the evolution of lung injury in murine models of BPD. Mice exposed to >60% oxygen dur-
ing the first days of life showed lung function abnormalities that persisted until 67 weeks 
of age12, but the precise evolution of lung function during the acute phase of hyperoxic 
injury, followed by recovery in room air, has not been examined.
The objective of our study was to determine the evolution of lung function and sphingolip-
ids in hyperoxia-exposed newborn mice during both the acute hyperoxic phase and during 
recovery in room air. In addition, we studied the effect of pharmacological intervention on 
hyperoxia-induced lung damage by D-sphingosine supplementation during the recovery 
phase.
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materIaLs and methods
animals
C57BL/6 mice were obtained from Charles River (St. Constant, Quebec, Canada) and ani-
mal studies were conducted according to criteria established by the Canadian Council for 
Animal Care and approved by the Animal Care and Use Committee of the Hospital for Sick 
Children, Toronto, ON, Canada. 
hyperoxia-induced bpd
We used a modified hyperoxia model as described by Warner et al.13. Two pathogen-free 
timed pregnant C57BL/6 mice gave birth in room air. At postnatal day 1, the mothers and 
their pups were placed in paired Oxycycler exposure chambers (Biospherix Ltd, Lacona, 
NY). Litters were exposed to hyperoxia (80% O
2
) or room air for 28 days. Litter sizes were 
kept at 6 pups in both the hyperoxia and room air groups. Dams were switched daily. Oxy-
gen exposure was maintained for 28 days, after which the mice had gained enough weight 
to perform lung function measurements. Hyperoxia-treated litters were then exposed to 
room air for 7, 14 or 28 days. Room air control litters were treated in the same manner. 
D-sphingosine (Sigma-Aldrich) was administered daily (1.25 µg per g bodyweight, ip) to a 
subset of hyperoxia-treated litters during the first 5 days of recovery in room air. Control 
animals were treated with D-sphingosine in the same manner. At various times during 
these conditions, lung function was assessed, broncho-alveolar lavage (BAL) was per-
formed, and tissues was processed for histology (Supplementary figure S1).
Lung function measurements
Twenty-eight days after the start of hyperoxia, the Flexivent rodent ventilator (Scireq, Mon-
treal, Canada) was used to assess lung function as described in detail in the supplemen-
tary methods section. For the long-term follow-up experiments of hyperoxic mice in room 
air, mice were subjected to lung function measurements at postnatal day 35, 42 and 56.
bronchoalveolar lavage
Lungs were infused through the endotracheal tube with 600 µl sterile saline, followed by 
withdrawal and re-infusion two more times14,15. The collected fluid was centrifuged at 1400 
g for 8 minutes. The supernatant was collected in a siliconized eppendorf tube and stored 
at -80oC for mass spectrometry analysis.
measurement of sphingolipids 
Sphingolipid levels in BAL were measured as described in the supplementary methods 
section.
histology and morphometry
Following lung function measurements, the lungs were pressure inflated and processed 
for histology and morphometry as described in the supplementary methods section.
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statistics
All values are expressed as mean ± standard error of the mean, assuming a normal distri-
bution (Sigmaplot version 11 for Windows). Differences were assessed by Student’s t-test 
or, for comparison of three or more groups, by one-way analysis of variance followed by 
Tukey HSD comparison. Significance was inferred as p<0.05.
resuLts
Lung function measurements
In newborn mice exposed to 28 days of hyperoxia, Flexivent measurements revealed a 
significant increase in resistance and reduced compliance, total lung capacity, and forced 
vital capacity compared to controls (Figure 1A, Table 1). Long term follow-up of hyperoxia-
exposed mice showed recovery of lung function parameters to control levels after 1 week 
of recovery in room air. Total lung capacity, static and dynamic compliance took 2 weeks 
to normalize (Figure 1B). However, forced expirations remained abnormal during the 4 
weeks of recovery in room air. Flow-volume curves at 0 and 4 weeks of recovery showed 
persistent obstructive abnormalities with improvement of volume (Supplementary figure 
S2, Table 1). Addition of D-sphingosine during recovery in room air did not significantly 
improve lung function.
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Figure 1. Lung function measurements after 4 weeks of hyperoxia-exposure (A) and during recovery in room air 
(B) of hyperoxia-exposed mice and room air controls (n=12 per group for the 28 days’ timepoint except for MEF 
and PEF where n=8. n=6 for the 35, 42 and 56 days’ timepoints). Data are expressed as mean ± SEM. * = p<0.05, 
** = p<0.001.
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sphingolipid measurements
Sphingolipid levels in BAL by LC-MS/MS are shown in Tables 2-4. A significant increase in 
multiple sphingomyelin and ceramide species was found after 2 and 4 weeks of hyperoxia 
exposure (Figure 2, Table 2). In particular, long chain ceramides (Cer16:0 and Cer18:0) 
and very long chain ceramides (Cer24:0 and Cer24:1) were greatly elevated (Figure 2, Table 
2). Small, but significant increases were also found in sphinganine and a few dihydrocer-
amides, both precursors of ceramides formed by the de novo pathway. All four major sphin-
gomyelins (SM16:0, SM18:0, SM24:0, SM24:1) showed 2-4 fold increases after hyperoxia 
exposure. Following 2 weeks of recovery in room air, all sphingomyelin species in the BAL 
of the hyperoxia-treated group returned to control levels, but many ceramide species were 
still significantly elevated compared to controls (Figure 2, Tables 3 and 4). Treatment with 
D-sphingosine accelerated the normalization of ceramides in room-air (Figure 3, Tables 3 
and 4).
histological analysis
Compared to room air controls (Figure 4A), histological sections of hyperoxia-exposed 
lungs (Figure 4B) showed a homogeneous pattern of decreased alveolar septation, 
table 2. Sphingolipids in bronchoalveolar lavage at 14 and 28 days of hyperoxia exposure.
sphingolipid exposure time 14 days exposure time 28 days
room air hyperoxia room air hyperoxia
Sphinganine 0.31 (0.27-0.37) 0.15 (0.13-0.22) * 0.32 ± 0.07 0.34 ± 0.10
Sphingosine 1.24 ± 0.27 0.66 ± 0.18 ** 0.79 ± 0.17 1.64 ± 0.30 **
Ceramide 16:0 4.35 ± 1.08 2.43 ± 0.83 ** 3.75 (3.61-4.17) 37.28 (24.52-44.05) *
Ceramide 18:0 0.99 (0.92-1.17) 1.12 (0.95-1.21) 1.06 (0.93-1.17) 3.07 (2.38-3.49) **
DihydroCeramide 18:0 0.12 (0.09-0.18) 0.10 (0.08-0.14) 0.18 (0.12-0.23) 0.29 (0.26-0.42) *
Ceramide 20:0 0.47 (0.41-0.56) 0.54 (0.51-0.64) * 0.60 (0.55-
0.70) 
1.91 (1.68-2.32) **
Ceramide 22:0 2.91 (2.56-3.26) 2.34 (2.22-2.94) 4.08 (3.50-
4.93) 
7.47 (7.03-9.50) *
Ceramide 24:0 7.74 (7.31-8.81) 7.48 (6.72-9.03) 18.66 (15.59-20.99) 32.49 (26.7-39.29) **
Ceramide 24:1 9.65 (8.93-10.80) 10.72 (9.55-
13.42) 
14.75 ± 7.11 38.81 ± 8.96 **
DihydroCeramide 24:0 0.37 (0.33-
0.43) 
0.40 (0.28-0.53) 0.79 (0.73-
1.12) 
1.72 (1.42-1.90) 
* 
Sphingomyelin 16:0 156.5 (152.6-168.3) 237.6 (207.5-281.5) ** 219.3 (196.9-248.3) 708.0 (511.6-757.7) **
Sphingomyelin 18:0 10.29 (9.51-11.13) 20.05 (15.8-25.0) ** 13.50 (12.17-
15.96) 
47.75 (33.73-53.61) **
Sphingomyelin 24:0 38.93 (36.91-41.58) 78.64 (62.19-110.09) ** 82.00 (66.70-92.07) 273.00 (244.20-351.00) 
**
Sphingomyelin 24:1 105.1 (100.5-114.1) 245.0 (187.4-322.0) ** 137.2 (112.7-167.6) 806.4 (501.7-903.3) **
BAL fluid from 12 mice per group was collected and sphingolipids were quantified by LC-MS/MS. Results are expressed in ng / 200µl of BAL 
fluid. * = p<0.05, ** = p<0.001 when compared to control animals at the same time-point.
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table 3. Sphingolipid measurements after D-sphingosine supplementation at 1 week of recovery.
sphingolipid room air for 35 days room air+ 7 
days room air + 
d-sphingosine
hyperoxia+ 7 days 
room air
hyperoxia+ 7 
days room air 
+d-sphingosine
Sphinganine 0.38 ± 0.04 0.39 ± 0.05 0.54 ± 0.14 0.65 ± 0.15 * 
Ceramide 16:0 11.65 (11.51-13.19) 15.43 (13.43-16.46) 23.04 (19.91-25.99) * 23.46 (17.45-28.41) *
Ceramide 18:0 1.26 ± 0.24 1.30 ± 0.13 2.26 ± 0.34 * 1.95 ± 0.54
DihydroCeramide 18:0 0.11 ± 0.01 0.15 ± 0.07 0.23 ± 0.10 0.34 ± 0.29
Ceramide 20:0 0.63 ± 0.14 0.66 ± 0.11 1.26 ± 0.19 * 1.03 ± 0.29
Ceramide 22:0 3.57 ± 0.64 3.94 ± 0.58 5.81 ± 0.10 * 5.02 ± 1.33
Ceramide 24:0 10.97 ± 2.08 12.44 ± 0.91 21.89 ± 1.32 * 20.43 ± 6.25 *
Ceramide 24:1 10.83 ± 1.26 12.72 ± 1.79 19.67 ± 1.36 * 20.20 ± 5.81 *
DihydroCeramide 24:0 0.39 ± 0.11 0.48 ± 0.03 0.75 ± 0.02 * 0.80 ± 0.09 *
Sphingomyelin 16:0 208.25 ± 17.24 263.87 ± 27.13 458.93 ± 67.89 * 408.40 ± 113.22 *
Sphingomyelin 18:0 8.07 ± 0.99 9.93 ± 1.91 30.15 ± 4.88 * 20.35 ± 7.89 *
Sphingomyelin 24:0 40.83 ± 3.60 51.28 ± 15.89 169.73 ± 30.46 * 119.80 ± 45.65 *
Sphingomyelin 24:1 82.66 ± 9.98 101.71 ± 25.85 270.85 ± 25.53 * 232.93 ± 63.17 *
BAL fluid from 3 mice per group was collected and sphingolipids were quantified by LC-MS/MS. Results are expressed in ng / total amount 
of BAL fluid per mouse. * = p<0.05, ** = p<0.001 when compared to the room air controls at the same time-point.
table 4. Sphingolipid measurements after D-sphingosine supplementation at 2 weeks of recovery.
sphingolipid room air for 42 days room air+ 14 
days room air + 
d-sphingosine
hyperoxia+ 14 days 
room air
hyperoxia+ 14 
days room air 
+d-sphingosine
Sphinganine 0.50 ± 0.10 0.47 ± 0.09 0.46 ± 0.08 0.47 ± 0.09
Ceramide 16:0 12.85 ± 1.51 13.27 ± 1.04 18.70 ± 5.20 15.71 ± 0.48
Ceramide 18:0 1.11 ± 0.11 1.32 ± 0.11 1.87 ± 0.42 * 1.59 ± 0.09
DihydroCeramide 18:0 0.22 ± 0.17 0.14 ± 0.01 0.19 ± 0.08 0.14 ± 0.02
Ceramide 20:0 0.56 ± 0.07 0.63 ± 0.07 0.92 ± 0.21 * 0.84 ± 0.13
Ceramide 22:0 3.23 ± 0.39 3.92 ± 0.50 4.72 ± 0.99 * 4.71 ± 0.26 *
Ceramide 24:0 11.28 ± 1.05 11.28 ± 1.13 19.69 ± 5.04 * 17.03 ± 0.97
Ceramide 24:1 10.52 ± 1.29 11.52 ± 0.96 17.78 ± 4.40 * 15.45 ± 1.06
DihydroCeramide 24:0 0.33 ± 0.04 0.41 ± 0.05 0.84 ± 0.20 * 0.71 ± 0.34
Sphingomyelin 16:0 283.7 ± 38.1 254.2 ± 24.08 319.3 ± 90.74 278.3 ± 38.9
Sphingomyelin 18:0 10.24 (9.69-11.6) 9.18 (8.52-9.52) 11.50 (8.24-15.80) 9.37 (8.54-9.98)
Sphingomyelin 24:0 48.60 (3.29-49.72) 39.69 (37.14-42.49) 55.60 (37.60-71.05) 49.02 (44.34-54.46)
Sphingomyelin 24:1 110.5 (107.7-111.3) 105.6 (93.0-106.1) 176.2 (123.2-218.0) 115.5 (110.3-118.5)
BAL fluid from 3 mice per group was collected and sphingolipids were quantified by LC-MS/MS. Results are expressed in ng / total amount 
of BAL fluid per mouse. * = p<0.05, ** = p<0.001 when compared to room air controls at the same time-point.
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Figure 2. Representative sphingolipid measurements performed during hyperoxia treatment and recovery in 
room air. Results represent a total of 12 mice per group for the 14 and 28 days’ time-points in hyperoxia and 3 
mice per group for the 35,42 and 56 days’ time-points of recovery in room-air Cer: ceramide, SM: sphingomyelin. 
* = p<0.05, ** = p<0.001, when compared to room air treated mice at the same time-point.
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Figure 3. Representative sphingolipid measurements after 1 and 2 weeks recovery in room-air with and 
without D-sphingosine (DS) treatment. Results represent a total of 12 mice per group for 28 days’ time-point 
in hyperoxia and 3 mice per group for the 35, 42 and 56 days’ time-points of recovery in room-air and the 
D-sphingosine supplementation experiments. Cer: ceramide, SM: sphingomyelin. Grey * represents a significant 
change in hyperoxia treated mice when compared to normoxia treated mice at the same time-point. Black * 
represents a significant change in hyperoxia + DS treated mice when compared to normoxia + DS treated mice 
at the same time-point. * = p<0.05, ** = p<0.001. 
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Figure 4. Effect of hyperoxia and subsequent room air recovery on lung histology.  Representative histological 
sections of room air-exposed newborn mice (A), hyperoxia-treated newborn mice after 4 weeks of exposure 
(B) and hyperoxia-treated newborn mice that were allowed to recover for another 4 weeks in room-air (C) are 
shown. Sections were stained with hematoxylin and eosin. Morphometry results (D) are expressed as mean ± 
SEM for both room air and hyperoxia groups for mean linear intercept (n=8), radial alveolar counts (n=8), and 
alveolar number (n=4). Morphometry results for 4 weeks of recovery in room-air (E) are expressed as mean 
± SEM for mean linear intercept (n=4) and radial alveolar count (n=3). * = p<0.05 ** = p<0.001. (See colour 
section, page 185).
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compared to room air-exposed newborn mice. Morphometry demonstrated a significant 
increase in mean linear intercept, a reduction in radial alveolar count and in the number 
of alveoli. Lung sections of mice exposed to 4 weeks of hyperoxia and allowed to recover 
in room air (Figure 4C) showed fewer and enlarged alveoli when compared to room air 
controls. No significant difference in mean linear intercept and radial alveolar count was 
noted at 1, 2 and 4 (Figure 4E) weeks of recovery in room air. Interestingly, when com-
pared to hyperoxia-exposed non-treated mice (Figure 5A), mice treated with D-sphingo-
sine for 5 days immediately after hyperoxia exposure (Figure 5B) had a significantly lower 
mean linear intercept and higher radial alveolar count (Figure 5C) at 2 weeks of recovery 
in room air. Mean linear intercept and radial alveolar counts of hyperoxia-exposed and 
D-sphingosine-treated mice did not return to control levels.
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Figure 5. Effect of D-sphingosine supplementation on lung histology. Representative histological lung sections 
are shown after 4 weeks of hyperoxia exposure followed by 2 weeks of room air recovery (A), and 4 weeks of 
hyperoxia exposure followed by 2 weeks of room air recovery with D-sphingosine supplementation (B). Sections 
were stained with hematoxylin and eosin. High power inserts were taken at 200x magnification. Morphometry 
results (C) represent a total of 3 mice per group and are expressed as mean ± SEM for all groups. * = p<0.05. (See 
colour section, page 186).
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dIscussIon
In this study we examined BAL sphingolipid levels, lung function and histology in 
newborn mice during hyperoxia exposure and after recovery in normoxia. Our findings 
showed that 4 weeks of hyperoxia exposure causes alveolar damage and obstructive lung 
function abnormalities, together with increased sphingolipid levels, including ceramides. 
We demonstrated normalization of ceramides and partial improvement of lung function, 
but found no improvement in histological abnormalities within 4 weeks of recovery in 
room air. D-sphingosine supplementation during normoxic recovery accelerated ceramide 
normalization and improved hyperoxia-induced alveolar arrest, but did not affect lung 
function.
In our hyperoxia model, the increased airway resistance, decreased mean forced expiratory 
flow and forced expiratory volume could be caused by airway remodelling as a conse-
quence of ongoing inflammation13. The observed changes in lung function are similar to 
those reported for newborn mice after 14 days of 85% oxygen exposure16. Another possible 
explanation for the lung function changes is a reduced number of alveolar attachments 
leading to decreased radial traction, which would result in airway narrowing and earlier 
airway collapse during expiration17. Prolonged exposure to hyperoxia in newborn mice 
caused an arrest in alveolarization, thereby delaying the formation of secondary septa, 
reducing alveolar number and increasing alveolar wall thickness. In the present study, this 
decrease in alveolarization was reflected in the radial alveolar counts. 
At the end of 4 weeks hyperoxia exposure, we observed a combined obstructive and 
restrictive pattern that shifted to an obstructive pattern at the end of 4 weeks recovery in 
room air. The persistent abnormal forced expiration measurements, as well as the abnor-
mal morphology after 4 weeks in room air indicate incomplete recovery and a permanently 
altered lung structure. Velten et al. studied newborn mice exposed to 85% O
2
 for 14 days, 
which recovered for 14 days in room air, and these newborns developed an increased 
resistance at 14 days, followed by an increased compliance of the lungs at 28 days16. Yee 
et al. noted a reduced compliance after 4 days of 100% O
2
 exposure in newborn mice, and 
an increased compliance at 67 weeks of age12. They speculated that the transient decrease 
in compliance during the acute phase of hyperoxic injury was due to pulmonary edema, 
impaired surfactant protein-C production and pro-inflammatory free oxygen radicals. 
Both studies seemed to indicate that the response of the newborn lung to hyperoxia can 
be divided into two stages: acute lung injury characterized by a less compliant lung, and 
chronic lung injury, characterized by a more compliant lung. Our measurements after 
4 weeks of recovery could reflect an intermediary phase, between acute and long term 
hyperoxia-induced lung injury, in which edema and inflammation decreases, and the lung 
becomes more compliant. We observed partial recovery of lung function, but no appar-
ent recovery in morphology after 4 weeks of recovery in room air. This emphasizes the 
importance of obtaining both structural and physiological data when tracking changes 
in disease state or monitoring the effects of an intervention. The persistence of morpho-
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logical abnormalities in our mouse model is in line with the abnormalities seen in adult 
survivors of BPD18,19, and the persistent abnormal lung function parameters are consistent 
with results of lung function measurements performed in human survivors of BPD20,21, 
making this model a good choice for intervention studies aimed at repairing hyperoxia-
induced lung damage.
Ceramides play an important role in apoptosis and lung inflammation22,23. Kolliputti et al. 
recently showed that ceramides regulate endothelial permeability and the inflammatory 
process caused by hyperoxia in adult mice24. Ceramides have long been known to medi-
ate acute lung injury by increasing alveolar permeability and proinflammatory cytokine 
production25, but no studies have reported detailed ceramide profiles in neonatal hyperox-
ia-induced lung damage and during recovery in room air. Our study shows that multiple 
ceramide and sphingomyelin species are increased during exposure of neonatal pups to 
hyperoxia. Long chain ceramides (Cer16:0, Cer18:0, Cer20:0) have anti-proliferative and 
pro-apoptotic effects26, whereas very long-chain ceramides (Cer22:0, Cer24:0, Cer24:1) 
promote cell proliferation27. We observed an 8-fold increase in long chain Cer16:0 dur-
ing hyperoxia, suggesting a role for increased apoptosis via ceramide signaling in this 
hyperoxia model. Indeed, increased apoptosis has been observed in the lungs of mice and 
rats exposed to hyperoxia28–30, similar to the findings in autopsy lungs of BPD patients31. 
Very long chain(24:0, 24:1) ceramides demonstrated a 2-3 fold increase in our model, sug-
gesting a role for proliferation, possibly of smooth muscle cells, which have been shown 
to proliferate in rat and mouse models of hyperoxia-induced BPD12,29,32. Both ceramides 
and sphingomyelin levels were increased, suggesting that the increase in ceramides is not 
caused by breakdown of sphingomyelin via sphingomyelinase. The increased sphingo-
sine levels (Table 2) may indicate increased ceramide formation via the salvage pathway, 
although the general increase in most sphingolipids argued against activation of that 
pathway. Based on the observation that both sphinganine and dihydroceramides were 
increased (Table 2), we hypothesize that hyperoxia activates the pulmonary de novo path-
way of ceramide synthesis in the newborn. Further studies focusing on the activity of the 
rate-limiting enzyme serine palmitoyltransferase would be needed to confirm the increase 
in the de novo synthesis.
Long chain ceramides have been shown to increase the permeability of endothelium33, 
which causes endothelial leakage34 and might contribute to the reduced compliance of 
the lungs seen in our hyperoxia model. We postulate that reduced forced expiratory flows 
might be related to structural changes, such as a reduced number of alveolar attachments, 
and remained low during air recovery. In contrast, resistance and compliance may be 
determined by reversible factors in the lung, such as inflammation and endothelial leak-
age. Our study shows that sphingolipid levels, including ceramides, returned to normal 
within 4 weeks of recovery in room air, corresponding to the time course of lung func-
tion changes. It may well be that when the primary stress factor (hyperoxia) disappears 
during recovery in room air, leading to a decrease in sphingolipids, lung inflammation 
and edema, resulting in partial recovery of lung function. However, no additional effect of 
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D-sphingosine supplementation on partial lung function recovery was observed. Note that 
sphingolipid levels were measured in BAL, providing a good estimate of the sphingolipid 
metabolism in the broncho-alveolar compartment, but they may not represent sphingo-
lipid metabolism in the interstitial and vascular compartment. Further research into the 
complexity of the interaction between these different compartments is warranted.
Treatment with D-sphingosine significantly decreased ceramide levels after 1 and 2 weeks 
of recovery in room air. Lung morphometry showed an improvement of mean linear 
intercept and radial alveolar count after 4 weeks of recovery in the D-sphingosine-treated 
animals compared to untreated control mice. These findings suggest that D-sphingosine 
supplementation had a beneficial effect on the alveolar injury caused by hyperoxia expo-
sure, and that lower ceramide levels might be responsible for this improvement in alveolar 
histology. A reduction in the amount of apoptosis is the most likely mechanism by which 
D-sphingosine acts, but further experiments are needed to confirm this hypothesis. 
No obvious beneficial effects on lung function were found, which could well be due to 
imperfect agreement between measures of lung structure and function. The incomplete 
recovery of histology, sphingolipid levels and lung function after D-sphingosine treatment 
and the absence of a significant difference in these parameters between hyperoxic mice 
with and without D-sphingosine might be due to dose and/or timing of the supplemen-
tation, or might have been missed due to a relatively small number of observations. Our D-
sphingosine dose was based on a study by Diab et al. who showed that adult mice injected 
with D-sphingosine at 20µg per mouse for 5 consecutive days had significantly increased 
sphingosine-1-phosphate (a pro-survival sphingolipid) levels in homogenized lung tissue 
at day 5 after the start of administration35. The administration of D-sphingosine in our 
model started after hyperoxia exposure and lasted for 5 days. It is possible that earlier or 
longer supplementation might yield better results.
One could argue that prevention of damage by adding D-sphingosine at an earlier time 
point would be preferable. We decided for another approach, as currently there are no 
reliable predictors to indicate which infant will develop BPD, making it difficult to target 
preventative treatment to those who might benefit. Therefore, we supplemented D-sphin-
gosine only during the recovery phase to see if this might stimulate repair of hyperoxia-
induced damage.
In summary, we demonstrated that hyperoxia in the newborn mouse lung caused a tran-
sient increase of sphingolipids, including ceramides, which returned to normal during 
recovery in room air, while histology remained abnormal. The time course of sphingolipid 
reduction during recovery matched the normalization of airway resistance and compli-
ance. Importantly, D-sphingosine supplementation during recovery accelerated the 
normalization of ceramides, and significantly improved hyperoxia-induced lung damage. 
We propose that D-sphingosine and other inhibitors of bioactive sphingolipids should be 
studied further for their potential to reduce lung damage in human preterm infants who 
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require neonatal oxygen treatment. The ultimate goal would be to develop a new strategy 
to prevent or correct bronchopulmonary dysplasia.
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suppLementary methods
Lung function measurements
Animals were anesthetized with an ip injection of Ketamine (150 mg/kg) and Xylazine (10 
mg/kg) before tracheostomy. A 25G endotracheal tube was inserted and sutured in place 
to prevent leakage. After intraperitoneal injection of Pancuronium (5 mg/kg) the animal 
was ventilated at 150 breaths/min with a tidal volume of 10 mL/kg and lung function was 
measured using the Flexivent ventilator (SCIREQ, Montreal, QC, Canada). The flexivent 
measures flow-volume relations of the respiratory system and uses forced oscillations to 
discriminate between the airways and the alveolar compartment. The “Total Lung Ca-
pacity” (TLC), “Snapshot” (based on single-compartment model), and “Primewave-8” 
(based on constant phase model) perturbations were used to measure lung function. For 
the “TLC” maneuver, the lung is inflated to +30 cmH
2
O and deflated afterwards. For the 
“Snapshot” maneuver, three sinusoidal waves of in- and expiration provide the resis-
tance, elastance and compliance parameters. For the “prime-wave 8”, multiple frequency 
forced oscillations were applied which result in the tissue elasticity and airway resistance 
parameters. Volume-driven pressure-volume loops were also obtained and provided the 
total lung capacity, inspiratory capacity from zero pressure and static and dynamic compli-
ance. All measurements were repeated until 4 successful recordings with a coefficient 
of determination of >0.95 were obtained. Animals also underwent forced expirations by 
inflating to TLC and then rapidly applying a negative pressure of -55 cmH
2
O to the expira-
tory valve. In the current state of small animal ventilator technology, this technique is the 
closest to mimicking forced expiratory spirometry in humans. Parameters obtained from 
this maneuver were the forced vital capacity, mean forced expiratory flow, peak forced 
expiratory flow and forced expiratory flow at 0.05, 0.1 and 0.2 seconds divided by forced 
vital capacity.
measurement of sphingolipids
BAL samples (200 µL), transferred to siliconized glass tubes containing 800 µL ultra-pure 
water, were spiked with a mixture of internal standards (C17 (d18:1/17:0) ceramide, (d17:1) 
sphingosine, (d17:1) sphingosine-1-phosphate and 17:0 (d18:1/17:0) sphingomyelin; 10 
ng of each). After addition of 2 mL of methanol/chloroform (1:1) samples were vortexed, 
centrifuged and the chloroform layer collected. After drying, samples were reconstituted 
in 100 µL ethanol that was acidified with 0.2 mL of formic acid and transferred to sili-
conized minivials for analysis. Liquid chromatography tandem mass spectrometry was 
performed on an Agilent 1200 Series binary pump (Agilent Technologies Inc., Santa Clara, 
CA, USA) coupled to an API4000 triple-quadruple mass spectrometer (SCIEX, Concord, 
ON, Canada). Prior to analysis, Multiple Reaction Monitoring (MRM) mass transition 
parameters were optimized by infusion of pure standards (5 µl/min of 1 µg/mL). Reverse 
phase high performance liquid chromatography (HPLC) was performed using a Kinetex 
C18 column (Phenomenex, Torrance, CA, USA). Sample injection volume was 1-5 µL. The 
mobile phase consisted of (A) water/acetonitrile/methanol (2/1/1, v/v/v) and (B) tetrahy-
drofuran/acetonitrile/methanol (2/1/1, v/v/v) with both components containing 0.05% 
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formic acid. At a flow of 400 µL/min the HPLC gradient was as follows: initial conditions 
of 60:40 (A:B) were held for 4.5 min prior to injection, then held for another 2 min post 
injection and ramped to 15:85 (A:B) over 13 min. Conditions were held for 15 min and then 
returned to initial conditions. MS analysis was performed in positive electrospray Ioniza-
tion mode. The source temperature was maintained at 400°C with the ion spray voltage set 
at 5,000 V and nitrogen used as the Collision Induced Dissociation gas (Table 5 shows the 
MRM mass transitions and chromatographic retention times). For quantitative analysis a 
separate standard curve was generated for each analyte measured using MRM area ratios 
(Analyte Peak Area/IS Peak Area). Results were then calculated by plotting the sample area 
ratios against their respective analyte standard curve36,37.
table 5. Sphingolipid LC-MS/MS MRM mass transitions and chromatic retention times. 
name mrm mass transition (da) collision energy (ev) retention time (min)
(IS) So (d17:1)
(IS) Sphingosine-d7
So (d18:1) 
Sa (d18:1) 
(IS) So1P (d17:1)
So1P (d18:1)
Cer 8:0 
SM 12:0 
SM (DiHy) 12:0 
Cer 12:0 
(IS) SM 16:0-D31
SM 16:0 
SM 18:1 
(IS) SM 17:0
Cer 14:0 
SM 18:0 
(IS) Cer 16:0-D31
Cer 16:0 
Cer 18:1 
Cer(DiHy) 18:1 
(IS)Cer C 17
Cer 18:0 
SM 24:1 
Cer(DiHy) 18:0 
SM 24:0 
Cer 20:0 
Cer 24:1 
286.400/268.100
307.400/289.500 300.400/282.100
302.400/284.100
366.400/250.100 380.400/264.200
426.600/264.400
647.700/184.100
649.700/184.100
482.600/264.400
734.900/184.200
703.700/184.100
729.700/184.100
717.700/184.100
510.600/264.400
731.700/184.100
569.800/265.500
538.600/264.400
564.600/264.400
566.600/284.500
552.500/264.400
566.600/264.400
813.700/184.500 568.600/284.500
815.600/184.100
594.600/264.400
648.600/264.400
23
19
23
23
30
30
40
40
40
40
80
40
40
40
40
40
36
40
30
30
60
40
40
30
40
40
40
0.95
1.14
1.16
1.32
1.74
2.34
5.59
5.72
5.99
7.19
7.21
7.31
7.47
7.78
8.26
8.38
9.37
9.54
9.78
10.27
10.18
10.69
10.63
10.94
11.27
11.31
11.75
IS: internal standards, Cer: ceramide, Cer (diHy): dehydroceramide, SM: sphingomyelin, So: sphingosine, Sa: sphinganine.
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histology and morphometry
Following lung function measurements, animals were exsanguinated by cutting the 
abdominal aorta while still under anesthesia. After opening the thoracic cavity, heparin 
dissolved in phosphate buffered saline (PBS) was injected into the right ventricle of the 
heart and the lungs were flushed free of blood. A catheter was inserted into the trachea 
to allow 4% (w/v) paraformaldehyde (PFA) to inflate the tissue at a constant pressure of 
20 cm H
2
O. After 5 minutes, the catheter was removed and the trachea tied off. The lungs 
were removed from the thorax as a single block and fixed in 4% PFA overnight. Fixed 
lungs were embedded in paraffin at 60oC. Randomly orientated tissue blocks were cut into 
7 µm sections, stained with hematoxylin-eosin and Hart’s elastin stain, and morphometry 
was performed on digital images taken at x200 magnification. Images were captured from 
5 non-overlapping fields from each slide, with 4 slides per animal. Mean linear intercepts 
(Lm) and radial alveolar count (RAC) was measured and calculated38,39. For alveolar num-
ber determination, 20 randomly selected non-overlapping fields from sections obtained 
from 4 animals per group were examined. Each field was viewed at x200 magnification 
and alveolar number was counted and expressed per mm2 40.
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suppLementary FIgures.
Experimental group
0
Time in days
14 28 35 42
Control group
Experimental group
Experimental treated group
= Hyperoxia
= Normoxia
= D-Sphingosine
= End-point
56
Control treated group
Control group
supplementary figure s1. Time-line of experiments performed to measure lung function, collect BAL, and 
assess histology during hyperoxia exposure and recovery. 
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supplementary figure s2. Example of flow-volume curves after 4 weeks of hyperoxia exposure (A) and 4 
weeks of hyperoxia exposure followed by 4 weeks of room air recovery (B).
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abstract
Aim: The formation of alveoli is a largely postnatal process that involves the development 
of an extensive vascular network. The hypoxia-inducible factor (HIF) family of transcrip-
tional regulators has been implicated in early pulmonary vasculature development. Our 
aim was to investigate whether HIF influences postnatal vascularization and alveologen-
esis in mice, and whether stable (constitutive-active) HIF could prevent hyperoxia-induced 
lung injury.
Methods: We assessed postnatal vessel and alveolar formation in transgenic mice, ex-
pressing a stable, constitutive-active, HIF-1α-subunit (HIF-1αΔODD) in the distal lung 
epithelium. In addition, we compared lung function, histology and morphometry of neo-
natal transgenic and wild type mice subjected to hyperoxia.  
Results: Postnatal lungs of HIF-1αΔODD mice had a greater peripheral vessel density and 
displayed advanced alveolarization compared to control lungs. Stable HIF-1α expression 
was associated with an increased postnatal expression of angiogenic factors including 
vascular endothelial growth factor, angiopoietins 1 and 2, Tie2, and EphrinB2 and EphB4. 
Hyperoxia-exposed neonatal HIF-1αΔODD mice exhibited worse lung function and 
abnormal surfactant composition but had similar histological abnormalities compared to 
hyperoxia-exposed wild-type controls.
Conclusion: Expression of constitutive-active HIF-1α in the lung epithelium stimulated 
postnatal vessel growth via upregulation of angiogenic factors. The increase in postnatal 
vasculature was accompanied by enhanced alveolar formation. However, stable HIF-1α ex-
pression did not prevent hyperoxia-induced lung injury in neonates but instead worsened 
lung function due to alterations in surfactant composition.
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IntroductIon
Interaction between airways and blood vessels is critical for lung development1,2. Early 
lung development occurs in a relatively hypoxic environment in utero3. This low oxygen 
environment is beneficial for pulmonary vascular development and is mediated via the 
hypoxia-inducible factor (HIF) family of transcriptional regulators1,2. Growth and matura-
tion of the capillary network is vital for creating a proper blood-air barrier and to make 
gas exchange possible. Alveoli are formed through the process of septation, whereby 
secondary septa emerge from existing primary septa4. The capillary layer from the primary 
septum is pulled into the newly formed secondary septum and therefore the new sep-
tum contains a double capillary layer, which is later reduced to a single capillary layer5. 
Although birth is often considered the end of organogenesis and the start of growth and 
maturation, the development and maturation of alveoli in humans and most other mam-
mals is largely a postnatal process. Impaired septation has been observed as one of the 
consequences of neonatal pulmonary damage in preterm newborns, called Bronchopul-
monary Dysplasia (BPD)6. Important features of BPD are decreased alveolarization and 
abnormal vessel growth7,8. Furthermore, patients suffering from BPD have low levels of 
pulmonary vascular endothelial growth factor (VEGF)9. Indeed, pharmacological blockade 
of VEGF signaling impairs postnatal lung development in newborn rats10. Hyperoxia expo-
sure in newborn mice has been used to replicate the characteristic alveolar arrest seen in 
BPD11, and is used to study the pathogenesis and pathophysiology of BPD12,13 and develop 
potential treatments14–16. For instance, VEGF gene therapy improved vascular development 
and prevented hyperoxia-induced BPD in newborn rats14. VEGF is a target gene for HIF 
and pharmacological HIF stabilization has been shown to increase the expression of VEGF 
and to stimulate angiogenesis17–20. Thus, strategies aimed at increasing HIF are of major 
interest as a way to potentially improve the outcome of early lung injury in prematures.
The HIF family consists of heterodimers comprised of one of three alpha subunits and 
a beta subunit. The most extensively studied isoform of the three α-subunits is HIF-1α. 
HIF-1α is a highly conserved transcription factor present in almost all human organs and 
cell types21. HIF-1α controls up to 500 genes, many of these being involved in endothe-
lial cell proliferation and survival20. Under normoxic conditions the α-subunit is rapidly 
hydroxylated and targeted for proteosomal degradation22. Since oxygen regulates the 
interaction between airways and vessels during development via HIF1,2, we investigated 
whether expression of a stable (constitutive-active) HIF-1α in the developing lung epi-
thelium during postnatal lung development would result in accelerated vascularization 
and alveolarization23. Furthermore, since decreased levels of HIF-1α have been found in 
BPD17,24 we investigated whether stable expression of HIF-1α during postnatal hyperoxia 
exposure could promote alveolarization and prevent or ameliorate the lung damage in a 
hyperoxia-induced BPD model12,13.
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materIaLs and methods
transgenic mice
The human full-length HIF-1α cDNA construct (generous gift of Dr. Semenza, Johns 
Hopkins University) was used as template to generate the HIF-1αΔODD mutant. The 
deletion mutant (HIF-1αΔ
401-603
) was constructed by overlap extension using PCR as previ-
ously described25. The biological activity of the HIF-1αΔODD mutant was confirmed in 
JEG3 and 293T cells using a HIF-responsive reporter construct (Supplementary figure S1). 
Transgenic SFPTC-HIF-1αΔODD (C57BL/6 X SJL) F2 embryos were generated according 
to Hogan et al26. Mice were bred according to a protocol approved by the Animal Care and 
Use Committee of the Hospital for Sick Children.
hyperoxia-induced bpd model
We used a modified hyperoxia model as described previously27. Briefly, two pathogen-
free timed pregnant C57BL/6 and two HIF-1αΔODD mutant mice gave birth in room air. 
At postnatal day 1, the mothers and their pups were placed in paired Oxycycler exposure 
chambers (Biospherix Ltd, Lacona, NY). Litters were exposed to hyperoxia (80% O
2
) or 
room air. Litter sizes were kept at 6 pups in both the hyperoxia and room air groups. Dams 
were switched daily. Oxygen exposure was maintained for 28 days, after which the mice 
had gained enough weight to perform lung function measurements and histology.
Lung function measurements
Twenty-eight days after the start of hyperoxia, the Flexivent rodent ventilator (Scireq, Mon-
treal, Canada) was used to assess lung function as described previously27. 
Immunostaining, immunoblotting and quantitative rt-pcr (qpcr)
Lungs were fixed under constant inflation at 10 cm H
2
O. Immunostaining was performed 
using the avidin-biotin (ABC) immunoperoxidase method28. Immunoblotting was per-
formed as previously described29 on lysates of nuclei (Nuclear enrichment kit, Pierce). 
qPCR was carried out as described in the supplementary methods section.
morphometric analysis of paraffin-embedded lung
All morphometric assessments were performed on the right middle lobe. The lungs were 
embedded in paraffin wax, cut in 5 µm sections and stained with haematoxylin and eosin. 
Morphometric assessments were performed on coded images to mask control and trans-
genic lungs. Digital images were captured using a Leica digital imaging system (Leitz, 
Wetzlar, Germany) at 20X magnification with random sampling of all tissue in an unbi-
ased fashion. Images of 10 non-overlapping fields from each slide, with 3 slides/animal, 
and 5 animals per group were captured. Tissue fractions and secondary crests densities 
were measured as previously described30. Mean linear intercepts (Lm) were measured 
and calculated as described by Dunnill31. Radial alveolar counts (RAC) were performed 
as described by Cooney32. Alveolar surface area per unit lung volume were calculated as 
described by Kawakami and coworkers33. Slides were stained for elastin to enhance recog-
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nition of vessels after wich the number of small vessels (diameter range 20 to 65 µm) per 
field was assessed. Average values were calculated for 10 images per slide, and the average 
value for the 3 slides was used to calculate an average value for each animal.
Light- and electron microscopy of resin-embedded lung
Postnatal lung tissues were fixed under constant inflation at 10 cm H
2
O and processed for 
electron microscopy as previously described34. Alveolar vessel and lipid-laden interstitial 
cell density was determined as described in the supplementary methods section.
statistical analysis
All values are presented as mean ± SEM. Statistical significance was determined by one 
way ANOVA, followed by post hoc analysis using Duncan’s multiple range test where 
significant differences were found between groups (JMP software); a value of p<0.05 was 
inferred as statistically significant. A more detailed description of all methods can be 
found in the supplementary methods section.
resuLts
hIF-1α expression
In control mice, pulmonary expression of mouse HIF-1α mRNA remained stable between 
embryonic day 18.5 and postnatal day 21 (Figure 1A). In contrast, pulmonary levels of total 
(mouse plus human) HIF-1α mRNA were significantly increased (>15-fold) in E18.5 HIF-
1αΔODD mice. The total amount of HIF-1α mRNA decreased postnatally in the trans-
genic mice, but it remained significantly greater (>3-fold) than that of C57BL/6 control 
lungs as a result of Sftpc-driven expression of human HIF-1αΔODD in the transgenes 
(Figure 1B). Immunohistochemical analysis revealed that HIF-1α protein was upregulated 
in the distal epithelial type II cells of transgenic lungs when compared to control lungs 
during all postnatal ages (Supplementary figure S2). Western blot analysis corroborated 
these findings and further showed that the immunoreactive product was the 80 kDa HIF-
1αΔODD recombinant protein (Figure 2A-top panel).
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vegF expression
Total VEGF expression in C57BL/6 control lungs was constant between E18.5 and post-
natal day 21 (Figure 2B-top panel). The amount of total VEGF mRNA was significantly 
greater in HIF-1αΔODD lungs at all gestational days compared to control lungs. We tested 
the possibility that VEGF isoform expression could be different among the control and 
HIF-1αΔODD lungs. We found that the mRNA expression of the VEGF
188
 isoform was 
specifically increased in the HIF-1αΔODD lungs at all gestational days (Figure 2B-bottom 
panel). Transcript levels for the VEGF
120
 isoform were slightly, but significantly, increased 
at postnatal day 2 and 8, while VEGF
164
 mRNA expression was not altered in the HIF-
1αΔODD lungs. Western blot analysis confirmed an increase in VEGF, migrating as a 23 
kDa protein in SDS-PAGE under reducing conditions, in HIF-1αΔODD lungs at E18.5 and 
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Figure 1. Measurements of total HIF-1α and human HIF-1α∆ODD gene expression in C57 control lungs and 
HIF-1α∆ODD lungs during postnatal development. Levels of (A) total (mouse and human) HIF-1α mRNA and (B) 
human HIF-1α∆ODD in murine postnatal lung, as assessed by real-time qPCR. The number of HIF-1α transcripts 
was significantly greater in HIF-1αΔODD mice, which was due to increased human HIF-1αΔODD mRNA 
expression. Data are expressed as mean ± SEM for 4 lungs in each group. * = p<0.05.
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Figure 2.  Immunoblot analysis of HIF-1α and VEGF gene expression in C57 control lungs and HIF-1α∆ODD 
lungs. (A) Western blot of HIF-1α and VEGF on E18.5 and PN8 lungs. Equal loading and transfer was probed with 
β-actin. (B) Expression of total VEGF mRNA and expression of VEGF188, VEGF164 and VEGF120 mRNA in murine lung, 
as assessed by real-time qPCR. Data are expressed as relative fold changes in expression when compared to 
E18.5 lungs. Data are expressed as mean ± SEM for 4 lungs in each group. * = p<0.05. (See colour section, page 
187).
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postnatal day 8 (Figure 2A-middle panel). VEGFR2 mRNA expression was not affected 
by HIF-1αΔODD overexpression when compared to controls (not shown). Pulmonary 
Angiopoietin(Ang)1, Ang2 and Tie2 mRNA levels were increased at postnatal days 8 and 
14 while transcript levels for EphrinB2 and EphB4 were increased in the transgenic lungs 
at postnatal days 2, 8 and 14 (Supplementary figure S3).
vessel formation
To assess if vascularization was increased in HIF-1αΔODD lungs we counted the number 
of small peripheral vessels (diameter ranging from 20 to 65 µm) and found a significant 
increase in postnatal vessel density in the HIF-1αΔODD lungs compared to the C57BL/6 
control lungs (Figure 3A). In addition, we determined the alveolar vessel density by elec-
tron microscopy. We observed a greater alveolar vessel density in HIF-1αΔODD transgenes 
compared to control C57BL/6 mice at postnatal days 14 and 21 (Figure 3B). Increased 
expression of the endothelial marker CD31 (Pecam-1) at postnatal days 8 and 14 further 
corroborated these findings (not shown).
alveolarization
HIF-1αΔODD lungs exhibited increased structural complexity in comparison to C57BL/6 
pups during days 2, 8, and 14 of the post gestational period (Figure 4a, b, c vs. e, f, g). 
Tissue fraction analysis confirmed a significant increase in the tissue-to-air ratio in HIF-
1αΔODD pups vs. C57BL/6 control pups on postnatal days 2, 8, and 14 (Figure 4). The 
number of alveoli per unit area was higher in HIF-1αΔODD pups vs. C57BL/6 control 
pups in general, but significantly higher in HIF-1αΔODD pups on postnatal days 8 and 14 
(Figure 4). To quantify alveolar development, we calculated the secondary crest number 
per field and the secondary crest/tissue ratio. Secondary crest counts per unit area were 
significantly increased in HIF-1αΔODD pups vs. C57BL/6 control pups on postnatal days 
2, 8, and 14, but when corrected per tissue fraction secondary crest formation was only 
increased during the early postnatal period (Figure 4). The number of Ki67-positive (pro-
liferative) crests was significantly increased in the HIF-1 mutant mice at postnatal days 2, 
8 and 14 (not shown), suggestive of increased secondary crest formation. To further evalu-
ate alveolar development, we measured mean linear intercept (Lm) and alveolar surface 
area per unit lung volume. The Lm decreased in the HIF-1αΔODD and C57BL/6 control 
pups with advancing postnatal age (Figure 5A). HIF-1αΔODD pups had significantly 
lower Lm on postnatal days 8 and 14 when compared to C57BL/6 control pups, consistent 
with a reduction in airspace diameter and enhanced alveolar formation. In line with these 
findings, alveolar surface density increased in both HIF-1αΔODD and C57BL/6 control 
pups throughout postnatal gestation (Figure 5A). We observed a significantly increased 
alveolar surface density in HIF-1αΔODD pups on postnatal days 8 and 14 when compared 
to C57BL/6 control pups, consistent with enhanced alveolar formation.  
Surfactant protein C (SFPTC) is a marker for alveolar type II cells35 while aquaporin 5 and 
T1α are alveolar type I cell markers36. Sftpc mRNA expression peaked around birth and 
decreased with advancing postnatal gestation as previously described37. Constitutive-
active HIF-1α had no effect on Sftpc gene expression (Figure 5B), although the percent-
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Figure 3. Effect of stable HIF-1α-expression on vascular formation during postnatal development. (A) Small 
vessel (diameter range 20 to 65 μm) density was increased in HIF-1α∆ODD lungs compared to C57 control lungs 
at all gestational ages except at PN21. (B) Alveolar vessel density was also increased in HIF-1α∆ODD lungs, 
specifically at PN14 and 21. 
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Figure 4. Histology and morphometry of neonatal C57BL/6 control lungs and HIF-1α∆ODD lungs. Hematoxylin 
and eosin staining of HIF-1α∆ODD lungs (e-h) showed increased parenchymal tissue per unit area of lung and 
smaller distal airspaces compared to C57BL/6 lungs (a-d) consistent with enhanced alveologenesis (Bar = 200 
µm). Tissue fraction and number of alveoli per unit area were significantly increased in HIF-1α∆ODD lungs at 
postnatal day 2, 8 and 14. The secondary crest/tissue ratio was increased in HIF-1α∆ODD pups at postnatal days 
2 and 8. Secondary crest number per unit area was significantly increased in HIF-1α∆ODD lungs at postnatal 
days 2, 8 and 14. Data are expressed as mean ± SEM for five pups in each group. * = p<0.05. (See colour section, 
page 188).
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age of SFTPC-positive cells was increased at postnatal day 14 in the HIF-1αΔODD lungs 
(25.35±2.62 vs 17.97±2.18 % of total cells, HIF-1αΔODD vs control C57BL/6 lungs, 
P<0.05, n=4-6 animals per group; 6 fields per animal; minimum of 1500 cells counted). 
Aquaporin 5 gene expression increased with advancing gestation and was significantly 
upregulated in the HIF-1αΔODD lungs at postnatal days 2, 8 and 14 (Figure 5B). T1α 
transcript levels were also increased in the HIF-1αΔODD lungs compared to controls (not 
shown). The latter findings are consistent with enhanced alveolar type I cell formation. 
Gene expression of tropoelastin and lysyloxidase remained unchanged in HIF-1αΔODD 
mice compared to wild-type controls at all postnatal days (not shown).
Lipid droplet-laden interstitial cells
Electron microscopic analysis of the HIF-1αΔODD lungs revealed an increase in number 
of lipid droplet-laden interstitial cells. These cells resided in the interstitium (Figure 6A-C) 
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Figure 5. Morphometric alveolar measurements and expression of surfactant protein C and aquaporin 5. (A) 
A significant decrease in mean linear intercept and alveolar surface area per unit lung volume was observed 
in HIF-1α∆ODD pups at postnatal days 8 and 14, consistent with enhanced alveolar formation. Values are 
presented as mean ± SEM for five pups in each group. (B) Expression of surfactant protein C and aquaporin 5 
mRNA expression in murine lung, as assessed by qPCR. Data are expressed as relative fold changes in expression 
when compared to E18.5 lungs. Data are expressed as mean ± SEM for 4 lungs in each group. * = p<0.05.
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and their numbers were significantly increased in lungs of HIF-1αΔODD mice at postnatal 
days 8, 14 and 21 when compared to their C57 age-matched controls (Figure 6D).
effects of hyperoxia
Prolonged (28 days) exposure of newborn C57BL/6 mice to hyperoxia increased lung 
resistance and reduced compliance and total lung capacity (Figure 7). While newborn 
HIF-1αΔODD mice showed similar lung function changes after prolonged hyperoxia 
Figure 6. Stable HIF-1α-expression increases number of lipid-laden interstitial (Ito) cells during postnatal 
development. Toluidine blue staining of ultrathin section shows an increase in lipid-laden cells (arrows) in HIF-
1α∆ODD lungs (A) vs. C57 control lungs (B) at PN14. (C) Electron micrograph of lipid droplet-laden interstitial 
(Ito) cells (* denotes lipid droplets). (D) Number of lipid droplet-laden interstitial cells was significantly increased 
at PN 8, 14 and 21. * = p<0.05. (See colour section, page 189).
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exposure (Figure 8), these changes were significantly more pronounced than in C57BL/6 
mice (Table 1). In contrast to lung function, histological and morphometric analyses 
revealed no difference between C57BL/6 and HIF-1αΔODD mice exposed to 80% oxygen 
(Figure 8). Both groups exhibited a similar reduction in alveolar septation when exposed 
to hyperoxia (Figure 8A vs. B, Figure 8D vs. C) which was corroborated by comparable 
morphometric changes in Lm and RAC when comparing hyperoxia- vs. normoxia-exposed 
mice (Figure 8E). Immunohistochemical analysis revealed an increase in the relative num-
ber of transgene HIF-1α expressing cells in hyperoxia-exposed neonatal HIF-1αΔODD 
mice compared to room air littermate controls while the percentage of SFTPC- and Ki67-
positive cells remained constant (Table 2). Prolonged neonatal hyperoxia of C56BL/6 mice 
caused no change in the percentage of SFTPC-positive cells or HIF-1α mRNA expression. 
Since stable HIF-1α upregulated VEGF expression in normoxia we determined VEGF and 
VEGFR2 mRNA expression in HIF-1αΔODD mice exposed to hyperoxia. Surprisingly, 
pulmonary expression of both genes was significantly downregulated in hyperoxia (VEGF: 
1.0±0.17 vs. 0.64±0.12 fold change relative to normoxia. VEGFR2: 1.0±0.07 vs. 0.49±0.23 
fold change relative to normoxia. Normoxia vs. hyperoxia, mean± SD, p<0.05, n=6 pups 
per group). Since HIF has been shown to affect surfactant production38,39, we examined 
whether changes in surfactant phosphatidylcholine (PC) content and composition could 
account for the worsening of lung function in the hyperoxia-exposed HIF-1αΔODD mice. 
Prolonged neonatal hyperoxia markedly increased total PC content in the bronchoalveolar 
lavage (BAL) of the HIF-1αΔODD mice and significantly altered its composition (increas-
ing 16:0/14:0PC, decreasing 16:0/18:1PC and maintaining 16:0/16:0PC levels) when com-
pared to normoxia-exposed littermates (Table 3).
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Figure 7. Flexivent measurements of C57BL/6 mice exposed to hyperoxia show an increase in resistance, 
compliance and total lung capacity. Stable HIF-1α expression in the HIF-1α∆ODD mice showed a further 
increase in resistance, compliance and total lung capacity, when compared to hyperoxia-treated C57BL/6 mice. 
Each dot represents the average of 4 accepted (coefficient of determination: COD>0.95) measurements for one 
individual mouse; the bar indicates the group mean. * = p<0.05, ** = p<0.001.
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dIscussIon
In the present study we found that pulmonary expression of constitutive-active HIF-1α 
accelerated postnatal alveolar formation via an increase in postnatal vascularization, 
probably as a result of up-regulated expression of VEGF and other angiogenic molecules. 
Nonetheless, constitutive-active HIF-1α did not protect newborn mice against hyperoxia-
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Figure 8. Representative histological sections of normoxia-exposed C57BL/6 mice (A), hyperoxia-exposed 
C57BL/6 mice (B), normoxia-exposed HIF-1α∆ODD mice (C) and hyperoxia-exposed HIF-1α∆ODD mice (D) are 
shown. Sections were stained with hematoxylin and eosin. Morphometry results (E) are expressed as mean ± 
SEM for mean linear intercept and radial alveolar counts. * = p<0.05, ** = p<0.001. (See colour section, page 
190).
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table 1. Invasive (Flexivent) lung function measurements.
parameter unit c57bL/6 hIF-1α∆odd
normoxia (n=5) hyperoxia (n=6) normoxia (n=9) hyperoxia (n=8)
Resistance cmH2O/mL 1.13 (1.05-1.16) 1.46 (1.27-1.57) ** 1.08 ± 0.04 2.28 ± 0.11 **/ 
##
Dynamic Compliance mL/cmH2O 0.018 (0.017-0.019) 0.014 (0.014-0.016) * 0.018 ± 0.001 0.009 ± 0.001 **/ 
##
Static Compliance mL/cmH2O 0.041 ± 0.001 0.020 ± 0.001 ** 0.044 (0.037-0.049) 0.012 (0.011-0.016) **/ 
##
Airway Resistance cmH2O/mL 0.39 (0.37-0.40) 0.45 (0.42-0.50) * 0.53 (0.46-0.58) 0.71 (0.64-0.72) **/ 
##
Tissue Specific 
Elasticity
cmH2O/mL 50.26 ± 1.27 53.38 ± 1.92 50.53 ± 1.85 87.41 ± 3.53 **/ 
##
Total lung capacity mL 0.39 (0.37-0.42) 0.29 (0.29-0.30) ** 0.45 ± 0.02 0.22 ± 0.01 **/ ##
Inspiratory Capacity 
from zero pressure
mL 0.60 ± 0.02 0.33 ± 0.01 ** 0.66 (0.56-0.73) 0.21 (0.20-0.27) **/ ##
During invasive lung function measurements, an average for each individual mouse was calculated from 4 accepted (coefficient of 
determination: COD>0.95) measurements for each parameter. Values are expressed as mean ± SEM when normally distributed and 
median + (range) when not normally distributed.  * = p<0.05, ** = p<0.001 when compared to control animals (C57BL/6 hyperoxia vs 
C57BL/6 normoxia and HIF-1α∆ODD hyperoxia vs HIF-1α∆ODD normoxia), ## = p<0.001 when compared C57BL/6 hyperoxia. 
table 2. Immunohistochemical analysis of hyperoxia-exposed HIF-1α∆ODD.
marker normoxia (n=6) hyperoxia (n=6) t-test
HIF-1α 3.42 ± 1.24 10.96 ± 4.00 * 0.003
SFTPC 25.35 ± 2.62 24.61 ± 2.71 NS
Ki67 14.42 ± 2.50 16.39  ± 4.89 NS
Immunohistochemical analysis in hyperoxia-exposed neonatal HIF-1α∆ODD mice compared to room air littermate controls. Values are % 
of totals cells with at least 1500 cells counted and expressed as mean ± SEM. * = p<0.05, when compared to control animals. 
table 3. Surfactant phosphatidylcholine (PC) content and composition in hyperoxia-exposed HIF-1α∆ODD 
mice.
total pc normoxia (n=5) hyperoxia (n=5) t-test
23.58 ± 1.43 109.96 ± 19.04 * 0.002
pc species normoxia (n=5) hyperoxia (n=5) t-test
16:0/16:0 59.80 ± 2.82 58.35 ± 3.89 NS
16:0/14:0 3.93 ± 0.48 15.08 ± 1.87 * 0.000005 
16:0/18:0 1.75 ± 0.30 2.03 ± 0.23 NS
16:0/18:1 21.87 ± 1.78 10.71 ± 1.99 * 0.000007 
16:0/18:2 5.50 ± 0.60 5.24 ± 1.17 NS
16:0/20:4 3.25 ± 0.45 4.78 ± 0.92 * 0.005 
18:0/18:1 0.50 ± 0.20 0.51 ± 0.09 NS
18:0/18:2 1.18 ± 0.28 1.97 ± 0.18 NS
18:0/20:4 2.10 ± 1.09 2.46 ± 0.65 NS
Surfactant phosphatidylcholine (PC) content and composition in hyperoxia-exposed HIF-1α∆ODD mice. Total PC is expressed in µg/150µl 
of BAL. PC species are expressed in % of total BAL PC. Data are expressed as mean ± SEM. * = p<0.05, when compared to control animals.
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induced alveolar arrest but instead worsened hyperoxia-induced lung function abnormali-
ties and altered the surfactant composition.
HIF plays an important role in early pulmonary organogenesis and postnatal alveolariza-
tion. Blocking HIF-1α expression in the early embryonic lung led to a decrease in vascu-
larization1 while removal of HIF-1α in pulmonary epithelial cells caused pups to die with 
RDS-like symptoms within hours of parturition39. Removal of HIF-2α in mice resulted in 
impaired lung maturation38, whereas overexpression of HIF-2α was found to be lethal and 
lungs from these mice revealed dilated alveoli, diminished alveolar type I cells and aber-
rant type II cells40. Loss of HIF was associated with diminished epithelial VEGF expres-
sion38,39. Conversely, stabilization of HIF enhanced early lung vascularization2, enhanced 
lung growth, and improved oxygenation and lung compliance19. Enhancing HIF stability 
has been shown to increase the expression of VEGF and to stimulate angiogenesis17,18. 
VEGF gene therapy has been shown to prevent hyperoxia-induced BPD in newborn rats by 
stimulating vascular development14. Hence, strategies aimed at increasing HIF are of ma-
jor interest as a way to potentially improve the outcome of early lung injury in prematures.
Our studies were confined to the classical alveolarization period in mice (pnd 1-21) and 
suggested that stable (constitutive-active) expression of HIF mainly affects the early 
onset of septation (pnd 4-21). Prior to secondary crest eruption from the saccular walls, 
myofibroblasts proliferate and migrate to discrete areas of the saccular walls, where they 
deposit tropoelastin at the sites of future secondary crest formation, thus forming the 
elastic fibers. Although we found an increase in lipid droplet-laden interstitial cells (also 
termed lipofibroblasts), which have myofibroblasts properties and produce elastin and 
other extracellular matrix proteins41, we did not notice any alteration in gene expression 
of tropoelastin or lysyloxidase (a cross-linking protein) in the HIF-1αΔODD mice com-
pared to wild-type controls at all postnatal days. The catch-up in alveolarization at later 
gestation (pnd 21) was surprising since alveolar vessel density was still enhanced in the 
HIF-1αΔODD mice.
The exact mechanisms that regulate alveolar formation and development remain poorly 
understood, although experimental data have given some insight in molecular regula-
tion of alveolarization4,14,24,42. Many studies showed loss of alveoli and pulmonary vas-
culature in neonatal pulmonary disease both in animal models and in humans7,43,44. We 
found that expression of stable HIF-1α enhances postnatal alveolarization as well as pe 
ripheral small vessel formation. We speculate that the continuous activation of the HIF-1 
pathway and subsequent upregulation of the VEGF pathway accounted for this enhanced 
alveolar development. A specific isoform, VEGF
188
, was upregulated in the HIF-1αΔODD 
mice at all gestational days. VEGF
188
 is a cell surface- and extracellular matrix-associated 
isoform45. Galambos46 and Ng47 showed that a balance of VEGF isoforms is necessary 
for proper blood vessel branching morphogenesis in the lung. Moreover, absence of 
VEGF
164
 and VEGF
188
 isoforms impaired lung microvascular development and delays 
airspace maturation46. Hence, it is likely that the stimulation of alveolarization seen in 
HIF-1αΔODD mice is caused by the rise in VEGF
188
 expression. This is further supported 
by observations showing that VEGF-induced angiogenesis was essential to alveolarization 
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in the developing rat lung, that VEGF and its receptors are decreased in lungs of infants 
dying with bronchopulmonary dysplasia43 and that in experimental BPD pulmonary VEGF 
or VEGF gene therapy14 stimulated vessel- and alveolar formation. These findings and our 
observations are compatible with the idea that distal lung vascularization is a driving force 
of alveolarization.
Based on previous pharmacological studies17,18 we speculated that constitutively active 
HIF-1α would protect newborn mice against hyperoxia-induced alveolar injury since it 
upregulates VEGF and stimulates alveolar vascularization in normoxia. Surprisingly, we 
found that newborn HIF-1αΔODD mice, when exposed to hyperoxia, had even worse lung 
function than hyperoxia-exposed C57BL/6 control mice. Yet, hyperoxia-induced changes 
in alveolar morphology were similar in both mice, leading us to postulate that biochemi-
cal changes at the alveolar level were responsible for this effect. VEGF has been shown to 
prevent hyperoxia-induced alveolar simplification in mice14 as well as enhance alveolariza-
tion in newborn mice after hyperoxia lung injury48,49. In contrast to normoxia, we found 
that stable HIF-1α expression during hyperoxia did actually decrease VEGF and VEGFR2 
expression. Also, Hosford et al. showed that newborn rat lungs had decreased VEGF and 
VEGFR2 levels at day 9 and 12 of hyperoxia exposure50. Similar decreases in VEGF and 
VEGFR2 have been reported for the brain of mice exposed to hyperoxia53. Interestingly, the 
decreased levels of VEGF and VEGFR2 in the cerebral cortex was associated with transient-
ly increased levels of HIF-1α and HIF-2α51. Thus, while HIF-1a transgene levels and VEGF 
mRNA correlate in room air they do not in the hyperoxia-treated group. Factor inhibiting 
HIF-1 (FIH-1) is an asparagyl hydroxylase, whose activity strictly depends on the presence 
of oxygen, which hydroxylates the HIF-1α carboxyl-terminal transactivation domain on 
Asn 803. This modification prevents its association with co-activators such as CBP/p300 
that are needed for full transcriptional activity. Since the HIF-1αΔODD transgene contains 
the original Asn 803 site, it is possible that its hydroxylation by FIH-1 in hyperoxia reduces 
the transcriptional activity of the HIF-1α transgene and thereby VEGF.
In our experiments, BAL phosphatidylcholine content in HIF-1αΔODD mice exposed to 
hyperoxia was increased, in contrast to previous studies39,52, and its composition altered. 
Altered BAL phosphatidylcholine composition has previously been shown to influence 
lung function both in animal disease models and in humans53–56. Previous studies in 
asthma, CF, idiopathic pulmonary fibrosis and acute respiratory distress patients showed 
that decreased lung function often correlates with decreased dipalmitoyl-PC (16:0/16:0PC) 
levels53,55,56. In our study, surface-active 16:0/16:0PC levels did not significantly change 
during hyperoxia exposure in the HIF-1αΔODD mice. A correlation between decreased 
palmitoyloleic-PC (16:0/18:1PC) levels and decreased lung function has been shown in 
a mouse model of bleomycin-induced pulmonary fibrosis54, and our hyperoxia-exposed 
HIF-1αΔODD mice also showed decreased 16:0/18:1PC levels in BAL. Together with the 
increased palmitoylmyristoyl-PC (16:0/14:0PC) levels during hyperoxia-exposure this may 
affect the surface packing and adsorption of 16:0/16:0PC into the alveolar air/liquid inter-
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face57, thereby negatively affecting surfactant and lung compliance in hyperoxia-exposed 
HIF-1αΔODD mice.
In conclusion, our data show that overexpression of constitutive-active HIF-1α in room air 
was associated with increased postnatal vascularization and alveolarization through up-
regulation of angiogenic factors. Stable HIF-1α overexpression did not prevent hyperoxia-
induced injury in neonates, but led to worsening of lung function, due to an altered surfac-
tant composition, specifically decreased palmitoyloleic phosphatidylcholine and increased 
palmitoylmyristoyl phosphatidylcholine levels. 
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suppLementary methods
animal use
Animal protocols were in accordance with the Canadian Council for Animal Care guide-
lines and were approved by the Animal Care and Use Committee of the Hospital for Sick 
Children, Toronto, ON, Canada.
transgene construction
The human full-length HIF-1α cDNA construct (generous gift of Dr. Semenza, Johns Hop-
kins University, Baltimore, MD, USA) was used as template to generate the HIF-1αΔODD 
mutant. The deletion mutant (HIF-1αΔ
401-603
) was constructed by overlap extension using 
PCR as previously described25. The deletion was confirmed by DNA sequencing. The bio-
logical activity of the HIF-1αΔODD mutant was confirmed using a HIF-responsive SEAP 
reporter construct. Two copies of EPO-HRE in tandem were subcloned into the Kpn I/Xho 
I restriction site of the pSEAP2-Promoter containing the SV40 promoter (Clontech, Moun-
tain View, CA). JEG-3 and 293T cells were co-transfected with EPO-HRE-SEAP2 and either 
pcDNA3.1 vector, pcDNA3.1-HIF-1α, or pcDNA3.1 HIF-1αΔODD plasmid.  SEAP2 activi-
ties were measured using the Phospho-Light TM reagent as outlined by the manufacturer 
(Tropix Inc. (Applied Biosystem) Bedford, MA). After confirmation of activity, the 1.95 kb 
HIF-1αΔODD cDNA was subcloned 3’ of the 3.7 kb human SP-C promoter38 and 5’of the 
SV40 small T intron and polyadenylation sequences. The expression cassette was excised 
with NdeI and NotI, purified using Glass Milk (Gene Clean Kit Bio 101, BioCan, Canada) 
and Elutip-D columns (Schleier and Schuell, NY), and ethanol precipitated.
production of transgenic mice 
Transgenic SFPTC-HIF-1αΔODD embryos were generated according to Hogan et al.26. 
DNA injections into pronuclei of (C57BL/6 X SJL) F2 embryos were carried out at a con-
centration of 3 ng/µl. The genotype was established by PCR analysis of genomic DNA 
extracted from the embryonic tail and confirmed by Southern blot analysis. The primers 
used were 5’-TCACCTCTGTCCCCTCTCCCTACG-3’ and 5’-CATTTCTCTCATTT CCTCAT-
GGTCA CATGG-3’.
Lung function measurements
Animals were anesthetized with an ip injection of Ketamine (150 mg/kg) and Xylazine (10 
mg/kg) before tracheostomy. A 25G endotracheal tube was inserted and sutured into place 
to prevent leakage. After intraperitoneal injection of Pancuronium (5 mg/kg) the animal 
was ventilated at 150 breaths/min with a tidal volume of 10 mL/kg and lung function was 
measured using the Flexivent ventilator (SCIREQ, Montreal, QC, Canada). The flexivent 
measures flow-volume relations of the respiratory system and uses forced oscillations to 
discriminate between the airways and the alveolar compartment. The “Total Lung Ca-
pacity” (TLC), “Snapshot” (based on single-compartment model), and “Primewave-8” 
(based on constant phase model) perturbations were used to measure lung function. For 
the “TLC” maneuver, the lung is inflated to +30 cmH
 2
O and deflated afterwards. For the 
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“Snapshot” maneuver, three sinusoidal waves of in- and expiration provide the resis-
tance, elastance and compliance parameters. For the “prime-wave 8”, multiple frequency 
forced oscillations were applied which results in the tissue elasticity and airway resistance 
parameters. Volume-driven pressure-volume loops were also obtained and provided the 
total lung capacity, inspiratory capacity from zero pressure and static and dynamic compli-
ance. All measurements were repeated until 4 successful recordings with a coefficient of 
determination of >0.95 were obtained.
Immunohistochemistry 
Immunohistochemical analyses were performed as previously described28. Rabbit poly-
clonal antibodies against HIF-1α (Cell Signaling Technologies, Danvers, MA) and Ki67 
(Dako Canada, Mississauga, ON) were used at 1:50 and 1:200 dilutions, respectively. 
Biotinylated goat anti-rabbit IgG (1:300) was used as secondary antibody. Color detec-
tion was performed according to instructions in the Vectastain ABC and DAB kit (Vector 
Laboratories, Burlingname, CA, USA) and counterstaining was performed with Carazzi’s 
haematoxylin. Control experiments were carried out by replacing the primary antibody 
with normal goat serum.
Immunofluorescence microscopy
Postnatal lungs were fixed under constant inflation of 10 cmH
2
O. Sections were incubated 
overnight with rabbit anti-VEGF (dilution of 1:800, Santa Cruz Biotechnology, Santa Cruz, 
CA), washed and incubated with biotinylated anti-rabbit IgG (dilution of 1:200, Vector 
Laboratories) and FITC-labelled strepavidin (dilution of 1:200, InVitrogen, Burlington, 
ON, Canada). Sections were thoroughly washed, incubated overnight with 1:50 diluted 
rabbit anti-HIF-1α, washed and incubated with biotinylated anti-rabbit IgG and FluoR594-
labelled strepavidin (dilution of 1:200, InVitrogen). Sections were mounted with DAPI and 
digital images were recorded with a Zeiss LSM500e confocal microscope.
electron microscopy
Postnatal lungs were fixed in 4% (v/v) paraformaldehyde (Sigma, St. Louis, MO, USA), 
0.5% (w/v) glutaraldehyde (Sigma, St. Louis, MO, USA) in phosphate buffered saline 
(PBS). Tissues were then rinsed three times with PBS, exposed to 1% (w/v) osmium tetrox-
ide (Marivac, PQ, Canada) followed by another three washes with PBS. The tissues were 
dehydrated through an ascending alcohol series and incubated three consecutive times 
in propylene oxide (Merivac, PQ, Canada). The propylene oxide was replaced with a 1:1 
mixture of propylene oxide and Epon (Marivac, PQ, Canada) and finally 3 times with 100% 
Epon. The Epon infiltrated tissues were placed in molds and the Epon was polymerized at 
70°C overnight. Ultrathin sections of the resulting blocks were cut using a diamond knife 
on a Reichert Ultracut microtome, placed onto 400-mesh copper grids and stained in 3% 
(w/v) uranyl acetate in double distilled water and then in 1% (w/v) lead citrate followed by 
several washes with double distilled water to remove excess stain. Samples were examined 
on a Philips 430 transmission electron microscope.
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rna isolation and real-time quantitative rt-pcr (qpcr)
Lung RNA was extracted with RNA easy kit (Qiagen, Mississauga, ON, Canada) and 
reverse transcribed using random hexamers (Invitrogen, Burlington, ON, Canada). The 
resulting templates were quantified by real-time PCR (ABI Prism 7900) using SYBR green 
I (Eurogentec North America, SanDiego, CA). Primers for total HIF-1α mRNA (measuring 
both mouse HIF-1α mRNA and human HIF-1αΔODD mRNA) were (F) 5’ATCCATGTGAC-
CATGAGGAAATGAGAG3’ and (R) 5’CCACACTGAGGTTGGTTACTGTTGGTA3’ while 
primers for measuring specifically human HIF-1α ΔODD mRNA were (F) 5’GTTGTGAGT-
GGTATTATTCAGC ACGACTTG3’ and (R) 5’AGTAGGTTCTTGTATTTGAGTCTGCAG-
CAAAG3’. Primers and TaqMan probes for total Vegf, Vegf
120
, Vegf
164
, and Vegf
188
 were 
similar to previously published sequences58, while primers and TaqMan probes for Ang1, 
Ang2, Tie2, EphrinB2, EphB4, Pecam-1, lysyl oxidase, tropoelastin, surfactant protein-C 
(Sftpc), aquaporin (Aqp) 5 and T1α were purchased from ABI as Assays-on-Demand™ for 
murine genes. Reactions were carried out in 96 well plates in triplicate. For each probe, 
a dilution series determined the efficiency of amplification of each primer-probe set. For 
the relative quantitation, PCR signals were compared between groups after normalization 
using 18S as an internal reference. Fold change was calculated according to Livak et al.59.
western blotting
Nuclei were isolated using a nuclear enrichment kit for tissue (Pierce, Rockford, IL). West-
ern blot analyses of nuclear lysates were performed as previously described(34). Primary 
antibodies were rabbit polyclonal anti-human HIF-1α (dilution of 1:1000, Cell Signaling 
Technology, Danvers, MA) and anti-VEGF (dilution of 1:350, Santa Cruz Biotechnology, 
Santa Cruz, CA) while goat anti-rabbit horseradish peroxidase–conjugated IgG was used 
as secondary antibody (dilution of 1:10,000, Jackson ImmunoResearch, Cedarlane Labora-
tories Limited, Canada). 
morphometric analysis of paraffin-embedded lung 
As rates of lung maturation vary between regions of the lung, all morphometric assess-
ments were performed on the right middle lobe. Lungs were embedded in paraffin wax, 
cut in 5 µm sections, and stained with haematoxylin and eosin. Morphometric assess-
ments were performed on coded images to mask the control and transgenic lungs. Digital 
images were captured using a Leica digital imaging system at 20X magnification with 
random sampling of all tissue in an unbiased fashion. Images of 10 non-overlapping fields 
from each slide, with 3 slides per animal, and 5 animals per group were captured. Tissue 
fractions and secondary crests densities were measured as previously described30. Mean 
linear intercepts were measured and calculated as described by Dunnil31. Alveolar surface 
areas per unit lung volume were calculated as described by Kawakami et al.33 Radial alveo-
lar counts were counted according to the Emery and Mithal method32. Slides were stained 
for elastin to enhance recognition of vessels and the number of small vessels (diameter 
range 20 to 65 µm) per field was assessed. Average values were calculated for 10 images 
per slide, and the average value for the three slides was used to calculate an average value 
for each animal. All morphometric values are mean ± SEM of 5 animals per time point.
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morphometric analysis of resin-embedded lung 
Overlapping images of toluidine blue stained 1µm sections were obtained using a Nikon 
digital camera and a 100X oil immersion lens. The images were analyzed using Image J 
(NIH, Bethesda, Md) and the total area in mm2 of alveolar space was calculated. Both Ito 
cells and vessels profiles were counted within these areas and the density of either profile 
is expressed as Ito cells or alveolar vessels/mm2. A minimum of 35 slides from each ani-
mal and 3 animals from each group were analyzed. Data are expressed as mean ± SD.
data presentation
Statistical significance was determined by one way ANOVA, followed by post hoc analysis 
using Duncan’s multiple range test where significant differences were found between 
groups (JMP software). A value of p<0.05 was inferred as statistically significant.
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suppLementary FIgures.
JEG-3
Fo
ld
 in
cr
ea
se
 in
 E
P
O
-S
E
A
P
 a
ct
iv
ity
  
0
10
20
30
*
* *
*
20% O2
2% O2
293T
Fo
ld
 In
cr
ea
se
 in
 E
P
O
-S
E
A
P
 a
ct
iv
ity
 
0
10
20
30
pcDNA3 HIF1α ODD HIF1α
pcDNA3 HIF1αODD HIF1α
20% O2
2% O2
*
*
*
*
supplementary figure s1. Biological activity of the HIF-1αΔODD construct. JEG-3 and 293T cells maintained 
at either 2 or 20% oxygen were co-transfected with EPO-HRE-SEAP2 (reporter construct containing 2 EPO-HRE) 
and either pcDNA3.1 vector, pcDNA3.1-HIF-1α, or pcDNA3.1 HIF-1αΔODD plasmid. Both full length HIF-1α and 
HIF-1αΔODD significantly increased EPO-HRE-SEAP2 activities. Full length HIF-1α induction of EPO-HRE-SEAP2 
decreased in cells cultured at 20% O2 while HIF-1αΔODD induced EPO-HRE-SEAP2 activity remained constant.
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supplementary figure s2. Immunohistochemical analysis of HIF-1α in C57BL/6 control lungs and HIF-
1α∆ODD lungs. Strong positive brownish staining for HIF-1α is noted in the nuclei of distal airway epithelial 
type II cells of HIF-1α∆ODD mice (B, B-I, D, D-I, F, F-I, H, H-I, J, J-I), but not C57BL/6 control mice (A,C,E,G,I) during 
all postnatal ages (E18.5: A,B,B-I; P2: C, D, D-I; P8: E, F, F-I; P14: G, H, H-I; P21: I, J, J-I. Bar = 200 mm (A-J); 50 mm 
(B-I, D-I, F-I, H-I, J-I). (See colour section, page 191).
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supplementary figure s3. Angiopoietin and ephrin expression in C57 control lungs and HIF-1α∆ODD lungs 
during postnatal development. Expression of Ang1 (A), Ang2 (B), Tie2 (C), EphrinB2 (D) and EphB4 (E) expression 
mRNA in murine lung, as assessed by real-time qPCR. Data are expressed as relative fold changes in expression 
when compared to E18.5 lungs. Data are expressed as mean ± SEM for 4 lungs in each group. * = p<0.05.
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abstract
Aim: To characterize airway ceramide profiles in a rodent model of elastase-induced 
emphysema and to examine the effect of pharmacological intervention directed towards 
ceramide metabolism.
Methods: Adult mice were anesthetized and treated with an intratracheal instillation 
of elastase. Lung function was measured, broncho-alveolar lavage fluid collected and 
histological and morphometrical analysis of lung tissue performed within 3 weeks after 
elastase injection, with and without sphingomyelinase inhibitors or serine palmitoyl-
transferase inhibitor. Ceramides in broncho-alveolar lavage (BAL) fluid were quantified by 
tandem mass spectrometry. 
Results: BAL fluid showed a transient increase in total protein and IgM, and activated 
macrophages and neutrophils. Ceramides were transiently upregulated at day 2 after 
elastase treatment. Histology showed persistent patchy alveolar destruction at day 2 after 
elastase installation. Acid and neutral sphingomyelinase inhibitors had no effect on BAL 
ceramide levels, lung function or histology. Addition of a serine palmitoyltransferase 
inhibitor ameliorated lung function changes and reduced ceramides in BAL. 
Conclusion: Ceramides were increased during the acute inflammatory phase of elastase-
induced lung injury. Since addition of a serine palmitoyltransferase inhibitor diminished 
the rise in ceramides and ameliorated lung function, ceramides likely contributed to the 
early phase of alveolar destruction and are a potential therapeutic target in the elastase 
model of lung emphysema.
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IntroductIon
Chronic Obstructive Pulmonary Disease (COPD) is a common and increasing source 
of morbidity and mortality in the developed world1 and is associated with a large finan-
cial burden2. Pulmonary emphysema, an important component of COPD, is caused by 
permanent destruction of alveoli, airflow obstruction and lung hyperinflation, leading 
to a decreased lung function and breathlessness. The pathogenesis is related to smoke 
exposure, but why only a minority of all smokers develops emphysema remains unclear. 
Reports suggest that inflammation is partly responsible. The inflammatory infiltrate seen 
in emphysema is similar to that found in infection and correlates to the extent of emphyse-
ma3, while the degree of cell death correlates to the amount of inflammation4. In humans, 
airway inflammation persists for many years after smoking cessation5. Sphingolipids are 
important structural components of biological membranes and have recently been shown 
to serve as messenger molecules in cell proliferation, apoptosis, cell contact and adhe-
sion, endothelial barrier function and during inflammation6–14. Ceramide is the central 
molecule in the sphingolipid pathway15 and is formed either de novo from the condensation 
of palmitate with serine via the activity of a serine palmitoyltransferase (SPT), by the sal-
vage pathway via sphingosine or via degradation of sphingomyelin by sphingomyelinase 
(SMase)16. Ceramide is degraded by ceramidase to sphingosine which can be phosphory-
lated to sphingosine-1-phosphate (S1P)17. Ceramide and S1P form a rheostat17,18 whereby 
ceramide stimulates apoptosis and cell cycle arrest while S1P stimulates cell survival 
and proliferation. Sphingolipid metabolism has been shown to be altered in a variety of 
diseases, including cystic fibrosis19,20 and asthma21. Ceramide has been shown to trigger 
apoptosis in an experimental mouse model of emphysema22, and increased levels of apop-
tosis have been found in the lungs of patients with severe cigarette-induced emphysema23. 
Increased ceramide levels have also been shown to influence surfactant production24 and 
activity25. Since ceramide levels are increased in the lungs of patients with smoke-induced 
emphysema22, ceramide upregulation might be an important pathogenetic element in 
emphysema development. We investigated ceramide profiles in the lungs and examined 
the effect of pharmacological interventions targeting SMases and SPT in an animal model 
of elastase-induced emphysema. 
methods
animals 
Animals were obtained from Charles River (St. Constant, Quebec, Canada) and animal 
studies were conducted according to criteria established by the Canadian Council for 
Animal Care and approved by the Animal Care and Use Committee of the Hospital for Sick 
Children, Toronto, ON, Canada. Female adult C57BL/6 mice, weighing between 22 and 25 
grams, were used for all experiments.
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elastase-induced lung injury
Porcine pancreatic elastase (Type I, aqueous suspension, ≥4.0 units/mg protein, Cal-
biochem, EMD biosciences, USA) was dissolved in sterile saline to create a volume for 
tracheal instillation of 100 µl per mouse with a concentration of 4.8 Units/100 g body-
weight. Animals were anesthetized with 3% isoflurane and intraperitoneal (ip) administra-
tion of Ketamine (75 mg/kg) and Xylazine (5 mg/kg). Following induction of anesthesia, a 
25G intubation tube was inserted past the vocal cords and 100 µl of elastase instilled into 
the trachea. Control animals were treated similarly, but received sterile saline instead of 
elastase. BAL was collected from mice at t = 1, 2, 3, 4, 5, 8, 14 and 21 days after elastase 
instillation to measure sphingolipids and inflammatory markers.
Lung function measurements
At day 21 following instillation of elastase, the Flexivent rodent ventilator (Scireq, Mon-
treal, Canada) was used to assess lung function as previously published26.
broncho-alveolar lavage
Lungs were infused through the endotracheal tube with 3x 600 µl sterile saline, followed 
by withdrawal27,28. The collected fluid was centrifuged at 1400 g for 8 min. The superna-
tant and remaining lung tissue was collected in siliconized eppendorf tubes and stored at 
-80oC for mass spectrometry analysis.
histology of the lungs
Following lung function measurements, histology and morphometry of the lungs was 
performed as previously described26.
measurement of ceramides
Ceramide levels in BAL and remaining lung tissue were measured by tandem mass spec-
trometry as previously described26. The analysis was performed by the Analytical facility 
for Bioactive Molecules, The Hospital for Sick Children, Toronto, Canada.
ceramide inhibitor experiments
Desipramine (acid SMase inhibitor, 20 mg/kg bodyweight), zoledronic acid (acid SMase 
inhibitor, 0.1 mg/kg bodyweight), sphingolactone (neutral SMase inhibitor, 1 mg/kg 
bodyweight) (Sigma–Aldrich, St. Louis, MO), and myriocin (SPT inhibitor, 1 mg/kg 
bodyweight) (Cayman Chemicals, Ann Arbor, MI) were administered via ip injection 2 
hours before elastase instillation and 6, 24, 48 and 72 hours after elastase instillation. 
Each sphingolipid inhibitor experiment consisted of 4 groups: 1) control mice, 2) control 
mice treated with an ip injection of vehicle, 3) elastase-treated mice with an ip injection of 
vehicle and 4) elastase-treated mice with an ip injection of sphingolipid inhibitor dissolved 
in the appropriate vehicle. Half of the number of the mice in each group was sacrificed at 
day 2 after elastase instillation to measure sphingolipid levels and inflammatory markers 
in BAL. The other mice underwent lung function measurements at day 14 after elastase 
instillation before histology and morphometry.
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Immunofluorescent staining
Immunofluorescencent staining was performed according to a previously published 
protocol with slight modification29. Tissue sections were de-waxed in xylene, rehydrated 
using decreasing ethanol series (100% to 70%), before being washed in 1xPBS/0.03% 
(vol/vol) Triton-100-X. Tissue permeabilization was achieved by boiling in 10 mM sodium 
citrate (pH 6) for 15 minutes at 95OC, and cooled for 30 minutes in room temperature. 
Nonspecific antibody binding was blocked by incubation with a solution containing 10% 
(vol/ vol) normal donkey serum (Jackson ImmunoResearch, Cedarlane Laboratories, Burl-
ington, Ontario) and 1% (vol/vol) bovine serum albumin in PBS at room temperature for 1 
hour. The sections were washed and incubated for 1 hour with 1:100 diluted anti-ceramide 
monoclonal IgM antibodies (Glycobiotech, Borstel, Germany). The slides were washed 
again and stained for 30 min with a 1:200 diluted Cy3-labeled donkey anti-mouse IgM 
(Jackson ImmunoResearch,). After rinsing, the samples were mounted with 4,6-diamidi-
no-2-phenylindole (DAPI) mounting medium (Vector, Burlington (ON)) and analyzed on a 
Leica fluorescence microscope.
western blotting
Lung tissues were lysed, protein content measured and aliquots (50 ug protein) were sepa-
rated on 4-12% Bis-Tris precast polyacrylamide gels (Invitrogen, Cat. NP0322BOX) and 
transferred to PVDF membranes. After blocking with 5% (w/v) skim milk in TBST (20 mM 
Tris, 137 mM NaCl, 0.1% Tween 20) membranes were incubated with either goat anti-acid 
ceramidase antibody (1:500 dilution, T-20, Santa Cruz Biotechnology, CA), rabbit anti-acid 
sphingomyelinase (1:2000 dilution, H-181, Santa Cruz Biotechnology, CA) or goat anti-
neutral ceramidase (1:500 dilution, S-20, Santa Cruz Biotechnology) overnight at 4°C. The 
next day the membranes were washed with TBST and incubated with either horseradish 
peroxidase–conjugated donkey anti-goat (1:20.000 dilution) or goat anti-rabbit (1:20.000 
dilution) in 5% (w/v) skim milk in TBST at RT for 1-2 hrs. After several washes with TBST, 
protein bands were visualized using an enhanced chemiluminescence detection kit. Band 
densities were quantified using Scion Image software (Version 1.6, National Institutes of 
Health, Bethesda, MD, USA). Equal protein loading was confirmed by immunoblotting for 
β-actin of same membrane.
statistics 
All values are presented as mean ± standard error of the mean assuming normal distribu-
tion (Sigmaplot 11 for Windows). Differences were assessed by Student’s t-test or, for 
comparison of more than two groups, by two-way analysis of variance followed by Holm-
Sidak comparison test. Significance was inferred where p<0.05.
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resuLts
baL analysis
A 4-fold increase in total ceramide and dihydroceramide levels was found at day 2 after 
elastase instillation when compared to saline-treated controls (Figure 1 and Table 1). 
Ceramide levels were 20-fold greater than dihydroceramide levels.  Specifically, long chain 
and very long chain ceramides (Cer16:0, Cer22:0, Cer24:0 and Cer24:1) were increased. All 
ceramides and dihydroceramides returned to baseline levels within 5 days after elastase 
treatment. No difference in ceramide levels were noted in remaining lung tissue samples 
(not shown), therefore only BAL was analyzed in subsequent experiments. Neither 
desipramine, zoledronic acid or sphingolactone treatment altered ceramide levels (Table 
2), but myriocin treatment ameliorated elastase-induced increases in multiple ceramides 
(Cer22:0, Cer24:0, Cer24:1), and dihydroceramides (18:0 and 24:0) (Figure 2, Table 3). 
Protein and IgM content (Figure 3A, C) and cell counts (Figure 3B) in BAL were increased 
at day 1, 2 and 3 after elastase injection. Cytospins from the same BAL fluid showed an 
increase in normal and activated “foamy” macrophages, and neutrophils, which normal-
ized by day 5 after elastase injection (Figure 3D). Neither desipramine, zoledronic acid nor 
sphingolactone treatment had any effect on the above mentioned parameters. Myriocin 
treatment decreased BAL protein levels, shifted the neutrophil/macrophage balance to-
wards neutrophils (Figure 4), but had no significant effect on IgM. 
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Figure 1. Ceramide and dihydroceramide levels in BAL fluid during the first 21 days after elastase injection. 
Results represent a total of 4 mice per group for days 1, 3 and 4, 8 mice per group for days 8, 14, 21 and 12 mice 
per group for days 0, 2 and 5. * = p<0.05 
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table 3. Ceramides after Myriocin treatment.
sphingolipid control  
(n=5)
control + myriocin  
(n=9)
elastase  
(n=9)
elastase + myriocin  
(n=10)
Ceramide 16:0 30.01 ± 6.65 22.23 ± 7.95 41.04 ± 18.77 21.69 ± 4.91 []
Ceramide 18:0 3.13 ± 0.58 2.86 ± 0.75 4.00 ± 1.89 2.61 ± 0.60 []
Ceramide 20:0 1.94 ± 0.47 1.93 ± 0.43 2.73 ± 1.18 2.02 ± 0.43
Ceramide 22:0 7.97 ± 1.67 7.99 ± 3.42 15.13 ± 7.96 * 9.11 ± 3.02 []
Ceramide 24:0 37.34 ± 9.00 33.24 ± 13.50 77.75 ± 44.65 * 39.72 ± 13.00 []
Ceramide 24:1 24.66 ± 7.60 17.33 ± 8.02 41.48 ± 20.83 * 19.44 ± 6.27 []
Dihydro Ceramide 18:0 0.38 ± 0.21 0.37 ± 0.20 0.70 ± 0.27 * 0.44 ± 0.17 []
Dihydro Ceramide 24:0 1.97 ± 1.18 1.83 ± 0.65 6.12 ± 3.94 * 3.42 ± 2.21 []
BAL fluid was collected and processed using LCMS. Data are expressed as mean + SEM in ng/ml BAL fluid. * = p<0.05 when compared to 
Control. # = p<0.05 when compared to Control + Myriocin. [] = p<0.05 when compared to Elastase + Myriocin. 
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Figure 2. Ceramide and dihydroceramide levels in BAL fluid at day 2 after elastase injection and myriocin 
treatment. Results represent a total of 5 mice for control, 9 mice for control + myriocin, 9 mice for elastase and 
10 mice for elastase + myriocin group. * = p<0.05 when compared to Control. # = p<0.05 when compared to 
elastase.
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Figure 3. Biochemical measurements in BAL fluid: protein levels (A) and cell count (B) at day 1, 2 and 3 after 
elastase injection. IgM levels (C) measured by ELISA. Cytospin slides (D) and haemotoxilin-eosin stained 
histological slides from control mice (E1 at 200x magnification, F1 at 400x magnification) and elastase-treated 
mice at 2 days after elastase injection (E2 at 200x magnification, F2 at 400x magnification) and 5 days after 
elastase injection (E3 at 200x magnification, F3 at 400x magnification). Arrows indicate neutrophils, arrowheads 
indicate macrophages. Graphs represent an n=4 for each group. * = p<0.05. (See colour section, page 192).
Chapter 5
96
enzyme expression
Western blot analysis of enzymes partaking in ceramide metabolism showed decreased 
acid ceramidase levels during the first 5 days after elastase treatment, reaching signifi-
cance at day 3 and 5. Neutral ceramidase levels were only significantly downregulated at 
day 1 after elastase injection. Acid sphingomyelinase levels were only significantly upregu-
lated at day 3 after elastase instillation (Figure 5).
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Figure 4. Protein levels, IgM content, neutrophil and macrophage percentages in BAL fluid at day 2 after 
elastase instillation and myriocin treatment. ** = p<0.05 compared to controls. # = p<0.05 compared to 
elastase-treated mice.
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Lung function
Lung function measurements of elastase-treated mice showed a significant reduction in 
resistance and tissue-specific elastance and an increase in dynamic compliance compared 
to controls (Figure 6, Table 4). Neither desipramine, zoledronic acid nor sphingolactone 
had any effect on lung function in elastase-treated animals compared to vehicle-treated 
elastase-exposed mice (Table 4). Elastase-treated mice receiving myriocin showed a 
significant decrease in compliance and increase in tissue elasticity compared to control 
elastase-exposed mice (even with a limited number of mice). Myriocin also prevented the 
decrease in resistance, normally seen in elastase-treated mice, compared to vehicle-treated 
elastase-exposed mice (Figure 6, Table 5).
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Figure 5. Densitometric expression analysis of acid sphingomyelinase, acid- and neutral ceramidase proteins 
accompanied by representative western blots. Data are expressed as mean ± SEM. n=4 for day 1, 2 and 3, n=3 
for day 4 and 5. * = p<0.05 and ** = p<0.001 compared to control levels (which were set at 1). 
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Figure 6. Lung function 2 weeks after elastase injection in myriocin-treated mice. Results represent 6 mice for 
the control group, 5 mice for the control + myriocin treated groups, 6 mice for the elastase-treated and elastase-
treated + myriocin group. Data are expressed as mean ± SEM. ** = p<0.05 when compared to the control and 
control + myriocin group. [] = p<0.05 when compared to the elastase-treated group.
table 4. Invasive lung function measurements after Desipramine, zoledronic acid and sphingolactone 
treatment.
parameter unit control (n=9) elastase  
(n=10)
elastase + 
desipramine 
(n=5)
elastase + 
zoledronic acid 
(n=4)
elastase + 
sphingolactone 
(n=4)
Resistance (R) cmH2O/mL 0.67 ± 0.07 0.52 ± 0.03 * 0.47 ± 0.02 * 0.49 ± 0.01 * 0.54 ± 0.05 *
Compliance (C) mL/cmH2O 0.032 ± 0.004 0.052 ± 0.004 * 0.066 ± 0.007 * 0.067 ± 0.011 * 0.054 ± 0.007 *
Airway Resistance (Rn) cmH2O/mL 0.32 ± 0.03 0.23 ± 0.03 * 0.22 ± 0.02 * 0.25 ± 0.01 * 0.21 ± 0.02 *
Tissue Elasticity (H) cmH2O/mL 32.4 ± 4.2 16.9 ± 2.3 * 13.2 ± 1.3 * 13.9 ± 2.8 * 15.5 ± 2.7 *
Total lung capacity (A) mL 0.70 ± 0.05 0.78 ± 0.04 0.88 ± 0.02 0.89 ± 0.07 0.77 ± 0.03
Inspiratory Capacity (B) 
from zero pressure
mL 1.14 ± 0.09 1.30 ± 0.11 * 1.47 ± 0.028 * 1.57 ± 0.19 * 1.29 ± 0.09 *
Static Compliance (Cst) mL/cmH2O 0.078 ± 0.008 0.094 ± 0.009 * 0.108 ± 0.002 * 0.115 ± 0.014 * 0.094 ± 0.008 *
During invasive lung function measurements, an average for each individual mouse was calculated from 4 accepted (coefficient of 
determination: COD>0.95) measurements for each parameter. * = p<0.05 when compared to Control. # = p<0.05 when compared to 
Elastase.
Ceramides: a Potential Therapeutic Target in Pulmonary Emphysema 
99
5
histology and morphometry
Histological analysis of the lung at day 2 following elastase injection revealed the presence 
of erythrocytes in the alveolar spaces and massive influx of neutrophils and macrophages 
(Figure 3E). Alveolar enlargement was present from day 2 onwards. Erythrocytes and most 
of the inflammatory cells were cleared by day 5 after elastase injection. Immunofluores-
cent staining for ceramide showed increased positive reactivity in the epithelial lining and 
inflammatory cells in elastase-treated mice 2 days after elastase injection compared to 
controls (Figure 7). Three weeks after elastase installation we observed a patchy pattern of 
alveolar destruction leading to enlarged airspaces. This was reflected in a significant in-
crease in mean linear intercept and decrease in alveolar number. Mice treated with SMase 
table 5. Invasive lung function measurements after Myriocin treatment.
parameter unit control  
(n=6)
control + 
myriocin (n=5)
elastase  
(n=3)
elastase + 
myriocin (n=3)
Resistance cmH2O/mL 0.44 ± 0.03 0.43 ± 0.03 0.37 ± 0.01 * 0.41 ± 0.03
Compliance mL/cmH2O 0.056 ± 0.005 0.055 ± 0.002 0.082 ± 0.005 * 0.063 ± 0.005 
# []
Airway Resistance cmH2O/mL 0.22 ± 0.01 0.22 ± 0.02 0.16 ± 0.03 * 0.18 ± 0.01 
#
Tissue Elasticity cmH2O/mL 17.3 ± 1.5 17.3 ± 0.8 9.9 ± 1.1 * 14.0 ± 1.4 
# []
Total lung capacity mL 0.93 ± 0.05 0.95  ± 0.03 0.99 ± 0.05 0.93 ± 0.03
Inspiratory Capacity from zero 
pressure
mL 1.47 ± 0.08 1.49 ± 0.07 1.42 ± 0.06 1.36 ± 0.11
Static Compliance mL/cmH2O 0.105 ± 0.006 0.106 ± 0.005 0.104 ± 0.004 0.097 ± 0.009
During invasive lung function measurements, an average for each individual mouse was calculated from 4 accepted (coefficient of 
determination: COD>0.95) measurements for each parameter. * = p<0.05 when compared to Control. # = p<0.05 when compared to 
Control + Myriocin. [] = p<0.05 when compared to Elastase.
A C
DB
Figure 7. Immunofluorescent images of ceramide expression. Control (A at 100x magnification, B at 400x 
magnification), elastase-treated mice 2 days after elastase injection (C at 100x magnification, D at 400x 
magnification). Ceramide (red), cell nuclei (DAPI blue) and autofluorescence (green). (See colour section, page 
193).
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inhibitors or STP inhibitor showed no significant signs of histological recovery compared 
to elastase-treated controls (Table 6).
dIscussIon
In this study we showed that intratracheal elastase caused a transient inflammatory re-
sponse with influx of erythrocytes and inflammatory cells in the alveolar spaces, combined 
with an increase in multiple ceramide and dihydroceramide species in BAL fluid which 
peaked at day 1 and 2 and returned to control levels 3 days after elastase instillation. 
Ceramide expression was primarily localized to the epithelium and to inflammatory cells. 
Sphingomyelinase inhibitors did not prevent or reduce the effects of intratracheal elas-
tase. In contrast, SPT inhibition reduced sphingolipid and protein levels and ameliorated 
lung function changes after elastase instillation.
Apoptosis of alveolar cells has been shown to play a crucial role in the development of 
emphysema30–32. Petrache et al. showed that direct intratracheal instillation of a synthetic 
short chain ceramide caused emphysema-like defects33 and observed increased ceramide 
levels in the lungs of individuals with cigarette smoke-induced emphysema33. Our study 
shows for the first time that ceramide levels are increased in the first few days following 
the intratracheal instillation of elastase in mice. Earlier studies have described an in-
crease in apoptosis in the elastase-induced emphysema model34–37. Long chain ceramides 
(Cer16:0, Cer18:0) have been shown in cancer cells to exhibit anti-proliferative and pro-
apoptotic effects38. Our study shows that long chain ceramides are increased a few days 
after elastase instillation and we speculate that they were responsible for triggering apop-
tosis. Long chain ceramides have also been shown to increase the permeability of the lung 
endothelium after cigarette-smoke39 and thereby enhance endothelial leakage leading to 
edema formation40. In our model we found evidence of significant edema formation at day 
2 and 3 after elastase instillation, as measured by increased IgM and protein levels in the 
BAL fluid. Our observation of long chain ceramides being increased at those time-points 
is suggestive of a causal role of ceramides in this model. The elastase-induced emphy-
sema model does not mimic the low-grade, long-term inflammatory pathophysiology of 
smoke-induced pulmonary emphysema in patients41. However, it is an excellent model to 
accurately reproduce the histological damage seen in emphysematous lungs and to evalu-
ate the effect of interventions. The short developmental time of the model when compared 
to genetic or cigarette smoke models makes it easier to perform multiple experiments in a 
relatively short time period.
Staining of lung sections from patients with cystic fibrosis or lung emphysema for 
ceramides showed that ceramide formation is increased in the airway epithelium20. By im-
munofluorescent staining we indeed found increased ceramides in the airway epithelium, 
in agreement with the increased ceramide levels in BAL which mainly contains products 
from epithelial cells. We also found positive immunofluorescence signals for ceramide in 
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alveolar macrophages, which could be due to uptake of apoptotic alveolar epithelial cells, 
or internal ceramide production42, triggered by the inflammatory response after elastase.
Sphingomyelinase inhibition has been examined in a variety of animal models. In a model 
of cystic fibrosis, acid sphingomyelinase inhibitors (desipramine and amitriptyline) an-
dand a glycosphingolipid inhibitor (Miglustat) decreased pulmonary inflammation14,43. In 
spinal cord injury, an inhibitor of acid sphingomyelinase (NB6) and an inhibitor of de novo 
ceramide synthesis (Fumonisin B1) reduced spinal cell apoptosis and inflammation after 
injury, and improved motor function44. Zoledronic acid has been shown to specifically 
inhibit acid sphingomyelinase45. Sphingolactone has previously been shown to ameliorate 
LPS-induced acute lung injury in mice by inhibiting neutral sphingomyelinase, thereby 
decreasing ceramide levels in the present study. Treatment with myriocin (SPT inhibitor) 
produced a marked reduction in overall sphingolipid levels, which suggests that de-novo 
ceramide synthesis was responsible for this increase. The de novo pathway was also impli-
cated in VEGF-inhibition-induced emphysema, demonstrating the importance of de novo 
ceramide generation in the process of alveolar destruction33. This is further corroborated 
by the observation that neither acid- nor neutral sphingomyelinase inhibitors were able 
to block the increase in ceramides. Inadequate dosing of these inhibitors seems unlikely 
since similar doses have been used successfully in other animal models46–48. Since inhibi-
tion of synthesis of very long acyl chain (C22-C24) ceramides in Cer synthase 2 knockout 
mice has been shown to elevate C16-ceramide and sphinganine levels49, it is possible that 
inhibition of one specific step in the complex ceramide pathway leads to unintended alter-
ations in individual ceramide metabolites. In the present study, desipramine exhibited an 
unexpected effect, namely upregulation of very long chain ceramides in both vehicle and 
elastase-treated mice. However, zoledronic acid, another inhibitor of acid sphingomyelin-
ase, did not have this effect. Desipramine has previously been described to not only inhibit 
ASMase, but also acid ceramidase and other lysosomal enzymes45,50. This non-specific 
inhibitory effect could account for the different effects on sphingolipid levels compared to 
zoledronic acid. Acid sphingomyelinase protein levels were transiently upregulated after 
elastase instillation, suggesting that it may have contributed to the transient increase in 
ceramides. However, the contribution must have been minimal as we found no effect of 
acid sphingomyelinase inhibitors. The increased ceramide levels after elastase instillation 
could also be due to reduced degradation by ceramidases. However, a major role in the 
transient rise in ceramides is unlikely since ceramide levels returned to normal 5 days after 
elastase instillation while acid ceramidase levels were still decreasing. The initial decrease 
of neutral ceramidase after elastase instillation may have contributed to the early increase 
in ceramide levels but neutral ceramidase levels were already increased and normalized at 
the time (day 2) ceramide levels peaked. Thus, contribution of neutral ceramidase to the 
elevation in ceramides after elastase treatment is most likely minimal.
Blocking the de-novo pathway of ceramide synthesis by myriocin had a positive effect on 
lung function but no effect on histology. A possible explanation for this structure-func-
tion discrepancy is that ceramides reduce surfactant synthesis, due to downregulation 
of Thyroid Transcription Factor-1 (TTF-1), and this may affect lung function without a 
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measurable morphological alteration24,51. However, our observed absence of a change in 
saturated phosphatidylcholine content in BAL of elastase-treated and control mice (not 
shown) makes this explanation less likely. Clinical studies in humans also show that struc-
tural abnormalities of the lungs and airways are at best weakly correlated with changes 
in lung function, and this is especially true for localized or inhomogeneous structural 
abnormalities, as seen in our model52,53. Alternatively, the morphometric methodology 
may be insufficiently sensitive to demonstrate relatively small changes that might underlie 
significant functional improvement. More sensitive approaches to the analysis of lung 
structure might be needed. Such approaches may include, but are not limited to, micro CT 
and advanced functional MRI imaging techniques.
It could be argued that desipramine, being a tricyclic antidepressant, and zoledronic 
acid, a bisphosphonate, have limited specificity to influence ceramide metabolism. 
Desipramine is known to inhibit the re-uptake of norepinephrine and to a lesser extent 
serotonin54, however, both catecholamines are unlikely to affect ceramide levels in BAL. 
Zoledronic acid binds and blocks farnesyl diphosphate synthase in the HMG-CoA reduc-
tase pathway, preventing the formation of metabolites essential for sub-cellular protein 
trafficking. As a bisphosphonate it may bind to calcium in bone, thereby preventing the 
functioning of osteoclasts, the only bone-resorbing cells in the body56. Again, it is very 
unlikely that these additional actions of zoledronic acid interfered with our ceramide out-
comes. Importantly, we showed that neither desipramine nor zoledronic acid influenced 
BAL ceramide levels, which argues against a significant contribution of SMases in the 
production of ceramides in our elastase model57.
In conclusion, we demonstrated the involvement of ceramides and dihydroceramides in 
elastase-induced emphysema. Our findings suggest an important role for ceramides in the 
acute phase of elastase-induced emphysema. Further experiments should be undertaken 
to better evaluate the preventive and therapeutic potential of ceramide inhibition in this 
emphysema model, and ultimately in humans with COPD and emphysema.
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abstract
Aim: to characterize the evolution of lung function and -structure in elastase-induced em-
physema in adult mice and the effect of mesenchymal stromal cell (MSC) administration 
on these parameters. 
Methods: adult mice were treated with intratracheal (4.8 units / 100 gr bodyweight) 
elastase to induce emphysema. MSCs were administered intratracheally or intravenously, 
before or after elastase injection. Lung function measurements, histological and morpho-
metric analysis of lung tissue were performed at 3 weeks, 5 and 10 months after elastase 
and at 19, 20 and 21 days following MSC administration. 
Results: elastase-treated mice showed increased dynamic compliance and total lung 
capacity, and reduced tissue-specific elastance and forced expiratory flows at 3 weeks after 
elastase, which persisted during 10 months follow-up. Histology showed heterogeneous 
alveolar destruction which also persisted during long-term follow-up. Jugular vein injec-
tion of MSCs before elastase inhibited deterioration of lung function but had no effects on 
histology. Intratracheal MSC treatment did not modify lung function or histology. 
Conclusion: elastase-treated mice displayed persistent characteristics of pulmonary 
emphysema. Jugular vein injection of MSCs prior to elastase reduced deterioration of lung 
function. Intratracheal MSC treatment had no effect on lung function or histology. 
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IntroductIon
Chronic Obstructive Pulmonary Disease (COPD) is the most common chronic lung disease 
in adults, characterized by an incompletely reversible airflow limitation, and is associ-
ated with high mortality1 and health-care costs2. Pulmonary emphysema is an important 
component of COPD, and is characterized by alveolar destruction, resulting in a reduced 
alveolar surface area and increased alveolar size3. Not all patients with pulmonary em-
physema exhibit airflow limitation, respectively COPD4, showing that there is a discrep-
ancy between lung function and histological abnormalities. Oxidative stress, sustained 
inflammation and protease-antiprotease imbalance5 are believed to be major contributors 
to the pathogenesis of COPD. To date no curative therapy is available, and smoking ces-
sation and domiciliary oxygen supplementation only prolong survival in a small subset of 
patients with resting PaO
2 
< 60 mmHg6.
Mesenchymal stromal cells have recently emerged as a successful, cell-based therapy in a 
variety of models of lung disease, such as hyperoxia7, bleomycin8 and endotoxin-induced 
lung injury9. MSCs are multipotent stromal cells that have the ability to self-renew. The hy-
pothesis for the mechanism underlying the beneficial effects of MSC treatment has shifted 
from engraftment and differentiation of MSCs in the target organ towards the effects of 
paracrine factors produced by these MSCs10. Levels of engraftment below 1% were found 
in several studies11–14. Thus, it is highly unlikely that engraftment is responsible for the 
favourable effects of MSCs in various models of lung injury11,15–17. MSC have been shown to 
inhibit apoptosis18 and secrete anti-inflammatory mediators19 and growth factors, such as 
epidermal growth factor20 and hepatocyte growth factor21. It has been shown that the intra-
venous infusion of conditioned medium, derived from MSCs, prevents LPS-induced lung 
injury, supporting that MSCs exert their effect via paracrine signalling22. Katsha et al. have 
shown that treatment with MSCs improves histological and morphometrical outcome in a 
low dose elastase-induced emphysema model (1 Unit/100 gram bodyweight) and decreases 
inflammatory cytokine levels23. Also Cruz et al. have shown that injection of bone marrow 
mononuclear cells (BMNCs) improves histological and morphometrical outcome in a low 
dose (4 times 0.4 Units/100 gram bodyweight) elastase model24. Based on the results of 
MSC treatment in different animal models, a phase II-trial of intravenous mesenchymal 
stem cell infusion in COPD patients was started in 2008. The interim report of this study 
stated that, although this treatment was safe and reduced C-reactive protein levels, lung 
function in these patients did not improve25. The absence of an improvement in lung 
function suggests that MSCs did not repair the structural defect26. Since these human trial 
findings were not in line with the aforementioned animal studies23,24, the question arises 
whether the animal models may not mimic human COPD, and whether a better response 
to MSC is seen because of a lower level of lung damage. One possibility is that the elastase 
dose had been too low to cause the desired level of alveolar damage. We therefore exam-
ined the effects of MSC treatment in a mouse model of emphysema, using a relatively high 
dose of elastase (4.8 Units / 100 gram bodyweight). Since some previous studies24,25 used 
an intravenous route of MSC administration while others23 used intratracheal delivery, we 
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tested both methods of administration of MSCs, aiming at either prevention or repair of 
lung injury. 
methods
animals
All animals were obtained from Charles River (St. Constant, Quebec, Canada). Animal 
studies were conducted according to the criteria established by the Canadian Council for 
Animal Care and approved by the Animal Care and Use Committee of the Hospital for 
Sick Children, Toronto, ON, Canada. Adult C57BL/6 mice were used for all experiments 
described below, except for the extraction of MSCs from bone marrow, for which 4 week 
old C57BL/6 mice were used.
elastase-induced lung injury
Porcine pancreatic elastase (Type I, aqueous suspension, ≥4.0 units/mg protein, Calbio-
chem, EMD biosciences USA) was dissolved in sterile saline to create a total volume for 
injection of 100 µl per mouse, with a concentration of 4.8 Units / 100 gram bodyweight, a 
dosage used previously27–29. Animals were anesthetized with 3% isoflurane and ip admin-
istration of Ketamine (75 mg/kg) and Xylazine (5 mg/kg). Following induction of anes-
thesia, a 25G intubation tube was inserted past the vocal cords and 100 µl of elastase was 
injected into the trachea. Control animals were treated similarly, but received sterile saline 
instead of elastase. 
mesenchymal stromal cell extraction and characterization
Bone marrow was collected from 4-week old C57BL/6 mice. Mice were sacrificed by 
cervical dislocation, and the tibia and femur removed, from which the bone marrow was 
extracted by flushing with Dulbecco’s Modified Eagle Medium (DMEM). The suspension 
was filtered using a 70µm sterile filter before being cultured using StemXVivo Mesen-
chymal Stem Cell expansion medium (R&D systems, Minneapolis, USA) according to a 
modified protocol30. Mesenchymal stromal cells were isolated by plastic adherence, and 
prior to injection, passage 8 adherent MSCs were characterized using flow cytometry. 
MSCs characterized according to the International Society of Cellular Therapy consensus 
in 2006 must fulfill the following three criteria: (1) MSC must be adherent to plastic under 
standard tissue culture conditions; (2) MSC must express the cellular markers CD73, 
CD90 and CD105, and must not express CD34, CD45, CD14 or CD11b; and (3) MSC must 
have the capacity to differentiate into mesenchymal lineages under in vitro conditions31. 
Adherent cells were collected from their culture flasks by trypsin digestion and a subset 
of cells were stained with primary conjugated antibodies for CD34, CD45, CD73, CD105 
and Sca-1 (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s 
protocol. Expression of the above mentioned markers was characterized using a Gallios 
flow cytometer (Beckman Coultier, Mississauga, Canada). A differentiation assay was per-
formed on passage 8 MSCs to test their multi-lineage differentiation capacity. According 
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to a protocol by Lama et al.32, MSCs were cultured in different media to obtain adipogenic, 
chondrogenic, and osteogenic differentiation. Adipogenic: DMEM + 1µM dexamethasone 
+ 10µM insulin + 200µM indomethacin + 0.5mM isobutyl-methyl xanthine. Chondro-
genic: DMEM + 10ng/mL TFG-β1. Osteogenic: DMEM + 100nM dexamethasone + 10mM 
beta-glycerophosphate + 0.05mM ascorbic acid-2-phosphate. Histological staining for 
adipocytes (Oil-red stain), osteoblasts (Von Kossa stain) and chondrocytes (Alcian Blue 
stain) were performed according to a previously published protocol32. 
mesenchymal stromal cell administration
MSCs were dissolved in plasmalyte (Baxter, Mississauga, Canada) at a concentration of 
500,000 cells per 200µl for intratracheal instillation and at a concentration of 100,000 cells 
per 100µl for jugular vein injection.
Intratracheal instillation of mscs
Animals were anesthetized with 3% isoflurane and ip administration of Ketamine (75 mg/
kg) and Xylazine (5 mg/kg). Following induction of anesthesia, a 25G intubation tube was 
inserted past the vocal cords and 500.000 MSCs suspended in 200µl of plasmalyte were 
injected into the trachea. Control animals were treated similarly, but received plasmalyte 
only. To test whether MSCs could prevent elastase-induced lung injury, intratracheal MSC 
installation was performed 24 hours before elastase injection in experimental group 1, 
and 24 hours after elastase injection in experimental group 2. To test whether MSC’s could 
repair elastase-induced lung injury, intratracheal MSC installation was also performed 21 
days after elastase treatment (Supplementary figure S1).
Infusion of mscs via the jugular vein 
Animals were anesthetized with 3% isoflurane, which was maintained during the entire 
procedure. The jugular vein was exposed and 100,000 MSCs suspended in 100µl plasma-
lyte were slowly infused. Pressure was applied on the jugular vein until bleeding ceased, 
the wound was sutured and the animals were allowed to recover. Jugular vein MSC infu-
sion was performed 30 minutes before intratracheal elastase injection. 
Lung function measurements
At multiple time points (Supplementary figure S1) following the instillation of elastase 
and/or MSC treatment, unrestrained whole body plethysmography (Buxco Research Sys-
tems, Wilmington, NC, USA) was used to measure breathing frequency, tidal volume and 
minute volume. Afterwards the Flexivent rodent ventilator (Scireq, Montreal, Canada) was 
used to invasively assess lung function (described in detail in the supplementary methods 
section) following a protocol previously published33.
bronchoalveolar lavage
A subset of mice was used to obtain BAL samples only. Immediately after sacrificing the 
animal, the lungs were lavaged at 6 hours, and 1-5, 8,14 and 21 days after elastase injection 
through a separate endotracheal tube with 3 x 600 µl sterile saline, followed by withdraw-
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al34,35. The collected pooled aliquots were centrifuged at 1400 g for 8 min. The supernatant 
was collected for cytokine analysis.
measuring cytokines
Cytokines were measured in BAL fluid using xMAP technology on a Luminex 200 (Lu-
minex Corporation, Austin, Texas, USA) using a milliplex kit from EMD Millipore Cor-
poration (Billerica, Massachusetts, USA) according to the manufacturers protocol. The 
following analytes were measured: IL-1β, IL-6, IL-10, IL-13, MCP-1, TNF-α, KC, GM-CSF.
histology of the lungs
Following lung function measurements, histology was performed as described in the 
supplementary methods section.
statistics 
All values are presented as mean ± standard error of the mean when normally distributed 
(Sigmaplot version 11 for Windows). Differences were assessed by Student’s t-test or, for 
comparison of more than two groups, by one-way analysis of variance, followed by Tukey 
HSD comparison test. p< 0.05 was considered significant.
resuLts
elastase-induced alveolar injury
Elastase-treated mice showed significant decreases in resistance and tissue-specific 
elastance, and significant increases in dynamic compliance, total lung capacity and static 
compliance when compared to saline-treated mice. Forced expiration measurements 
revealed a significant increase in forced vital capacity and a significant decrease in mean 
forced expiratory flow in elastase-treated mice (Figure 1, Table 1). At 5 months and 10 
months after elastase instillation, the increase in dynamic compliance and FVC, as well as 
the decrease in tissue-specific elastance and forced expiratory flows seen at 3 weeks after 
elastase had persisted (Figure 2, Table 2). No significant changes in plethysmographic 
lung function parameters were found when compared to saline-treated controls (Table 
2). Histology at 21 days after elastase showed a heterogeneous pattern of alveolar destruc-
tion with enlarged airspaces. This was reflected in a significant increase in mean linear 
intercept and a reduced alveolar number. No significant change in radial alveolar count 
was detected. Histological analysis of lungs at 5 and 10 months after elastase treatment 
revealed a persistent, heterogeneous pattern of enlarged airspaces and an increased mean 
linear intercept (Figure 3). Elastin staining at 21 days after elastase administration showed 
a disorganized pattern of elastin distribution in elastase-treated mice compared to con-
trols. No significant difference in elastin content per total tissue area was observed (Figure 
4). Histological slides of elastase-treated mice showed influx of inflammatory cells, and 
cytokine levels in BAL fluid showed a transient increase in IL-6, keratinocyte-derived-che-
mokine (KC) and MCP-1 levels at day 2 after elastase injection. Cytokine levels returned to 
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baseline at day 3 and remained stable for the follow-up period of 3 weeks. Levels of IL-1β, 
IL-10, IL-13 and GM-CSF were below the detectable range (Figure 5, Table 3).
mesenchymal stromal cell characterization
Passage 8-adherent bone marrow stromal cells were characterized by differentiation assay 
and showed differentiation into adipocytes, chrondrocytes and osteoblasts. Flow cytom-
etry revealed that a subset of bone marrow cells was positive for CD105 (28.2%), CD73 
(28.8%), CD90 (69.2%) and Sca-1 (99.5%) and negative for CD34 (0%) and CD45 (0%) 
(Supplementary figure S2).
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Figure 1. Lung function measurements 21 days after elastase instillation (n=30) and in saline controls (n=25). 
Data are expressed as mean ± SEM. * = p<0.05.
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Figure 2. Lung function measurements during long-term follow-up of elastase-treated mice (n=30 for 21 days. 
n=5 for 5 and 10 months) and saline controls (n=25 for 21 days. n=5 for 5 and 10 months). Data are expressed 
as mean ± SEM. * = p<0.05, ** = p<0.01.
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table 2. Non-invasive (WBP) lung function measurements.
parameter unit control (n=23) elastase-treated (n=27)
Breathing Frequency Breaths/Min 315 (201-381) 334 (264-398)
Tidal Volume mL 0.27 (0.23-0.30) 0.28 (0.24-0.32)
Minute Volume mL/Minute 82 (53-119) 94 (66-140)
Inspiratory Time sec 0.06 (0.06-0.11) 0.06 (0.06-0.08)
Expiratory Time sec 0.18 (0.14-0.21) 0.15 (0.11-0.22)
Peak Inspiratory Flow mL/sec 7.38 (4.22-8.49) 8.30 (5.85-9.53)
Peak Expiratory Flow mL/sec 3.59 (2.28-5.73) 4.45 (3.04-6.44)
Relaxation Time msec 0.11 (0.09-0.12) 0.09 (0.07-0.12)
End Inspiratory Pause msec 4.94 (4.85-5.22) 5.01 (4.91-5.14)
End Expiratory Pause msec 28.4 (19.4-41.1) 25.8 (15.1-55.0)
Enhanced Pause (PenH) 0.46 (0.38-0.55) 0.45 (0.35-0.57)
During whole body plethysmography (WBP), mice were allowed to adjust to the measuring chambers for 30 minutes, afterwards 
measurements were taken continuously for 60 minutes, and an average was calculated for each mouse individually. * = p<0.05, ** = 
p<0.001 when compared to control animals.
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Figure 3. Representative histological sections of saline-controls (A), elastase-treated mice 21 days after 
injection (B) and elastase-treated mice 10 months after elastase injection (C). Sections were stained with 
hematoxylin and eosin. Morphometry results (D) are expressed as mean ± SEM for both control and elastase-
treated group for mean linear intercept (n=35), radial alveolar counts (n=6), and alveolar number (n=4). 
Morphometry results for 5 and 10 months of recovery in room-air (E) are expressed as mean ± SEM for mean 
linear intercept (n=5). * = p<0.05 ** = p<0.001. (See colour section, page 194).
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Intratracheal msc instillation 
Intratracheal instillation of 5x105 of MSCs at 24 hours before, and at 24 hours or 21 days 
after elastase treatment had no effect on lung function or histology performed 21 days 
after MSC injection (Supplementary figure S3, Table 4).
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Figure 4. Hart’s Elastin stain of histological slides of the lungs of saline-treated (A) and elastase-treated mice 
(B) 21 days after injection. Morphometry shows the quantification of the elastin content when adjusted for total 
tissue area (C). All morphometrical data is expressed as mean ± SEM, n=5 for control and elastase-treated mice. 
# = p<0.05.
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Intravenous msc infusion
Infusion of 105 MSCs 30 min before intratracheal instillation of elastase ameliorated the 
increase in dynamic compliance and tissue-specific elastance in elastase-treated animals 
compared to controls (Figure 6, Table 4). Intravenous MSC infusion had no effect on his-
tology or morphometry (Supplementary figure S3).
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dIscussIon
In this study, we induced pulmonary emphysema in adult mice by tracheal instillation 
of a relatively high dose of elastase. Three weeks after elastase administration we found 
evidence of histological abnormalities and obstructive lung function, characteristic of pul-
monary emphysema. The structural and functional changes persisted up to 10 months and 
were not affected by intratracheal administration of MSC prior or after the injury. Jugular 
vein MSC treatment before elastase injection showed an improvement in lung function but 
no change in histology.
Intratracheal instillation of elastase resulted in increased dynamic compliance, total lung 
capacity, FVC and decreased tissue-specific elastance and forced expiratory flows 3 weeks 
after elastase injection. These results agree with earlier findings at 3 weeks after elastase 
injection36–38 and are likely due to a loss of elastin and disruption of the integrity of the 
alveolar wall with loss of alveolar attachments. Indeed, we observed extensive alveolar 
damage. Hart’s staining on lung tissue showed a disorganized elastin deposition after 
elastase treatment. Disorganisation of elastin fibers and loss of alveolar attachments 
reduces elastic recoil of the lung. This is likely to contribute to the decreases in forced 
expiratory flows, as well as to the static hyperinflation. Loss of structural integrity of the 
peripheral lung with disruption of the alveolar walls and loss of alveolar attachments 
could also be responsible for the increase in total lung capacity (TLC). A possible mecha-
nism of increased TLC could be air trapping. However, we consider this unlikely, because 
the simultaneous increase in FVC argues against substantial air trapping. Note that the 
forced lung function manoeuvres performed in this study differ from those used in clinical 
setting because we used a negative pressure at the tracheal opening, whereas in human 
subjects the driving force is a positive pressure from the diaphragm and thoracic wall. 
This negative pressure could lead to earlier airway collapse and more pronounced airway 
obstruction than active forced exhalation.
In this study, we used both non-invasive and invasive lung function measurements. Non-
invasive measurements are advantageous in longitudinal studies in which animals can be 
repeatedly measured, but the overall sensitivity for detecting lung function abnormalities 
appeared lower than that of invasive measurements39. The invasive measurements were 
more robust and sensitive, and accurately reflected alterations in lung mechanics. Thus, 
the Flexivent method was superior for detecting physiological differences in lung me-
chanics in mice with elastase-induced lung injury, in agreement with earlier findings in 
hyperoxia-induced lung injury40. The main advantage of whole body plethysmography is 
its repeatability. However, de Vleeschauwer et al. have recently shown that intubating mice 
for repeated invasive measurements yielded the same results as performing a tracheoto-
my41 and therefore we consider Flexivent measurements the method of choice for future 
experiments.
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To our knowledge, no long-term functional measurements have been performed in the 
elastase-induced mouse model of emphysema. During long term follow-up, we found no 
evidence of recovery of lung injury. This suggests that the elastase model is suitable for 
intervention studies aimed at tissue repair. The repeated use of lung function measure-
ments in this model enables us to monitor disease progression and treatment efficacy in 
a manner that may be relevant to clinical practice. The findings with the forced expiration 
measurements do not agree with all other findings reflecting emphysema. We believe that 
this might well be due to the smaller number of animals used for the forced expiratory 
measurements, and the relatively large variation within the groups. Overall, these mea-
surements suggest that forced expiration measurements are less sensitive, with a larger 
variation between animals in the same group, then the other lung function measurements 
obtained with the Flexivent system.
In our emphysema model, intratracheal MSC installation shortly after elastase injection, 
aiming to prevent lung injury, had no effect on lung function or histology. We chose the 
intratracheal route to ensure that the injected MSCs came into direct contact with the dam-
aged alveolar epithelial layer. This intratracheal approach was successfully applied in the 
study by Katsha et al.23. As mentioned before, our elastase dose was significantly greater 
than that of Katsha et al. which might account for the difference in outcome of MSC treat-
ment. We have repeated the intratracheal MSC experiments in a rat model of emphysema 
(elastase dose: 30 Units / 100 gram bodyweight) and 5x105 rat bone marrow-derived MSCs 
(not shown). These experiments also showed no effect of intratracheal MSC treatment on 
lung function, histology and morphometry, indicating that our results are reproducible in 
different species.
We also administered MSCs intratracheally 21 days after elastase injection to induce repair 
of elastase-induced lung injury. MSC injection had no effect on lung function or histology. 
The discrepancy between our negative results of repair by MSCs and those of others, with 
long-lasting low grade inflammation in a low-dose elastase model and effects of intratra-
cheal MSC injection shortly after elastase7,8,20,42, may be due to the absence of a persisting 
inflammatory component in our emphysema model. Since MSCs have been shown to 
possess anti-inflammatory properties, administering them 21 days after elastase injection, 
when cytokine levels had normalized, might reduce their ability to exert positive effects on 
lung function and histology.
COPD has been shown to possess a large vascular disease component43. CT images of 
COPD patients show a decrease in small pulmonary vessels, even in smokers with mild 
emphysema44. Compared to non-smokers, COPD patients show increased invasion of 
inflammatory cells in the vascular adventitial layer45. The extent of pulmonary vascular re-
modelling  directly correlates with the severity of the endothelial inflammation46. Intrave-
nous injection of MSCs creates a systemic anti-inflammatory response on the endothelial 
surface of the pulmonary vasculature. Thus, the anti-inflammatory milieu on the endo-
thelial side produced by MSCs injected via the jugular vein could decrease the vascular 
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inflammation shown to be present in the elastase-induced emphysema model47. There 
is a large body of work suggesting that MSC intervention using the endothelial route, 
either via the dorsal penile vein48 or via the tail vein8,19,49 could be successful in improv-
ing elastase-induced emphysema, thereby improving lung function. We used the jugular 
vein infusion method to infuse the cells closest to the pulmonary vasculature. Jugular vein 
infusion of 105 MSCs just prior to elastase installation to prevent elastase-induced lung 
injury significantly improved lung function in elastase-treated mice, while histology did 
not improve. Another possible explanation is that MSCs may have improved surfactant 
production or activity. It is well known that alveolar inflammation decreases surfactant 
production and activity50–52 and as MSCs have an anti-inflammatory effect they may have 
improved surfactant production or activity and thereby improved lung function in the 
absence of histological improvement. This hypothesis is less likely, since intratracheal in-
jection of MSCs showed no improvement in lung function. Delivery of MSCs directly into 
the alveolar spaces should generate a local anti-inflammatory effect, thereby improving 
surfactant function. This effect was not seen in the intratracheal injection groups. More 
work is needed to study the underlying mechanism responsible for the improvement in 
lung function after jugular vein injection of MSCs. 
In contrast to our work, Cruz et al. showed that intravenous injection of bone marrow 
mononuclear cells 3 hours after elastase injection decreased inflammatory parameters, 
but also improved histology and morphometry24. Unfortunately, they did not measure lung 
function. The main difference in methodology between our study and the study of Cruz et 
al. is that they used a much lower dose of elastase, resulting in less alveolar enlargement, 
as measured by a MLI score of 68.5 compared to our MLI score of 128. The difference in 
alveolar destruction severity might account for the difference in treatment outcome, with 
our higher elastase dose surpassing the injury threshold for an effect of MSC treatment on 
histology and morphometry.
A major limitation of our study is the difference in timing of intravenous and intratracheal 
MSC injection, which invalidates comparison of the two interventions in the present study. 
Future studies are needed to examine whether the intravenous route might be beneficial 
after elastase. Another limitation is the different cell numbers used for intratracheal MSC 
injections when compared to jugular vein MSC injections. Unfortunately, we were limited 
in the number of cells for jugular vein injection because of 100% injection-induced mortal-
ity when using higher doses, such as those used for intratracheal MSC injections.
concLusIon
Our results demonstrate that MSC injection via the jugular vein just before elastase pre-
vented lung function changes after elastase treatment. Intratracheal administration 24 
hours before and 24 hours after elastase injection did not prevent lung function changes. 
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The severity of elastase-induced lung injury may be an important determinant of the effect 
of MSC treatment.
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suppLementary methods
non-invasive lung function measurements
Animals were each placed in an individual plethysmograph and a 30 min interval was used 
for the animal to adjust to their new environment before the measurements were started. 
Measurements were continuously recorded for 1 h after which animals were returned to 
their cages. 
Invasive lung function measurements
Animals were anesthetized with an ip injection of Ketamine (150 mg/kg) and Xylazine (10 
mg/kg) before tracheostomy. A 25G endotracheal tube was inserted and sutured to prevent 
leakage. Following intraperitoneal injection of Pancuronium (5 mg/kg), the animal was 
ventilated at 150 breaths/min with a tidal volume of 10 mL/kg, and lung function was 
measured using the Flexivent ventilator (SCIREQ, Montreal, QC, Canada). The flexivent 
measures flow-volume relationships of the respiratory system, and uses forced oscilla-
tions to discriminate between the airways and the alveolar compartment. The “Total Lung 
Capacity” (TLC), “Snapshot” (based on single-compartment model), and “Primewave-8” 
(based on constant phase model) perturbations were used to measure lung function. For 
the “TLC” maneuver, the lung is inflated to +30 cmH
 2
O and deflated afterwards. For the 
“Snapshot” maneuver, three sinusoidal waves of in- and expiration provide the resistance, 
elastance and compliance parameters. For the “prime-wave 8”, multiple frequency forced 
oscillations were applied to measure tissue elasticity and airway resistance properties. 
Volume-driven pressure-volume loops were also obtained and provided TLC, inspiratory 
capacity from zero pressure and static and dynamic compliance. All measurements were 
repeated until 4 successful recordings, with a coefficient of determination of >0.95, were 
obtained. Animals also underwent forced expirations by inflating to TLC and then rapidly 
applying a negative pressure of -55 cmH
2
O to the expiratory valve. In the current state of 
small animal ventilator technology, this technique is the closest to mimicking forced ex-
piratory spirometry in humans. Parameters obtained from this maneuver were the forced 
vital capacity, mean forced expiratory flow, peak forced expiratory flow and forced expira-
tory flow at 0.05, 0.1 and 0.2 seconds.
histology and morphometry
Following lung function measurements, the animals were exsanguinated by cutting the 
abdominal aorta while still under anesthesia. The thoracic cavity was opened and heparin 
dissolved in phosphate buffered saline (PBS) was injected into the right ventricle of the 
heart, and the lungs were flushed free of blood. A catheter was inserted into the trachea 
to allow 4% (w/v) paraformaldehyde (PFA) to inflate the tissue at a constant pressure of 
20 cmH
2
O. After 5 minutes, the catheter was removed and the trachea tied off. The lungs 
were removed from the thorax as a single block and fixed in 4% PFA overnight. Fixed lungs 
were embedded in paraffin at 60oC. Randomly orientated tissue blocks were cut into 7 µm 
sections, stained with hematoxylin-eosin and Hart’s elastic stain, and morphometry was 
performed on digital images taken at x200. Images were captured from 5 non-overlapping 
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fields from each slide, with 4 slides per animal. Mean linear intercepts (Lm) was measured 
and calculated53. For alveolar number determination, 20 randomly selected non-overlap-
ping fields from sections obtained from 4 animals per group were examined. Each field 
was viewed at x200 magnification and alveolar number was counted and expressed per 
mm2 54.
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suppLementary FIgures
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Control + MSC
Elastase + Jugular Vein MSC
supplementary figure s1. Time-line of all MSC experiments performed.
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CD34 CD45
CD105CD90Sca-1
BA C
CD73
D
supplementary figure s2. Differentiated MSCs were directly stained on 6 well plates for adipocytes (A, Oil-
red stain), osteoblasts (B, Von Kossa stain) and chondrocytes (C, Alcian Blue stain), and flow cytometry data 
(D) of passage 8 MSCs (red population) stained for CD34, CD45, CD73, CD90, Sca-1 and CD105 and passage 8 
unstained MSCs as control (orange population). (See colour section, page 195).
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supplementary figure s3. Representative histological sections of saline-controls (A), elastase-treated mice 
21 days after injection (B) and elastase-treated mice that received MSCs via the jugular vein route (C) and via 
the intratracheal route (D). Sections were stained with hematoxylin and eosin. Morphometry results (E) are 
expressed as mean ± SEM for all groups (n=4 per group) ** = p<0.001. (See colour section, page 196).
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IntroductIon
In this thesis we focused on lung injury and repair in two rodent models of human dis-
ease; hyperoxia-induced Bronchopulmonary Dysplasia and elastase-induced pulmonary 
emphysema. In chapter 2 we evaluated the available literature and provided an overview of 
the role of sphingolipids during lung growth and development. In chapter 3 we character-
ized lung function and sphingolipid profile during hyperoxia exposure and recovery in 
room air in our hyperoxia-induced Bronchopulmonary Dysplasia model, and examined the 
effect of D-sphingosine, a pro-proliferative sphingolipid, during recovery in room air. We 
examined the effect of constitutive hypoxia-inducible factor 1-alpha expression on postna-
tal alveolarization and lung vascularisation, as well as its effect on preventing hyperoxia-
induced lung injury in chapter 4. In the elastase-induced emphysema model we character-
ized ceramide levels, a pro-apoptotic sphingolipid, and examined the effects of blocking 
the de novo pathway of ceramide production on lung function and histology in chapter 5. 
Finally, we attempted to prevent elastase-induced lung injury by injecting mesenchymal 
stem cells in chapter 6.
chronIc Lung dIsease
The overall human life expectancy is gradually increasing, but there also is an increase 
in the number of patients living with and dying of chronic diseases. Of the 58 million 
deaths per year from all causes, 35 million are attributed to chronic disease1. Chronic lung 
diseases, including asthma, Chronic Obstructive Pulmonary Disease (COPD), pulmo-
nary hypertension and Bronchopulmonary Dysplasia (BPD)1, account for 4 millions of 
these deaths. Chronic lung diseases represent a major health problem, with respiratory 
symptoms being one of the major causes for visiting primary health care centres, ranging 
from 8 to 37%2. Chronic lung diseases are associated with a substantial loss of disability-
adjusted life years, and a high mortality3. BPD and COPD, both diseases with a decreased 
number of alveoli, occur in different stages of life, but share common ground in patho-
genesis, biological processes and etiological factors4.
bronchopuLmonary dyspLasIa
In the Netherlands, prematurity is the number 3 cause of death in children under 5 years 
of age, directly accounting for 35 percent of neonatal mortality5,6, and every week of pre-
term birth doubles the morbidity risk, up to 43% in preterms born between 23-27 weeks 
gestational age7. The percentage of preterm births increases with 1 percent each year, and 
worldwide projections show an expected 2.250.000 preterm births in the year 20258. A 
lower birth weight is associated with an increased risk of developing BPD9, and the rates 
of BPD in very preterm neonates (23-31 weeks gestational age) in Europe presently range 
from 10 to 25 percent10. Under the influence of advances in care of preterm infants the 
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survival of very preterm infants has improved. The increase in preterm births will cause a 
rise in overall prevalence of BPD. With the increased survival of very preterm infants and 
improvements in treatment of respiratory insufficiency, the ‘old’ BPD, characterized by 
parenchymal fibrosis, edema, vascular changes and inflammation, has evolved into the 
‘new’ BPD, with fewer and larger alveoli as a result of interrupted septation and abnormal 
vascular organization11. The change in histological character of the disease has sparked 
new research towards the possible altered pathogenesis of this ‘new’ BPD.
Even though progress has been made in the management of infants with BPD, cur-
rent treatment remains symptomatic. Antenatal steroids have reduced the incidence of 
neonatal death and respiratory distress, but have failed to reduce the incidence of BPD. 
Exogenous surfactant minimized the use of mechanical ventilation, but nasal continuous 
positive pressure and oxygen treatment with saturation targets between 88-95% did not 
prevent BPD, although it reduced BPD-associated mortality12,13. Vitamin A supplementa-
tion reduced oxygen dependence at 36 weeks postmenstrual age and improved BPD-asso-
ciated mortality in one study14, but due to the physical limitations of administering daily 
intramuscular injections in neonates this strategy has not been implemented as clinical 
standard of care.
chronIc obstructIve puLmonary dIsease
COPD is the most common chronic lung disease in adults and is associated with high 
mortality15 and health-care costs16. COPD severity is commonly based on the GOLD crite-
ria. GOLD staging requires an FEV1/FVC ratio below 0.70, and stages are based on FEV1, 
stage I >80% predicted, stage II between 50-80%, stage III between 30-60% and stage IV 
<30% predicted17. The prevalence of COPD (GOLD stage II and higher) was estimated at 
11.8% for men and 8.5% for women aged 40 and above18. The incidence of COPD is rising, 
especially among women. Currently the number 4 cause of death in the Unites States, 
COPD is predicted to surpass stroke and become the number 1 cause of death in the com-
ing decades19. 
There is no causal treatment for COPD. Smoking cessation is an important step in the 
treatment of COPD, and is currently the most effective measure to slow down the decline 
in lung function. Smoking cessation has been shown to be effective, also in heavy smokers 
and those with a poor baseline lung function. Smoking cessation improves lung function 
decline by 50%, when compared to patients who continue smoking20. Pharmacological 
treatment for COPD is primarily based on anti-inflammatory drugs and the use of bron-
chodilators, with oxygen supplementation as supporting measure. These treatments 
provide some symptom reduction and prevent exacerbations, but do not stop disease 
progression or decline in lung function that determines the high morbidity and mortal-
ity. For the Netherlands, the estimated prevalence of COPD will rise from 19 to 30 per 
1000 inhabitants in 2025, of which 2.4 per 1000 inhabitants will die due to COPD21. This 
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increase in morbidity and mortality calls for better treatments to prevent the development 
of COPD, but also requires new therapeutic strategies aimed at repairing the damaged 
lung. Many government programs have attempted to discourage smoking by raising 
tobacco tax, through education, by putting warning labels on cigarette packaging, and 
banning smoking in public areas, sometimes with documented striking success. Multiple 
awareness programs have been set up in developing countries to prevent the development 
of COPD due to the burning of wood and other biomass fuels indoors for cooking or heat-
ing3,22. Not all smokers develop COPD, therefore these methods will not provide relief for 
all patients or for patients who have already developed COPD. 
bpd and copd: sImILarItIes and dIFFerences
BPD and COPD share many pathophysiological pathways, such as increased apoptosis, 
vascular abnormalities, protease-antiprotease imbalance, oxidative stress and chronic 
inflammation4. Both diseases show permanently enlarged alveoli, but the mechanism be-
hind this enlargement differs, with arrested development in BPD, and active destruction of 
already existing alveolar walls in COPD. A decreased number of pulmonary vessels is seen 
in both BPD and COPD23. Animal models have shown that neonatal hyperoxia contributes 
to an increased susceptibility for cigarette-smoke induced pulmonary emphysema later 
in life24. BPD patients show lung function abnormalities that persist into adulthood25,26. 
A high prevalence of airtrapping27, parenchymal abnormalities28 and emphysema-like 
structural defects have been reported in over 80% of adult survivors of ‘old’ BPD29,30. We 
propose that the lungs of BPD patients may well be more susceptible to injurious factors31, 
making these patients more vulnerable for developing pulmonary emphysema earlier in 
life32. Figure 1, adapted from Bourbon et al.4 shows the interplay of factors and biological 
processes suggested to play a role in the development of BPD and COPD. 
We examined animal models of BPD and COPD to discover factors that contribute to the 
development/regulation of these diseases, to investigate repair mechanisms and evalu-
ate potential therapeutic interventions, and to determine the differences and similarities 
between the two clinical entities.
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anImaL modeLs oF dIsease
The mouse has been used in laboratories for decades to develop models of human lung 
disease, either by subjecting it to injury, administering toxic or damaging substances and/
or through genetic manipulation. Mice and men exhibit similar physiological processes 
and share 99% of the genome. Genetic studies have been performed for more than 100 
years33, evolving from studying naturally occurring genetic variants and crossbreeding 
these to obtain specific traits, to directly altering the genetic code using transgenes which 
can be expressed at any time point during embryonic development or maturation, and 
expression can be localized to one specific organ system. Animal models for BPD and 
pulmonary emphysema have been used and reviewed extensively in the past34–39. In this 
thesis, we used two different animal models, namely hyperoxia-induced Bronchopulmo-
nary Dysplasia (BPD) and elastase-induced pulmonary emphysema. 
Intrauterine / postnatal infections
VentilationOxygen Supplementation
Genetics
Cigarette smoke
Indoor  solid fuel use
Oxidative stress
Protease-Antiprotease imbalance
Apoptosis
Senescence
Disordered alveolarization / maintenance mechanism
Bronchopulmonary Dysplasia Pulmonary Emphysema
In ammation
Developing Lung Adult Lung
Figure 1. The interplay of factors and biological processes suggested to play a role in the development of BPD 
and COPD. (See colour section, page 197).
General Discussion
141
7
hyperoxIa-Induced bronchopuLmonary dyspLasIa
Alveolarization in mice occurs from postnatal day 4-14 (36 weeks-2 years postnatal in 
humans)40,41 and is followed by the microvascular maturation stage at postnatal day 14-21 
(from birth-3 years in humans), completing the lung development. The preferred rodent 
model of BPD is by exposing mice or rats to hyperoxia during the postnatal period. This 
model accurately reproduces the arrest in alveolarization, vascular changes and lung 
function abnormalities of BPD patients, and is reproducible, with little variation between 
subjects as long as litter sizes are kept equal during the 14 days of hyperoxia exposure42–44. 
A minor consideration when using this model is that lung function measurements require 
mice to be 28 days old before accurate measurements can be taken. At this age mouse 
lungs are considered adult lungs45, making it impossible to collect data on neonatal/ado-
lescent lung function in mice.
eLastase-Induced emphysema
Mouse models of COPD make use of various techniques to damage the lungs. These 
include inhalation of exogenous agents, such as porcine pancreatic or human neutrophil 
elastase, papain, coal dust, or cigarette smoke. Also, genetic knock-out models leading to 
alveolar enlargement have been developed34. A downside to these models is the limited se-
verity of the emphysema. Patients that require intense treatment for COPD in combination 
with home oxygen supplementation have GOLD stage III/VI, while most of the above de-
scribed animal models have lung abnormalities comparable to GOLD stage I/II46. We de-
cided to study the commonly used elastase-induced emphysema model, since it provides 
consistent results in terms of alveolar destruction37,47,48. It also is a model that allows us to 
increase the elastase dose to obtain more severe histological and lung function abnormali-
ties representing the characteristics seen in severe COPD (GOLD III/VI) patients. Recently 
the elastase model has been used to mimic COPD exacerbations by injecting LPS in the 
lungs of elastase-treated mice49,50. One of the major challenges in using this model is the 
small ‘therapeutic’ window for the elastase dose. Below this dose, mice show only minor 
histological abnormalities and no alterations in lung function, making in vivo follow-up 
impossible without having to sacrifice the animal. Above this dose, mice develop severe 
pulmonary haemorrhaging, resulting in a mortality rate of around 100 percent. To obtain 
adequate dosing, one should account for pulmonary dead space by injecting the elastase 
solution, followed by an additional air bolus equal to the measured dead space51. Proper 
intubation technique is important, since insertion of the endotracheal tube past the carina 
results in injection of the full dose of elastase into a single lung. This causes intense 
haemorrhaging and asphyxiation due to fluid overload in the lungs.   
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sphIngoLIpIds In bpd and copd
Technological advancement in the field of metabolomics has provided insight into a 
new area of biological characterization of lung diseases. In the last decade, sphingolipid 
research has greatly benefited from this new approach. Sphingolipids are present in every 
cell membrane of the human body and form a stable outer leaflet of the plasma membrane 
lipid bilayer providing a central pathway for the regulation of many cellular processes, 
among which apoptosis, proliferation, necrosis, inflammation, autophagy and cellular 
senescence52–55. Sphingolipids have also been shown to regulate embryonic vascular orga-
nization56. 
Many reviews are available describing the different causal and contributing factors that are 
relevant for the pathogenesis of BPD13,57,58. One of these factors is apoptosis57,59, a highly 
regulated form of cell death, influenced by many pathways60. Sphingolipids determine 
the balance between apoptosis and proliferation52,61. The most important pro-apoptotic 
sphingolipid is ceramide. Together with S1P, ceramide forms the so called sphingolipid 
rheostat, that regulates the balance between apoptosis and proliferation54,62,63. 
In our BPD model we found increased ceramide levels during hyperoxia, which returned to 
control levels during recovery in normoxia, and we discovered that adding an S1P precur-
sor increased the rate of recovery. These results might indicate a role for ceramide-induced 
apoptosis in this model, and illustrate the possibility of pharmacological modification 
of the ceramide-S1P balance. We showed that we can improve recovery in our hyperoxia-
induced BPD model, but we believe that prevention would be better than cure. Therefore, 
additional experiments should be undertaken to elucidate which ceramide-producing 
pathway is responsible for the increased ceramide levels, potentially to develop a preventa-
tive approach e.g. by pharmacological blockade of these pathways.
The main hypothesis underlying the pathophysiology of the development of pulmonary 
emphysema is that of cellular injury. Direct injury, leading to the destruction of alveoli, 
may be due to cigarette smoke, pollution or increased inflammation and apoptosis of 
alveolar type I, II and endothelial cells in the lung. Indeed, increased apoptosis has been 
found in lung samples of pulmonary emphysema patients64–66. New insights into the fac-
tors that determine the balance between apoptosis and proliferation have recently brought 
forth a new role for ceramides. We examined the contribution of ceramides to the develop-
ment of pulmonary emphysema. We found that ceramide levels increased in BAL during 
the initial inflammatory phase, similar to what has been found in the BAL fluid of active 
smoking COPD patients67. Blocking the de novo pathway of ceramide generation dimin-
ished the rise in ceramides and ameliorated lung function changes suggesting a role for 
ceramide-driven apoptosis in our model of pulmonary emphysema. This hypothesis is 
strengthened by the fact that intratracheal instillation of long-chain ceramides produced 
pulmonary emphysema68 and it is well-known that apoptosis plays a role in the develop-
ment of emphysema64,69,70. Therefore the ceramide/S1P rheostat might play a pivotal role 
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in the regulation of this process and could therefore be considered as a new therapeutic 
target in the treatment of COPD patients.
bpd and copd as ‘puLmonary vascuLar dIseases’
Angio- and vasculogenesis in lung development has been reviewed extensively71–73. Animal 
models and human autopsy specimens of BPD have shown abnormal distribution of ves-
sels and a decrease in small arteries58,74, suggesting that BPD is partly a vascular disease. 
COPD patients show a loss of alveolar capillary endothelial cells and small capillaries75,76, 
combined with decreased VEGF levels77. VEGFR blockade causes apoptosis and pulmo-
nary emphysema in mice78, further delineating the important vascular disease component 
in COPD.
Lung development normally occurs under hypoxic conditions79, and hypoxia-inducible 
factors (HIFs) are the main transcriptional regulators responsible for stimulating vascu-
lar development during this hypoxic period71,80. HIF is known as the master regulator of 
the hypoxic response and upregulation of HIF leads to the activation of genes81 necessary 
for proper lung vascular, and thereby alveolar, development as well as surfactant produc-
tion82,83. There are multiple isoforms of HIF, but a basic division can be made into an 
oxygen-sensitive subunit; HIF-1α, HIF-2α and HIF-3α, and a constitutively expressed 
subunit; HIF-1β/ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator)84. HIF-1α 
expression increases after hypoxia exposure85 and has been shown to influence vascular 
development through the regulation of VEGF mRNA levels86. HIF-1α is involved in many 
different types of human disease. In the lung decreased levels of HIF-1α have been found 
in BPD87,88 whereas increased levels of HIF-1α have been found in pulmonary hyperten-
sion89 and small and non-small cell lung cancers90. HIF-2α has been shown to be required 
for maturation of alveolar type II cells and proper surfactant production91,92, and is associ-
ated with pulmonary hypertension and Congenital Diaphragmatic Hernia (CDH)93 and is 
also increased in non-small cell lung cancer90. HIF-3α has been shown to play a role in 
epithelial cell differentiation and heart and lung development during the embryonic and 
neonatal phase94.    
We found that constitutive overexpression of HIF-1-alpha in alveolar epithelial cells led to 
enhanced alveolarization by stimulating postnatal vessel growth during normoxic condi-
tions. This led us to hypothesize that constitutive overexpression of HIF-1-alpha in our 
hyperoxia-induced BPD model could be beneficial, since vessel formation is decreased 
during postnatal hyperoxia exposure95. In contrast to our functional and morphological 
findings during normoxia exposure, we found the reverse during hyperoxia exposure, as 
constitutive overexpression of HIF-1-alpha led to a deterioration of lung function during 
hyperoxia exposure without significant histological changes. We believe this is due to 
inhibition of HIF-1-alpha expression by factors inhibiting HIF-1 (FIH-1), whose activity 
is oxygen-dependent, and increases under hyperoxic circumstances. The deterioration 
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of lung function during hyperoxia was most likely caused by the measured changes in 
surfactant composition, since previous studies have shown a correlation between sur-
factant composition and lung function96–99. To this date, no human data on HIF-1-alpha 
levels in BPD patients has been collected, making it hard to correlate our data to the clini-
cal setting. A drawback to data retrieved from autopsy specimens would be that most of 
these patients died under hypoxic circumstances, leading to increased HIF-1-alpha levels, 
which would not necessarily be causally involved in the disease process. Collection and 
correct determination of total lung HIF-1-alpha levels in tracheal aspirates is impossible 
due to the fact that we are looking at a transcriptional regulator only present in cells, thus 
tracheal aspirates will not represent the total HIF-1-alpha levels in lung tissue.
a new LInk between the deveLopment oF bpd and copd
In the above chapters we investigated two possible pathways influencing the development 
of BPD and COPD, figure 2 shows a summary of the pathways we believe to be involved 
in the development of BPD and COPD, as well as the hypothetical link between BPD and 
COPD: Lung injury in early life creates increased susceptibility for the development of 
pulmonary emphysema during adult life.
ceLL based therapy usIng mesenchymaL stem ceLLs
Mesenchymal stem cells, multipotent cells that possess the ability to self-renew100, have 
successfully been used in numerous rodent models of disease as therapeutic agent101–104, 
and recently their proposed mechanism of action has shifted from engraftment and differ-
entiation into resident cells, to a paracrine effect, excreting a variety of anti-inflammatory 
mediators and endothelial and epithelial growth factors105. Cell-based therapy with MSCs 
has been applied with favourable effects in various models of lung injury106–109. MSC have 
been shown to inhibit apoptosis110,secrete anti-inflammatory mediators111, growth factors, 
such as epidermal growth factor112 and hepatocyte growth factor113. It has been shown that 
the intravenous infusion of conditioned medium, derived from MSCs, prevents LPS-in-
duced lung injury, supporting that MSCs exert their effect via paracrine signalling114. In the 
past 5 years, several research groups have examined cell-based therapies in the hyperoxia-
induced BPD model, both in mice and rats, with different types of bone-marrow and um-
bilical cord-derived cells, and found attenuation and prevention of hyperoxia-induced lung 
injury101,115–117. The use of bone marrow-conditioned medium also showed amelioration of 
hyperoxia-induced lung injury by decreasing inflammation117. 
A driving factor in the development and progression of pulmonary emphysema is ongoing 
inflammation118–121. We showed that intravenous administration of mesenchymal stromal 
cells improved lung function when applied before elastase treatment, whereas intratra-
cheal administration of mesenchymal stromal cells yielded no therapeutic effect. These 
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Figure 2. Summary of the pathways believed to be involved in the development of BPD and COPD. (See colour 
section, page 198).
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results are in line with previous studies showing a positive effect of cell-based therapy via 
the intravenous route in the elastase-induced emphysema model104,122,123. Our experiments 
add to this data that even with severe pulmonary emphysema (using an elastase dose six 
times higher than that used in earlier studies looking at the effects of cell-based therapy), 
bone-marrow derived MSCs were still able to exhibit a therapeutic effect. Together with 
many other studies in different animal models102,103,117,124–127, this data shows the potential 
of stem cell treatment in animal models of lung disease with an inflammatory component.
Lung structure – FunctIon
In chapter 3, histology in our BPD model improved after D-sphingosine treatment, but no 
change in lung function was noted. In chapter 4, we noted a worsening of lung function 
in HIF-1αΔODD mice exposed to hyperoxia, whereas histology did not change. In chapter 
5, in the elastase-induced emphysema model, we found improved lung function after 
Myriocin treatment, but no change in histology was noted. In chapter 6 we also found 
an improvement in lung function after MSC treatment in the elastase-induced emphy-
sema model, but no alterations in histology. These data from our experiments once again 
confirm the discrepancy between lung structure and function. Clinical studies have shown 
that structural lung and airway abnormalities correlate weakly or not at all with lung func-
tion, especially for localized or inhomogeneous structural abnormalities128,129. A possible 
explanation is that morphometrics may be insufficiently sensitive to demonstrate relatively 
small changes that might underlie significant functional improvement or worsening, 
therefore more sensitive approaches to the analysis of lung structure should be studied, 
such as micro CT and advanced functional MRI imaging techniques. Although advanced 
imaging could shed light on more subtle morphometrical changes, these techniques 
would not be able to capture differences in surfactant composition, or paracrine effects 
leading to altered lung function parameters. We therefore stress the importance of a com-
bined approach of histological, biochemical and functional measurements when testing 
treatment effects in the lungs in animal models.
Future research perspectIves
• Proper long-term follow-up of BPD patients should take place in order to monitor the 
evolution of lung function during aging. This will gain new insights into the degree of 
premature aging of the lung in this patient group, leading to premature development of 
pulmonary emphysema-like defects. 
• Biobanks should be created to obtain and store tissue and BAL/tracheal aspirates in 
these patients, together with prospective clinical data, in particular ventilator settings, 
O
2
-supplementation, length of ventilation requirement, medication and many others 
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to provide a framework of samples and corresponding clinical parameters for future 
analysis. 
• Equally important is a longitudinal follow-up of the incidence of pulmonary hyperten-
sion in survivors of BPD130. Given the detrimental effects of hyperoxia on postnatal 
pulmonary development, a delicate balance exists in these patients. Relative hypoxia 
might be beneficial for pulmonary vascular growth71,80, but detrimental for cerebral 
development131,132, while hyperoxia, commonly seen with supplementary O2 in home set-
tings, induces oxygen radical production and may negatively affect pulmonary vascular 
growth. 
• Research should focus on measuring sphingolipid levels in ethically and physically 
obtainable human samples, to discover if sphingolipid levels, specifically ceramides, are 
altered. This data could subsequently lead to the development of new pharmacological 
intervention strategies aimed at preventing BPD. Unfortunately, the frequent occurrence 
of low grade chorioamnionitis as etiological factor for increased susceptibility to BPD, 
as well as intra-uterine growth restriction and pre-eclampsia, will not be tackled by this 
approach, since this would require prenatal treatment133–135. 
• Not all infants that are born preterm develop BPD, and so far there is no way of predict-
ing which preterm infant will develop BPD. Various potential biomarkers in tracheal 
aspirates have been studied to predict those at risk for BPD, but so far all results have 
been negative or irreproducible136. Genome-wide assays and targeted approaches have 
shown interesting results, but so far failed to identify those individuals susceptibility 
to developing BPD137,138. We propose that there could be a potential role for sphingo-
lipids as a biomarker to make a distinction between which preterm infants are at risk 
for developing BPD: increased ceramide levels indicate an increased activation of the 
apoptotic pathway and inflammatory pathway, leading to increased alveolar defects and 
inflammation. These characteristics could influence morbidity and mortality in BPD 
patients, and using sphingolipid profiles we might be able to predict which preterms 
are at risk of developing BPD, similarly to what has been shown looking at the relation 
between ceramide and S1P levels, and lung cancer risk139. 
• Sphingolipid levels could be used to measure the effect of pharmacological treatment 
or other interventions. As has been shown in other diseases, sphingolipid levels, more 
specifically the ceramide/S1P balance could also function as a prognostic tool140 predict-
ing outcomes. The substrate in which these sphingolipid could be measured is diverse, 
ranging from tracheal aspirates to BAL and lung tissue. A direct comparison between 
the levels in these different sample types is not always possible, although for BAL and 
tracheal aspirates a reasonable correlation has been shown with respect to cytokine 
measurements and inflammatory cell percentages141.
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• As shown in our experiments in Chapter 5, there is no good correlation between sphin-
golipid levels in tissue and BAL, therefore future experiments should collect both tra-
cheal aspirates/BAL and tissue samples, if this is clinically feasible. Extra caution should 
be taken when extrapolating results based on a single sample type or data representing 1 
time point in a process of ongoing evolution of the disease.  
• Further research in the area of sphingolipids and BPD should focus on discovering 
which enzymes in the sphingolipid pathway are responsible for the increased ceramide 
levels found and attempting to prevent hyperoxia-induced lung injury by treating mice 
with the appropriate enzyme inhibitors, based on the results from the above mentioned 
objective, from the start of hyperoxia-exposure. 
• Attempts to repair hyperoxia-induced lung injury should also be made. Stimulating 
proliferation of lung endothelial cells and alveolar type I and II cells, by adding sphin-
gosine-1-phosphate analogs at multiple time-points and increased doses after the injury 
has developed should be tested.
• In our pulmonary emphysema model, we concluded that de novo production of cerami-
des plays a role in the development of elastase-induced emphysema and this correlates 
well with the increased levels of ceramides found in the lungs of human COPD pa-
tients67. Studies have started looking at the interaction between ceramides and different 
signaling molecules, for instance RTP801, a hypoxic and oxidative stress sensor, has 
been shown to mutually upregulate ceramide levels after cigarette-smoke exposure142. 
This type of research should be continued to unravel the network of possible factors 
influencing the sphingolipid pathway during hypoxic and hyperoxic injury.   
• In general, the route of administration of pharmacological inhibitors of sphingolipid 
metabolism should be evaluated in detail, specifically to answer the question as to 
which route of administration; intravenous (systemic) vs inhalation (local), yields the 
best results, allowing for the lowest dose to be used with minimal side effects. The fact 
that inhalation creates an effect on the epithelial side, whereas intravenous administra-
tion has its effect on the endothelial side, should also be taken into consideration for 
the proposed therapeutic effect. 
• The acquired knowledge from sphingolipid inhibitor experiments could be used to 
attempt or optimize treatment in other animal models and human diseases where 
sphingolipids have been shown to play a role, such as cystic fibrosis, acute lung injury, 
asthma and viral infections of the respiratory tract55,61.
• We examined the effect of HIF-1-alpha on alveolarization and during hyperoxia expo-
sure. The effects of HIf-2-alpha and HIF-3-alpha on lung development have been stud-
ied, and indicate that these isotypes play an important role in the formation of alveoli, 
distal epithelial differentiation and surfactant formation. Overexpression of HIF-2-
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alpha was found to be lethal and lungs from these mice revealed dilated alveoli, di-
minished alveolar type I cells and aberrant type II cells92. HIF-3-alpha overexpression 
led to aberrant branching morphogenesis and decreased number of alveoli, although 
these mice survived94. Further research in this area should focus on the effect of these 
factors and the interplay between epithelial and endothelial cell lining in co-culture 
and single cell conditions given the expression of the different HIF isoforms in both 
cell types.
• In the area of mesenchymal stem cell research, we should focus our attention on the 
culture protocols and flowcytometric characterization of MSC. The flowcytometry 
markers used for the characterization of MSCs are diverse, although guidelines have 
been established143. Many research groups use a random subset of markers, making 
a comparison between papers impossible. Another area of characterization that re-
quires our attention is the comparison of MSCs from different locations. For instance, 
there are differences in differentiation capabilities and paracrine factor excretion 
between MSC derived from adipose tissue and those derived from bone-marrow144,145. 
• The different niche MSCs should be further characterized via flow cytometry and 
differentiation tests. In future experiments, we should look for specific stem cell 
populations that best fit our therapeutic needs. We should also continue to unravel the 
paracrine factors excreted by MSCs in order to better understand their mechanism of 
action and be able to make conscience decisions about when and how to administer 
these cells. The question remains whether direct injection of these factors creates the 
same results, since systemic administration could lead to severe side-effects. Mesen-
chymal stromal cells have the ability to home to sites of injury in the body to produce a 
specific paracrine effect on a local scale146. 
• Currently research labs are taking advantage of the homing ability of MSCs to use 
them as drug delivering vehicles, for instance in cancer therapy to deliver anti-
proliferative, pro-apoptotic and anti-angiogenic agents147. Timing of administration, 
amount of administrations and dosing should be evaluated in each model where 
MSCs are used, since these factors greatly influence treatment outcome148,149.
concLusIon
The evolution of chronic lung disease is the product of the underlying insult and a 
highly regulated, multifactorial cascade based on a balance between lung injury and 
repair over time. Sphingolipid metabolism plays an important part in maintaining 
this balance in well-established animal models of BPD and COPD. Within this context 
regulation of angiogenesis and vasculogenesis by hypoxia-inducible-factors determines 
proper alveolarization and incorrect expression either in time or dose is detrimental for 
postnatal lung development. Amongst the different therapeutic modalities, intravenous 
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mesenchymal stem cells, injected before or during the inflammatory peak, were shown to 
be effective in treating inflammation-based animal models of chronic lung disease, that 
mimic BPD and COPD. We propose that early lung injury may predispose for later develop-
ment of emphysema.
Future therapeutic interventions should take into account the increasing knowledge at the 
molecular level of vascular and epithelial differentiation and the response to inflammatory 
mediators.
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summary
The lung contains the largest surface of our body that is in direct contact with the environ-
ment and hence is exposed to many injurious components on a daily basis. The lung has 
a host of defense mechanisms to combat this constant invasion, but even with all these 
barriers, exogenous factors can still lead to lung injury. Worldwide, 15 million babies are 
born prematurely each year, and this incidence is on the rise. Preterm birth is an impor-
tant risk factor for the development of BronchoPulmonary Dysplasia (BPD), a disease 
characterized by interrupted septation and abnormal vascularization, leading to fewer and 
enlarged alveoli. BPD is believed to have a multifactorial pathogenesis, with many pre- and 
postnatal factors playing a role, and even though progress has been made in the manage-
ment of infants with BPD, current treatment remains symptomatic and limited. Pulmo-
nary emphysema and chronic bronchitis, together chronic obstructive pulmonary disease 
(COPD), are the most common chronic lung diseases in adults in the developed world, 
and are associated with a high mortality risk. COPD poses a large economic burden due to 
exacerbations leading to hospitalization and home oxygen use. Pulmonary emphysema is 
characterized by progressive destruction of alveolar walls, leading to loss of elastic recoil, 
airflow obstruction and hyperinflation. Oxidative stress, sustained inflammation and pro-
tease-antiprotease imbalance are believed to be major contributors to the pathogenesis of 
COPD. These factors also play a role in the development of BPD, and long-term follow-up 
indicates that preterm infants with BPD develop reduced lung function and abnormal lung 
structure through childhood and into adolescence. Structural lung abnormalities resem-
bling pulmonary emphysema have been reported in young adults with BPD (Chapter 1).
Sphingolipids play an important role in many biological processes, including apoptosis 
and proliferation, inflammation, vascular barrier integrity and smooth muscle cell con-
traction. The actions of sphingose-1-phosphate (S1P) promote proliferation and increased 
vascular barrier integrity, whereas ceramide enhances apoptosis and decreases vascular 
barrier integrity. These effects have been shown in a number of human and animal disease 
models, in relation to severe and prevalent diseases such as COPD, BPD, asthma and 
ARDS. Interventions in the sphingolipid pathway aimed at restoring the balance between 
ceramide and S1P levels have produced promising results in animal models. Pharmacolog-
ical strategies to restore the balance of S1P and ceramide should now be tested in humans. 
Performing the required studies in newborns to test the effect on BPD development and 
progression will be a challenge. There is good reason to pursue the clinical use of sphin-
golipid inhibitors, as they may well offer protection and benefit for patients with a variety 
of diseases that are associated with lung damage and repair, for which limited alternative 
treatments are available (Chapter 2). 
In Chapter 3 we demonstrated that hyperoxia in the newborn mouse lung caused a tran-
sient increase of sphingolipids, including ceramides, which returned to normal during 
recovery in room air, while histology remained abnormal. The decrease in sphingolipid 
levels during recovery matched the normalization of airway resistance and compliance. 
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Importantly, D-sphingosine supplementation during recovery accelerated the normal-
ization of ceramides, and significantly improved hyperoxia-induced lung damage. We 
propose that D-sphingosine and other inhibitors of bioactive sphingolipids should be 
studied further for their potential to reduce lung damage in human preterm infants who  
require neonatal oxygen treatment. The ultimate goal would be to develop a new strategy 
to prevent or correct bronchopulmonary dysplasia.
In Chapter 4 we showed that stable hypoxia inducible-factor 1 alpha (HIF-1α) overexpres-
sion in room air is associated with increased postnatal vascularization and alveolariza-
tion through upregulation of angiogenic factors. However, stable HIF-1α overexpression 
did not prevent hyperoxia-induced BPD in neonatal mice, but led to a worsening of lung 
function, due to an altered surfactant composition, specifically decreased palmitoyloleic 
phosphatidylcholine and increased palmitoylmyristoyl phosphatidylcholine levels. 
In Chapter 5 we showed that intratracheal elastase instillation caused a transient inflam-
matory response with influx of erythrocytes and inflammatory cells in the alveolar spaces, 
combined with an increase in multiple ceramide and dihydroceramide species in broncho-
alveolar lavage (BAL) fluid which peaked at day 1 and 2 and returned to control levels at 
day 3 after elastase instillation. Ceramide expression was primarily localized to the epithe-
lium and to inflammatory cells. Sphingomyelinase inhibitors did not prevent or reduce the 
effects of intratracheal elastase. In contrast, serine palmitoyl transferase (SPT) inhibition 
reduced sphingolipid and protein levels and ameliorated lung function changes after 
elastase instillation, demonstrating the involvement of ceramides and dihydroceramides 
in elastase-induced emphysema. Further experiments should evaluate the preventive and 
therapeutic potencies of ceramide inhibition in this emphysema model, and ultimately in 
humans with COPD.
In Chapter 6 we induced pulmonary emphysema in adult mice by tracheal instillation 
of a relatively high dose of elastase. Three weeks after elastase administration we found 
evidence of histological abnormalities and obstructive lung function, characteristic of 
pulmonary emphysema. The structural and functional changes persisted up to 10 months 
and were not affected by intratracheal administration of mesenchymal stem cells (MSC) 
prior or after the injury. Jugular vein MSC treatment before elastase injection did show an 
improvement in lung function but no change in histology. The severity of elastase-induced 
lung injury depended on the elastase dose used, and may be an important determinant of 
the effect of MSC treatment.
The general discussion in Chapter 7 discusses the studies presented in this thesis and re-
lates our findings to those of other studies performed on this subject and provides future 
research perspectives in the area of lung injury and repair. Sphingolipid metabolism plays 
an important part in maintaining the balance between lung injury and repair in well-estab-
lished animal models of BPD and COPD. Within this context regulation of angiogenesis 
and vasculogenesis by hypoxia-inducible-factors determines proper alveolarization and 
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incorrect expression either in time or dose is detrimental for postnatal lung development. 
Amongst the different therapeutic modalities, intravenous mesenchymal stem cell treat-
ment was shown to be effective in treating inflammation-based animal models of chronic 
lung disease.
Overall we conclude that evolution of chronic lung disease is the product of the underly-
ing insult and a highly regulated, multifactorial cascade based on a balance between lung 
injury and repair over time, and propose that early lung injury may predispose for later 
development of emphysema.
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samenvattIng
De long bevat het grootste lichaamsoppervlak dat in direct contact staat met de buiten-
wereld en wordt dagelijks blootgesteld aan potentieel schadelijke stoffen. Om deze con-
tinue invasie te weerstaan is de long uitgerust met een groot aantal verdedigingsmecha-
nismen, maar desondanks kunnen exogene factoren nog steeds aanzienlijke longschade 
veroorzaken.
Wereldwijd worden jaarlijks 15 miljoen baby’s prematuur geboren, en de incidentie neemt 
toe. Prematuriteit is een belangrijke risicofactor voor het ontstaan van zogenaamde Bron-
choPulmonale Dysplasie (BPD), een ziekte gekarakteriseerd door gestagneerde ontwik-
keling van alveoli en bloedvaten in de long met als gevolg een verminderd aantal en een 
groter formaat van alveoli op latere leeftijd. De pathogenese van BPD is multifactorieel, en 
zowel pre- als postnatale factoren spelen een rol. Ondanks alle verbeteringen rondom de 
zorg en behandeling van kinderen met BPD is genezing niet altijd mogelijk en is symp-
toombestrijding maar in beperkte mate te realiseren.
Chronische obstructieve longziekten (COPD), bestaande uit longemfyseem en chronische 
bronchitis, vormen in de westerse wereld de meest voorkomende chronische longziekte 
op de volwassen leeftijd en leiden tot een verhoogde kans op overlijden. Het gebruik van 
zuurstof in de thuissituatie en ziekenhuisopnames als gevolg van exacerbaties zorgen voor 
grote druk op de gezondheidszorg. Longemfyseem wordt gekarakteriseerd door pro-
gressieve destructie van alveolaire wanden resulterend in verlies van elasticiteit, luchtst-
roombeperking en hyperinflatie van de long. In de pathogenese van COPD spelen oxida-
tieve stress, voortgaande ontsteking en een verstoorde protease-antiprotease balans een 
rol. Deze factoren zijn ook van belang voor het ontstaan van BPD. Lange termijn follow-up 
van prematuren met BPD laat een verminderde longfunctie en abnormale longstructuur 
zien gedurende de kinderleeftijd tot aan de adolescentie. Structurele longafwijkingen, 
lijkend op longemfyseem zijn aangetoond bij volwassen BPD patiënten (Hoofdstuk 1).
   
Sphingolipiden spelen een belangrijke rol bij multipele biologische processen, onder an-
dere apoptose en proliferatie, ontsteking, doorlaatbaarheid van de vaatwand en contractie 
van gladde spiercellen. Sphingosine-1-fosfaat (S1P) stimuleert proliferatie en vermindert 
de doorlaatbaarheid van de vaatwand, terwijl ceramide apoptose stimuleert en voor een 
verhoogde doorlaatbaarheid van de vaatwand zorgt. Deze effecten zijn aangetoond in 
verschillende humane en proefdierstudies betreffende COPD, BPD, astma en acuut respi-
ratoir distress syndroom (ARDS). Interventies in de sphingolipiden pathway, gericht op 
het herstellen van de balans tussen ceramide en S1P, laten veelbelovende resultaten zien in 
proefdierstudies. Farmacologische strategieën om de balans te herstellen zullen nu getest 
moeten worden in humane studies. De uitdaging zal zijn om de studies, die noodzakelijk 
zijn om het effect op het beloop van BPD te testen, uit te voeren bij pasgeborenen. Er zijn 
goede redenen om onderzoek te doen naar het klinische nut van sphingolipideremmers, 
omdat deze voordelen kunnen bieden voor patiënten met verschillende ziekten die geasso-
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cieerd zijn met longschade en herstel, waarbij weinig alternatieve behandelmogelijkheden 
bestaan (Hoofdstuk 2). 
  
In hoofdstuk 3 laten we zien dat hyperoxie bij pasgeboren muizen histologische schade en 
een voorbijgaande verhoging in sphingolipiden, waaronder ceramiden, veroorzaakt. Na 
herstel in 21% zuurstof dalen deze waarden naar normaal maar de histologie blijft afwijk-
end. De normalisatie van de sphingolipiden gedurende herstel in 21% zuurstof verliep par-
allel aan de normalisatie van de longfunctie. De toediening van D-sphingosine gedurende 
de herstelperiode leidde tot een versnelde normalisatie van de ceramide waarden en tot 
verbetering van de door hyperoxie veroorzaakte longschade. Wij stellen voor het effect van 
sphingolipiden op longschade bij premature baby’s nader te onderzoeken. Met als uitein-
delijk doel om door interventie in het sphingolipiden metabolisme BPD te voorkomen dan 
wel te genezen.
In hoofdstuk 4 beschrijven we dat stabiele overexpressie van hypoxia-inducible-factor 1 
alpha (HIF-1α) geassocieerd is met toegenomen postnatale vascularisatie en alveolarisatie 
op basis van toename van angiogene factoren. Preventie van BPD bij neonatale muizen 
door stabiele HIF-1α overexpressie resulteerde juist in een verslechterde longfunctie ten 
gevolge van een veranderde surfactant samenstelling.   
In hoofdstuk 5 laten we zien dat intratracheale injectie van elastase een voorbijgaande 
ontstekingsreactie veroorzaakt met influx van erythrocyten en granulocyten in de alveo-
laire ruimte. Dit ging gepaard met verhoogde ceramiden in broncho-alveolaire lavage 
(BAL) vloeistof, met een piek op dag 1 en 2 en normalisatie op dag 3 na elastase injectie. 
Ceramide expressie werd primair gelokaliseerd in het alveolaire epitheel en in ontsteking-
scellen. Het effect van intratracheale elastase injectie werd niet voorkomen of verminderd 
door de toevoeging van sphingomyelinaseremmers. Serine palmitoyl transferase (SPT) 
remmers verminderden sphingolipiden wel en verbeterden de longfunctie na elastase 
injectie. Dit suggereert een rol voor ceramiden bij door elastase geïnduceerd longemfy-
seem. Toekomstige experimenten moeten zich richten op het evalueren van de preventieve 
en therapeutische mogelijkheden van ceramideremmers in dit longemfyseem model en 
uiteindelijk bij patiënten met COPD.
In hoofdstuk 6 beschrijven we een longemfyseem model waarbij we een relatief hogere 
dosis elastase toedienden. Drie weken na elastasetoediening vonden we histologische 
afwijkingen en een obstructieve longfunctie, karakteristiek voor longemfyseem. The struc-
turele en functionele afwijkingen bleven aanwezig tot 10 maanden na elastase toedien-
ing. Intratracheale behandeling met mesenchymale stamcellen (MSC) voor of na elastase 
toediening had geen effect op histologie en longfunctie. MSC behandeling via de vena 
jugularis voorafgaand aan elastase toediening liet een verbetering van de longfunctie zien, 
maar geen verandering in histologie. De ernst van het emfyseem was afhankelijk van de 
gebruikte elastase dosis, en een belangrijke bepalende factor van het effect van MSC.    
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In hoofstuk 7 bediscussiëren we de studies beschreven in dit proefschrift en relateren we 
onze bevindingen aan die van andere onderzoeksgroepen. Ook geven we aanbevelingen 
voor toekomstig onderzoek op het gebied van longschade en -herstel. Het sphingolipid-
emetabolisme speelt een belangrijke rol in de balans tussen longschade en herstel in veel 
gebruikte diermodellen van BPD en COPD. Binnen dit concept is het van belang dat de 
regulatie van angiogenese door hypoxia-inducible-factor bijdraagt aan normale alveolari-
satie en dat afwijkende expressie van deze factoren, zowel in de tijd als in dosering, leidt 
tot verstoring van de postnatale longontwikkeling. Van de verschillende therapeutische 
opties is intraveneuze mesenchymale stamcel injectie effectief bij de behandeling van 
chronische longziekten in diermodellen gebaseerd op schade door ontstekingsprocessen.
We concluderen dat het beloop van chronische longziekten bepaald wordt door de onder-
liggende ziekteactiviteit en het succes van de hierop reagerende herstelmechanismen. In 
deze cascade draait het om de balans tussen longschade en herstel. Hierbij kan long-
schade vroeg in het leven predisponeren voor longemfyseem op latere leeftijd.
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Skype tijdens onze sessies om de wereld weer eens te redden. Ellen, veel succes met jouw 
PhD stress. Werkontwijkend gedrag is maar een telefoontje van je verwijderd.  
Lieve opa, hoewel ik heb leren voetballen van de beste (en daarmee bedoel ik niet die man 
die meer praatte met de tegenstander dan voetbalde), is mijn profcarrière bij HFC Haarlem 
niet echt van de grond gekomen. Vandaar dat ik een andere weg heb bewandeld. Ik wil u 
bedanken voor de steun en interesse die u altijd heeft getoond.    
Pap, bedankt voor je onuitputtelijke inspiratie en het stimuleren van mijn onderzoeks-
geest. De Airport Express strippenkaart heb je goed gebruikt met al je bezoekjes aan To-
ronto op doorreis naar een congres of voordracht op uitnodiging. Deze bezoekjes hebben 
mij altijd goed gedaan ongeacht welk steak house we uitprobeerden. Bedankt dat je als 
coach binnen je vakje bent gebleven en ik je toch soms als wisselspeler mocht inzetten. Je 
ervaring met en tips rondom het promoveren zijn erg waardevol geweest. De lasagne zal 
altijd klaarstaan. 
Lieve mama, bedankt dat je altijd voor me klaar staat. Met een luisterend oor of goede 
adviezen, zowel over onderzoek als over alle andere dingen des levens. En niet te vergeten 
de speklapjes als ik weer in Nederland op vakantie was. Ik heb enorm veel van je kalmte en 
acceptatie van het leven geleerd. Dit zijn vaardigheden die elke keer van pas komen, zowel 
in het dagelijkse leven, als tijdens het doen van onderzoek. Je reactie toen ik onverwachts 
bij het huisje op Texel aan kwam rijden, een paar dagen eerder dan je had verwacht, zal me 
altijd bij blijven. 
Allerliefste Lara, bedankt dat je er altijd voor me bent, zowel om het plezier van een geac-
cepteerd artikel te vieren, als om de frustraties waar ik tegenaan liep tijdens het afronden 
van het proefschrift te doen vergeten. Bedankt voor het bewaken van mijn innerlijke rust 
en het duwtje in mijn rug als ik het nodig had! De steun die ik van jou voel is enorm en 
daar ben ik je erg dankbaar voor.
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Figure 4. Effect of hyperoxia and subsequent room air recovery on lung histology.  Representative histological 
sections of room air-exposed newborn mice (A), hyperoxia-treated newborn mice after 4 weeks of exposure 
(B) and hyperoxia-treated newborn mice that were allowed to recover for another 4 weeks in room-air (C) are 
shown. Sections were stained with hematoxylin and eosin. Morphometry results (D) are expressed as mean ± 
SEM for both room air and hyperoxia groups for mean linear intercept (n=8), radial alveolar counts (n=8), and 
alveolar number (n=4). Morphometry results for 4 weeks of recovery in room-air (E) are expressed as mean ± 
SEM for mean linear intercept (n=4) and radial alveolar count (n=3). * = p<0.05 ** = p<0.001.
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Figure 5. Effect of D-sphingosine supplementation on lung histology. Representative histological lung sections 
are shown after 4 weeks of hyperoxia exposure followed by 2 weeks of room air recovery (A), and 4 weeks of 
hyperoxia exposure followed by 2 weeks of room air recovery with D-sphingosine supplementation (B). Sections 
were stained with hematoxylin and eosin. High power inserts were taken at 200x magnification. Morphometry 
results (C) represent a total of 3 mice per group and are expressed as mean ± SEM for all groups. * = p<0.05.
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Figure 2.  Immunoblot analysis of HIF-1α and VEGF gene expression in C57 control lungs and HIF-1α∆ODD 
lungs. (A) Western blot of HIF-1α and VEGF on E18.5 and PN8 lungs. Equal loading and transfer was probed with 
β-actin. (B) Expression of total VEGF mRNA and expression of VEGF188, VEGF164 and VEGF120 mRNA in murine lung, 
as assessed by real-time qPCR. Data are expressed as relative fold changes in expression when compared to 
E18.5 lungs. Data are expressed as mean ± SEM for 4 lungs in each group. * = p<0.05.
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Figure 4. Histology and morphometry of neonatal C57BL/6 control lungs and HIF-1α∆ODD lungs. Hematoxylin 
and eosin staining of HIF-1α∆ODD lungs (e-h) showed increased parenchymal tissue per unit area of lung and 
smaller distal airspaces compared to C57BL/6 lungs (a-d) consistent with enhanced alveologenesis (Bar = 200 
µm). Tissue fraction and number of alveoli per unit area were significantly increased in HIF-1α∆ODD lungs at 
postnatal day 2, 8 and 14. The secondary crest/tissue ratio was increased in HIF-1α∆ODD pups at postnatal days 
2 and 8. Secondary crest number per unit area was significantly increased in HIF-1α∆ODD lungs at postnatal 
days 2, 8 and 14. Data are expressed as mean ± SEM for five pups in each group. * = p<0.05.
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Figure 6. Stable HIF-1α-expression increases number of lipid-laden interstitial (Ito) cells during postnatal 
development. Toluidine blue staining of ultrathin section shows an increase in lipid-laden cells (arrows) in HIF-
1α∆ODD lungs (A) vs. C57 control lungs (B) at PN14. (C) Electron micrograph of lipid droplet-laden interstitial 
(Ito) cells (* denotes lipid droplets). (D) Number of lipid droplet-laden interstitial cells was significantly increased 
at PN 8, 14 and 21. * = p<0.05.
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Figure 8. Representative histological sections of normoxia-exposed C57BL/6 mice (A), hyperoxia-exposed 
C57BL/6 mice (B), normoxia-exposed HIF-1α∆ODD mice (C) and hyperoxia-exposed HIF-1α∆ODD mice (D) are 
shown. Sections were stained with hematoxylin and eosin. Morphometry results (E) are expressed as mean ± 
SEM for mean linear intercept and radial alveolar counts. * = p<0.05, ** = p<0.001. 
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supplementary figure s2. Immunohistochemical analysis of HIF-1α in C57BL/6 control lungs and HIF-
1α∆ODD lungs. Strong positive brownish staining for HIF-1α is noted in the nuclei of distal airway epithelial 
type II cells of HIF-1α∆ODD mice (B, B-I, D, D-I, F, F-I, H, H-I, J, J-I), but not C57BL/6 control mice (A,C,E,G,I) during 
all postnatal ages (E18.5: A,B,B-I; P2: C, D, D-I; P8: E, F, F-I; P14: G, H, H-I; P21: I, J, J-I. Bar = 200 mm (A-J); 50 mm 
(B-I, D-I, F-I, H-I, J-I).
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Figure 3. Biochemical measurements in BAL fluid: protein levels (A) and cell count (B) at day 1, 2 and 3 after 
elastase injection. IgM levels (C) measured by ELISA. Cytospin slides (D) and haemotoxilin-eosin stained 
histological slides from control mice (E1 at 200x magnification, F1 at 400x magnification) and elastase-treated 
mice at 2 days after elastase injection (E2 at 200x magnification, F2 at 400x magnification) and 5 days after 
elastase injection (E3 at 200x magnification, F3 at 400x magnification). Arrows indicate neutrophils, arrowheads 
indicate macrophages. Graphs represent an n=4 for each group. * = p<0.05. 
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Figure 7. Immunofluorescent images of ceramide expression. Control (A at 100x magnification, B at 400x 
magnification), elastase-treated mice 2 days after elastase injection (C at 100x magnification, D at 400x 
magnification). Ceramide (red), cell nuclei (DAPI blue) and autofluorescence (green). 
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Figure 3. Representative histological sections of saline-controls (A), elastase-treated mice 21 days after 
injection (B) and elastase-treated mice 10 months after elastase injection (C). Sections were stained with 
hematoxylin and eosin. Morphometry results (D) are expressed as mean ± SEM for both control and elastase-
treated group for mean linear intercept (n=35), radial alveolar counts (n=6), and alveolar number (n=4). 
Morphometry results for 5 and 10 months of recovery in room-air (E) are expressed as mean ± SEM for mean 
linear intercept (n=5). * = p<0.05 ** = p<0.001.
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supplementary figure s2. Differentiated MSCs were directly stained on 6 well plates for adipocytes (A, Oil-
red stain), osteoblasts (B, Von Kossa stain) and chondrocytes (C, Alcian Blue stain), and flow cytometry data 
(D) of passage 8 MSCs (red population) stained for CD34, CD45, CD73, CD90, Sca-1 and CD105 and passage 8 
unstained MSCs as control (orange population).
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supplementary figure s3. Representative histological sections of saline-controls (A), elastase-treated mice 
21 days after injection (B) and elastase-treated mice that received MSCs via the jugular vein route (C) and via 
the intratracheal route (D). Sections were stained with hematoxylin and eosin. Morphometry results (E) are 
expressed as mean ± SEM for all groups (n=4 per group) ** = p<0.001. 
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Figure 1. The interplay of factors and biological processes suggested to play a role in the development of BPD 
and COPD. 
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Figure 2. Summary of the pathways believed to be involved in the development of BPD and COPD.


